<SEC-DOCUMENT>0001144204-18-058340.txt : 20181108
<SEC-HEADER>0001144204-18-058340.hdr.sgml : 20181108
<ACCEPTANCE-DATETIME>20181108160224
ACCESSION NUMBER:		0001144204-18-058340
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20180930
FILED AS OF DATE:		20181108
DATE AS OF CHANGE:		20181108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		181169603

	BUSINESS ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		804-827-2524

	MAIL ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv505699_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>FORM 10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 80%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended September
30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 80%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _________________
to _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission file number: 001-37544</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>AMPLIPHI
BIOSCIENCES CORPORATION</B></FONT><B> </B><BR>
(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">incorporation or organization)</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>91-1549568</B><BR>
(I.R.S. Employer Identification Number)</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3579 Valley Centre Drive, Suite 100</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>San Diego, California</B></P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>92130</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(858) 829-0829</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company as defined in Rule
12b-2 of the Exchange Act. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo;, &ldquo;smaller
reporting company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 35%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
filer </FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller
        reporting company&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
        growth company </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yes
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The number of shares of the Registrant&rsquo;s
Common Stock, par value $0.01 per share, outstanding at November 5, 2018 was 32,293,308.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 80%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.&nbsp;&nbsp;FINANCIAL INFORMATION</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements (unaudited)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management's Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II.&nbsp;&nbsp;OTHER INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></A></TD>
    <TD><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></A></TD>
    <TD><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of Proceeds</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults upon Senior Securities</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></A></TD>
    <TD><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></A></TD>
    <TD><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 6pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,499,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">5,132,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 6pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">615,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">253,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,114,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,385,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">591,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">In-process research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,661,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,661,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Acquired patents, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">253,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">276,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,619,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,138,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 6pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">714,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">578,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 6pt">Accrued expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,751,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,390,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,465,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,968,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">292,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred tax liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,147,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,147,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,766,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,407,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 6pt">Common stock, $0.01 par value; 67,000,000 shares authorized at September 30, 2018 and December 31, 2017; 16,468,308 and 9,498,928 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 6pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">408,684,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">401,842,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 6pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(401,996,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(394,206,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,853,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,731,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,619,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,138,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying condensed notes to consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_002"></A><B>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three Months Ended <BR> September 30,</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Nine Months Ended <BR> September 30,</TD><TD NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; font-weight: bold; padding-bottom: 1pt">Revenue</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">38,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">95,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development (benefit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">361,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(829,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,517,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,791,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,276,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,613,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,227,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,295,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Impairment charges</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,800,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,637,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">784,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,744,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,886,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,637,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(746,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7,744,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,791,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(37,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,997,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other income, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(46,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,003,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,606,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(779,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,790,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,788,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax benefit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,302,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,606,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(779,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,790,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,486,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Per share information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Net loss per share, basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.97</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,468,308</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,874,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,418,146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,326,139</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Net loss per share, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,496,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,874,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,418,146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,518,847</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying condensed notes to consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center"><B>Nine Months Ended September 30,</B></TD><TD STYLE="white-space: nowrap; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><B>(Unaudited)</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(7,790,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(10,486,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,997,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">366,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">568,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Charge for common stock issuance (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">519,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">268,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Amortization of patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Other non-cash adjustments, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Impairment charges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,302,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">218,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(595,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(85,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">370,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,954,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,823,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(41,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from sale of common stock and related warrants, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,159,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,353,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from exercises of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">198,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Proceeds from stock issuance under employee stock purchase plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Principal payments on note payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(510,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,362,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,877,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(633,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,014,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,132,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,711,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,499,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,725,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental schedule of non-cash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Offering costs included in accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">277,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying condensed notes to consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>AmpliPhi Biosciences Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Condensed Notes to Consolidated Financial
Statements<BR>
(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1. Organization and Description of the Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">AmpliPhi Biosciences Corporation (the &ldquo;Company&rdquo;)
was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics
Corporation changed its name to AmpliPhi Biosciences Corporation. The Company is dedicated to developing novel antibacterial therapies
called bacteriophage (phage). Phages are naturally occurring viruses that preferentially bind to and kill their bacterial targets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. Liquidity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">The Company has prepared its consolidated
financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities
in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash
flows. These circumstances raise substantial doubt about the Company&rsquo;s ability to continue as a going concern. The accompanying
financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification
of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the
Company&rsquo;s ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">As of September 30, 2018, the Company had cash and cash equivalents
of $4.5 million. On October 16, 2018, the Company completed an underwritten public offering of common stock, pre-funded warrants
and common warrants. The Company received aggregate gross proceeds from the offering of $6.8 million, before deducting the underwriting
discount and commissions and other offering expenses payable by the Company (see Note 10). Considering the Company&rsquo;s current
cash resources, including the net proceeds received from the public offering in October 2018, management believes the Company&rsquo;s
existing resources will be sufficient to fund the Company&rsquo;s planned operations until mid-2019. For the foreseeable future,
the Company&rsquo;s ability to continue its operations is dependent upon its ability to obtain additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3. Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company&rsquo;s significant accounting
policies are described in Note 3 to the consolidated financial statements included in the Company&rsquo;s Annual Report on Form
10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;). Since the date
of those financial statements, there have been no material changes to the Company&rsquo;s significant accounting policies. The
interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited,
Ampliphi Biotehnolo&scaron;ke Raziskave in Razvoj d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts
and transactions have been eliminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The accompanying unaudited consolidated
financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of
and for the year ended December 31, 2017 included in the Company&rsquo;s Annual Report on Form&nbsp;10-K, filed with the SEC. The
accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United
States of America (&ldquo;U.S. GAAP&rdquo;) for interim financial statements and in accordance with the instructions to Form 10-Q.
Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards
Codification (&ldquo;ASC&rdquo;) and Accounting Standards Update (&ldquo;ASU&rdquo;) of the Financial Accounting Standards Board
(&ldquo;FASB&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the opinion of management, the accompanying
consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for
the fair presentation of the Company&rsquo;s financial position and the results of its operations and cash flows for the periods
presented. Interim results are not necessarily indicative of results for the full year or any future period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The preparation of consolidated financial
statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported
in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and
judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes
to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such,
actual results may differ from management&rsquo;s estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development expenses are charged
to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators
and outside services, allocated facility, occupancy and utility expenses, which are partially offset by the benefit of tax incentive
payments for qualified research and development expenditures from the Australian tax authority (&ldquo;AU Tax Rebates&rdquo;).
The Company does not record AU Tax Rebates until payment is received due to the uncertainty of receipt. The Company received AU
Tax Rebates of approximately $1.2 million and $2.0 million during the three months ended September 30, 2018 and 2017, respectively.
AU Tax Rebates of $1.2 million have been recorded as an offset to research and development expense in the Company&rsquo;s consolidated
statements of operations for the three and nine months ended September 30, 2018. AU Tax Rebates of $2.0 million have been recorded
as an offset to research and development expense in the Company&rsquo;s consolidated statements of operations for the three and
nine months ended September 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Warrants are accounted for in accordance
with the applicable accounting guidance provided in ASC 815 - <I>Derivatives and Hedging</I> as either derivative liabilities or
as equity instruments depending on the specific terms of the warrants. Liability-classified instruments are recorded at fair value
at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities
in the consolidated statements of operations (see Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent Accounting Pronouncements Not Yet Adopted</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">In February 2015, the FASB issued ASU No.
2016-02, <I>Leases (Topic 842)</I>, which amends the FASB Accounting Standards Codification and creates Topic 842, &quot;Leases.&quot;
The new topic supersedes Topic 840, &quot;Leases,&quot; and increases transparency and comparability among organizations by recognizing
lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements.
The guidance is effective for reporting periods beginning after December 15, 2018 and mandates a modified retrospective transition
method. The Company plans to adopt this ASU on January 1, 2019. While the Company is still evaluating the timing and impact of
the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase
in the assets and liabilities recorded on its consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">In January 2017, the FASB issued ASU No.
2017-04, <I>Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment</I>. ASU 2017-04 removes Step
2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the
amount by which a reporting unit&rsquo;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill.
All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative
assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively, and is
effective for calendar year end companies in 2020. Early adoption is permitted for any impairment tests performed after January
1, 2017. Adoption of this ASU is not expected to have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recently Adopted Accounting Standards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In May 2014, the FASB issued ASU No. 2014-09, <I>Revenue from
Contracts with Customers (Topic 606)</I>. The ASU creates a single source of revenue guidance for companies in all industries.
The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into
contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards.
It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This
guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective
approach and is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted
this ASU as of January 1, 2018 using the modified retrospective approach. As of January 1, 2018, the Company had no revenue contracts
and therefore the adoption did not have an impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In August 2016, the
FASB issued ASU No. 2016-15, <I>Cash Flow Statements, Classification of Certain Cash Receipts and Cash Payments</I>, which addresses
eight specific cash flow classification issues with the objective of reducing diversity in practice. The amendments are effective
for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years.
The Company adopted this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&rsquo;s consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">In July 2017, the FASB issued ASU No. 2017-11,
which amends the FASB Accounting Standards Codification. Part I of ASU No. 2017-11, <I>Accounting for Certain Financial Instruments
with Down Round Features</I>, changes the classification analysis of certain equity-linked financial instruments (or embedded features)
with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods
within those fiscal years with early adoption permitted. The Company elected to early adopt this ASU as of January 1, 2018 and
the adoption did not have an impact on the Company&rsquo;s consolidated financial statements. <FONT STYLE="color: white">a</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">In June 2018, the FASB issued ASU No. 2018-07,
<I>Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, which amends
the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees
for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements
for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual
and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt
this ASU as of June 30, 2018 and the adoption did not have an impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>4. Fair Value Measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The guidance regarding fair value measurements
prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;1&mdash;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;2&mdash;Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&nbsp;3&mdash;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">The Company estimates the fair values of derivative liabilities
utilizing Level 3 inputs. No derivative liabilities have been transferred between the classification levels. Estimating the fair
values of derivative liabilities requires the use of significant and subjective inputs that may, and are likely to, change over
the duration of the instrument with related changes in internal and external market factors. The recurring fair value measurements
of the Company&rsquo;s derivative liabilities at September 30, 2018 and December 31, 2017 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Quoted&nbsp;Prices&nbsp;in</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Active&nbsp;Markets</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Significant&nbsp;Other</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Significant</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">for&nbsp;Identical</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Observable&nbsp;Inputs</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Unobservable</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Items&nbsp;(Level&nbsp;1)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Level&nbsp;2)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Inputs&nbsp;(Level&nbsp;3)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">September 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">June 2016 offering warrant liability</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                                  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                                  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">18,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">18,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">November 2016 offering warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">136,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">154,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">154,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">December 31, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">June 2016 offering warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">32,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">32,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">November 2016 offering warrant liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">260,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">292,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">292,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth a summary
of changes in the fair value of the Company's derivative liabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">June 2016</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">November 2016</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Offering</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Offering</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Warrant</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Warrant</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Derivative</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Liability</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Liability</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Liabilities</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%">Balance, December&nbsp;31, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">32,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">260,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">292,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Changes in estimated fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(14,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exercised warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(184,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(184,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance, September 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">136,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">154,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">The Company estimates the fair value of the June 2016 offering
warrant liability at each reporting date using the Black-Scholes valuation model. Inputs used in this valuation model include the
Company&rsquo;s stock price volatility, risk-free interest rates and expected term of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Historically, the Company estimated the
fair value of the November 2016 offering warrant liability at each reporting date using the Monte Carlo valuation model. Inputs
used in the Monte Carlo valuation model included the Company&rsquo;s stock price volatility, risk-free interest rates and expected
term of the warrants. Effective March 31, 2018, due primarily to the significant decrease in the number of warrants outstanding,
the Company simplified the method used and changed to the Black Scholes valuation model, which approximates the Monte Carlo valuation
model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>5. Net Loss per Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the computation
of basic and diluted net loss per share for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Nine Months Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Basic and diluted net loss per share calculation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left">Net loss, basic</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(1,606,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(779,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(7,790,000</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(10,486,000</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Change in fair value of November 2016 warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,546,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,627,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(779,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,790,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,032,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,468,308</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,874,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,418,146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,326,139</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Net loss per share, basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.97</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average shares outstanding, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,496,957</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,874,813</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,418,146</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">5,518,847</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Net loss per share, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.09</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.51</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">The following outstanding securities at September 30, 2018 and
2017 have been excluded from the computation of diluted weighted average shares outstanding for the three and nine months ended
September 30, 2018 and 2017, as they would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Nine Months Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,149,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,116,765</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,149,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,116,765</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,126,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,712,220</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,294,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,232,056</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Common stock (Note 6)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">523,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">523,210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,275,493</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,352,195</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,443,991</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,872,031</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>6. Stockholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Underwritten Public Offering of Common Stock, Pre-funded
Warrants and Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">On May 10, 2017, the Company completed
an underwritten public offering and sold 2,584,085 shares of its common stock and 4,483,334 pre-funded warrants to purchase common
stock in lieu of additional shares of common stock, and common warrants to purchase 8,000,000 shares of common stock. All of the
pre-funded warrants were exercised during the year ended December 31, 2017. The combined price to the public for each share of
common stock and accompanying common warrant was $1.50. The combined price to the public for each pre-funded warrant and accompanying
common warrant was $1.49. Each pre-funded warrant was exercisable for one share of common stock at an exercise price of $0.01 per
share. The common warrants are exercisable at a price of $1.50 per share of common stock, and will expire five years from the date
of issuance. The Company received net proceeds from the offering of approximately $9.4 million, after deducting $1.2 million in
offering costs including the underwriting discount and commissions and other offering expenses payable by the Company. The Company
evaluated the pre-funded warrants and common warrants issued in the May 2017 offering and determined that the warrants should be
classified as equity instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Registered Offerings of Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">On January 12, 2018, the Company completed
a registered public offering of 4,000,000 shares of its common stock at an offering price of $1.00 per share, for aggregate gross
proceeds of $4.0 million. The Company received net proceeds from the offering of approximately $3.4 million, after deducting placement
agent fees and other offering expenses payable by the Company. On March 22, 2018, the Company completed a registered direct offering
of 2,743,640 shares of its common stock at an offering price of $1.10 per share, for aggregate gross proceeds of $3.0 million.
The Company received net proceeds from the offering of approximately $2.8 million, after deducting placement agent fees and other
offering expenses payable by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Common Stock Issuance Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">On April 8, 2016, the Company entered into the Common Stock
Issuance Agreement (the &ldquo;CSIA&rdquo;) with certain former holders of the Company&rsquo;s Series B redeemable convertible
preferred stock (the &ldquo;Holders&rdquo;). Pursuant to terms of the CSIA, the Company agreed to issue a formula-based number
of shares of its common stock to the Holders for no additional consideration upon completion of one or more bona fide equity financings
in which the Company sells shares of its common stock below a specified price (a &ldquo;Dilutive Issuance&rdquo;) in a transaction
that occurs prior to the earlier of June 30, 2018 or such time as the Company has raised, following the date of the CSIA, $10.0
million in the aggregate (the &ldquo;Price Protection Obligations&rdquo;). In each of June 2016, November 2016 and May 2017, the
Company completed offerings of its common stock that constituted Dilutive Issuances under the CSIA. Due in part to limitations
on the number of shares issuable to the Holders under the rules of the NYSE American, no additional shares of common stock were
issued to the holders in connection with the November 2016 and May 2017 offerings prior to June 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June 27, 2017, the Company and the Holders
entered into an amendment to the CSIA (the &ldquo;Amendment&rdquo;) to, among other things, terminate the Price Protection Obligations.
In consideration for the termination of the Price Protection Obligations and a release of claims by the Holders, the Company agreed
to (i) issue to the Holders, within five business days of the Amendment, an aggregate of 28,684 shares of its common stock (the
&ldquo;First Issuance&rdquo;), which, under the rules of the NYSE American, was the maximum number of shares the Company was permitted
to issue to the Holders pursuant to the CSIA without further shareholder approval, and (ii) issue to the Holders in a subsequent
closing an aggregate 523,210 shares of common stock (the &ldquo;Second Issuance&rdquo;), subject to obtaining shareholder approval
of the Second Issuance at the Company&rsquo;s 2017 Annual Meeting of Shareholders and the Company&rsquo;s receipt of a release
of claims from the Holders at the time of the Second Issuance. On September 7, 2017 the Company&rsquo;s shareholders approved the
Second Issuance. The Company received a release of claims from each of the Holders and issued 523,210 shares of common stock on
September 19, 2017. The shares were valued at $519,000 as of September 19, 2017 based on the closing price of the Company&rsquo;s
common stock of $0.99 per share at September 19, 2017 multiplied by the 523,210 shares of common stock issued to the Holders. The
related charges of $111,000 and $519,000 were included as a component of general and administrative expense in the Company&rsquo;s
consolidated statements of operations for the three and nine months ended September 30, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At September 30, 2018, outstanding warrants
to purchase shares of common stock, accounted for as equity or liabilities, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Shares Underlying</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Expiration</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; text-align: right">8,640</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">82.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 38%; text-align: center">December 23, 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">8,492</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">8,492</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">120.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 1, 2019</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">41,872</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">107.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 16, 2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">31,519</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">40.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">March 31, 2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">106,381</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">22.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 3, 2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right">168,498</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.57</TD><TD STYLE="text-align: left">(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">November 22, 2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right; padding-bottom: 1pt; border-bottom: Black 1pt solid">7,920,933</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1.50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">May 10, 2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: right; border-bottom: black 2.5pt double">8,294,827</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;&nbsp;&nbsp;The exercise price
of the warrants is subject to adjustment upon future dilutive issuances of the Company&rsquo;s common stock and stock combination
events as defined in an exercise price adjustment provision in the warrant agreements. The exercise price will be adjusted downward
due to an event subsequent to September 30, 2018 (see Note 10).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the nine months ended September
30, 2018, warrants to purchase 217,400 shares of the Company&rsquo;s common stock, originally issued in connection with the November
2016 and May 2017 public offerings, were exercised for proceeds to the Company of $198,000. During the nine months ended September
30, 2018, warrants to purchase 19,691 shares of the Company&rsquo;s common stock expired. The weighted average exercise price of
outstanding warrants to purchase common stock at September 30, 2018 was $2.76 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>7. Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stock Option Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June 2016, the Company&rsquo;s stockholders
approved the 2016 Equity Incentive Plan (the &ldquo;2016 Plan&rdquo;). The 2016 Plan provides for the issuance of incentive awards
in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock
unit awards and performance-based stock awards. The awards may be granted by the Company&rsquo;s Board of Directors to its employees,
directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or
to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying
shares on the date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically
become exercisable over a four-year period following the date of grant. Upon the exercise of stock options, the Company issues
the resulting shares from shares reserved for issuance under the 2016 Plan. With the approval of the 2016 Plan, the remaining unallocated
shares under the Company&rsquo;s 2013 Stock Incentive Plan were allocated to the 2016 Plan and an additional 100,000 new shares
were added to the authorized share reserve under the 2016 Plan. Under the 2016 Plan, the number of shares authorized for issuance
automatically increases annually beginning January 1, 2017 and through January 1, 2026. On January 1, 2018, the number of shares
of common stock authorized for future issuance was automatically increased by 474,946 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company estimates the fair value of stock options with performance
and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured
at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite
service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below summarizes the total stock-based
compensation expense included in the Company&rsquo;s consolidated statements of operations for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine Months Ended September 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">38,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">32,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">113,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">133,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">66,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">253,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">435,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">120,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">98,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">366,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">568,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">Stock option transactions during the nine
months ended September 30, 2018 are presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Weighted</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Remaining</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Average</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Contractual</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Exercise</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Term</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(Years)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%">Outstanding at December 31, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,115,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3.17</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">8.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Forfeited/Cancelled</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,201</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding at September 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,149,164</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.08</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.28</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">118,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest at September 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">864,051</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3.80</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">90,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at September 30, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">361,773</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.77</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">39,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt">The aggregate intrinsic value of options
at September 30, 2018 is based on the Company&rsquo;s closing stock price on that date of $1.01 per share. As of September 30,
2018, there was $0.7 million of total unrecognized compensation expense related to unvested stock options, which the Company expects
to recognize over the weighted average remaining period of 2.2 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 15.1pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shares Reserved For Future Issuance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of September 30, 2018, the Company had
reserved shares of its common stock for future issuance as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Reserved</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; text-align: left">Stock options outstanding</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,149,164</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Employee stock purchase plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,172</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Available for future grants under the 2016 Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,127</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Warrants outstanding</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,294,827</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total shares reserved</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,938,290</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>8. Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, the Company may be involved
in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these
claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance
to cover many different types of liabilities, the Company&rsquo;s insurance carriers may deny coverage or policy limits may be
inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have
a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether
or not successful, could damage the Company&rsquo;s reputation and business. The Company is currently not a party to any legal
proceedings, the adverse outcome of which, in management&rsquo;s opinion, individually or in the aggregate, would have a material
adverse effect on our consolidated results of operations or financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>9. Related Party</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On March 22, 2018, the Company completed
a registered direct offering of 2,743,640 shares of its common stock at a price of $1.10 per share, including 181,820 shares sold
to One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II (&ldquo;One Funds&rdquo;). Two members of the Company&rsquo;s
board of directors are affiliated with One Funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>10. Subsequent Event</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">On October 16, 2018, the Company completed
an underwritten public offering and sold 14,875,000 shares of its common stock and 2,125,000 pre-funded warrants to purchase common
stock, and common warrants to purchase 17,500,000 shares of common stock. The combined price to the public for each share of common
stock and accompanying common warrant was $0.40. The combined price to the public for each pre-funded warrant and accompanying
common warrant was $0.39. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.01 per
share. The common warrants are exercisable at a price of $0.40 per share of common stock, and will expire five years from the date
of issuance. The Company received aggregate gross proceeds from the offering of $6.8 million, before deducting the underwriting
discount and commissions and other offering expenses payable by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_005"></A>Item 2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion and analysis of
our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements
and related notes included in this Quarterly Report on Form 10-Q, and the audited financial statements and notes thereto as of
and for the year ended December&nbsp;31, 2017 included in our Annual Report on Form 10-K filed with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Statements contained in this report
that are not statements of historical fact are forward-looking statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements concerning product
development plans, clinical development plans, the use of bacteriophages to kill bacterial pathogens, having resources
sufficient to fund our operations until mid-2019, future funding sources, general and administrative expenses, clinical trial
and other research and development expenses, capital expenditures, the expected benefits of our targeted phage therapies
strategy, tax credits and carry-forwards, and additional financings and litigation-related matters. <FONT STYLE="background-color: white">Words
such as &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;will,&rdquo; &ldquo;goal,&rdquo; &ldquo;potential&rdquo; and similar expressions are intended to identify
forward-looking statements, though not all forward-looking statements necessarily contain these
identifying words.&nbsp;</FONT>These statements are subject to risks and uncertainties. Our actual results could differ
materially from those anticipated in these forward-looking statements as a result of various factors, including those set
forth below under Part&nbsp;II, Item&nbsp;1A, &ldquo;Risk Factors&rdquo; and elsewhere in this Quarterly Report on Form 10-Q.
These forward-looking statements speak only as of the date on which they were made, and we undertake no obligation to update
any forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a clinical-stage biotechnology company
focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial
infections. Phages have a powerful and highly selective mechanism of action that enables them to bind to and kill specific bacteria.
We believe that phages represent a promising means to treat bacterial infections, especially those that have developed resistance
to current therapies, including the so-called multi-drug-resistant or &ldquo;superbug&rdquo; strains of bacteria. We are a leading
developer of bacteriophage therapeutics. We are combining our expertise in the manufacture of drug-quality bacteriophages and our
proprietary approach and expertise in identifying, characterizing and developing naturally occurring bacteriophages to develop
state-of-the-art therapeutics. We are developing bacteriophage products to combat multi- or pan-drug-resistant bacterial pathogens,
leveraging advances in sequencing and molecular biology. We have developed certain bacteriophage combinations that we believe maximize
efficacy and minimize development of resistance. We currently have two product candidates in clinical development, AB-SA01 and
AB-PA01 for the treatment of <I>Staphylococcus aureus,</I> or <I>S. aureus,</I> infections, including methicillin-resistant <I>S.
aureus</I>, or MRSA, and <I>Pseudomonas aeruginosa</I>, or <I>P. aeruginosa,</I> infections, respectively. Based on funding availability,
we would develop both product candidates for the treatment of serious or life-threatening, multi-drug resistant infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe our bacteriophage technology
may have unique application in the area of targeted medicine, and in May&nbsp;2017, we initiated a new strategic emphasis on targeted
therapies for serious or life-threatening antibiotic-resistant infections. In particular, we believe our bacteriophage technology
can be used to develop precisely targeted therapies for patients who suffer from serious or life-threatening antibiotic-resistant
bacterial infections and who have limited or no other satisfactory treatment options. Moreover, we believe our ability to target
bacteriophage therapies for antibiotic-resistant infections, combined with the ability of bacteriophage to disrupt biofilm and
having the potential to re-sensitize drug-resistant populations to antibiotics, represents what could be a powerful tool against
the growing global challenge of antibiotic-resistant infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under existing single-patient expanded
access guidelines (also referred to as &ldquo;compassionate use&rdquo;), established by the regulatory agencies, we have provided
targeted phage therapies to patients suffering from severe antibiotic-resistant infections who have failed prior antibiotic therapies.
We believe this strategic approach not only provides potential benefit to patients who have few or no other acceptable therapeutic
options, but also generates the clinical and microbiological data from these cases that we expect to support the potential validation
of the clinical utility of phage therapy, identify the most promising indications for&nbsp;further clinical development of our
AB-SA01 and AB-PA01 product candidates for <I>S. aureus</I> and <I>P.&nbsp;aeruginosa</I>, define optimal treatment regimens, and
inform our discussions with the U.S. Food and Drug Administration, or FDA, and other regulatory agencies in 2018 or later on defining
a potential path to market approval. We are initially making targeted phage therapies available under the appropriate regulatory
expanded access guidelines in the United States and in Australia, where we collaborate with select leading hospitals and key infectious
disease physician opinion leaders to identify eligible patients. We believe that the United States and Australia have favorable
regulatory frameworks and clinical expertise with respect to treating patients under single-patient expanded access guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have generally incurred net losses since
our inception and our operations to date have been primarily limited to research and development and raising capital. Since the
shift in our focus to novel therapeutics in February 2011 through September 30, 2018, we have received approximately $65.4 million
in net proceeds from the issuance of our equity securities and convertible debt securities. As of September 30, 2018, we had an
accumulated deficit of $402.0 million, $86.5 million of which has been accumulated since January of 2011, when our company began
its focus on bacteriophage development. We anticipate that a substantial portion of our capital resources and efforts in the foreseeable
future will be focused on completing the development and obtaining regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently expect to use our existing
cash and cash equivalents for the continued research and development of our product candidates, including through our targeted
phage therapies strategy, and for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect to continue to incur significant
and increasing operating losses at least for the next several years. We do not expect to generate product revenue unless and until
we successfully complete development and obtain marketing approval for at least one of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may also use a portion of our existing
cash and cash equivalents for the potential acquisition of, or investment in, product candidates, technologies, formulations or
companies that complement our business, although we have no current understandings, commitments or agreements to do so. Our existing
cash and cash equivalents will not be sufficient to enable us to complete all necessary development of any potential product candidates.
Accordingly, we will be required to obtain further funding through one or more other public or private equity offerings, debt financings,
collaboration, strategic financing or licensing arrangements or other sources. Adequate additional funding may not be available
to us on acceptable terms, or at all. If we are unable to raise capital when needed or on acceptable terms, we may be required
to defer, reduce or eliminate significant planned expenditures, restructure, curtail or eliminate some or all of our development
programs or other operations, dispose of assets, enter into arrangements that may require us to relinquish rights to certain of
our product candidates, technologies or potential markets, file for bankruptcy or cease operations altogether. Any of these events
could have a material adverse effect on our business, financial condition and results of operations and result in a loss of investment
by our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On January 12, 2018, we completed a registered
public offering of 4,000,000 shares of common stock at an offering price of $1.00 per share, for aggregate gross proceeds of $4.0
million. We received net proceeds from the offering of approximately $3.4 million, after deducting placement agent fees and other
offering expenses payable by us. On March 22, 2018, we completed a registered direct offering of 2,743,640 shares of common stock
at an offering price of $1.10 per share, for aggregate gross proceeds of $3.0 million. We received net proceeds from the offering
of approximately $2.8 million, after deducting placement agent fees and other offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September&nbsp;2018, we announced that
we had received the official minutes from our August 2018 Type B Pre-IND meeting with the FDA regarding our proposed clinical development
of AB-SA01 for the treatment of <I>S. aureus</I> bacteremia infections as well as patients with a hip or knee prosthetic joint
infection due to <I>S. aureus</I>. The FDA expressed general agreement with our proposed clinical trial designs and, based on the
current FDA feedback, no additional clinical or nonclinical data are required to proceed with two proposed randomized clinical
trials. The first such clinical trial would be a Phase 1/2 randomized, controlled clinical trial to evaluate the safety and efficacy
of AB-SA01, administered intravenously with the best available antibiotic therapy, compared to placebo plus best available antibiotic
therapy, in approximately 100 patients with <I>S. aureus</I> bacteremia. The second such clinical trial would be a Phase 1/2 randomized,
controlled clinical trial to evaluate the safety and efficacy of AB-SA01, administered by intra-articular injection and then intravenously
with the best available antibiotic therapy, compared to placebo plus the best available antibiotic therapy, in approximately 100
patients with a hip or knee prosthetic joint infection due to <I>S. aureus</I> as an adjunct to surgical treatment. We expect that
we would produce our proprietary bacteriophage therapeutics for these clinical trials at our wholly owned manufacturing facility,
which is good manufacturing practices (GMP) certified by the governmental authorities in the jurisdiction in which it operates.
We believe our GMP-facility has the capacity to produce our proprietary bacteriophage therapeutics for these clinical trials through
a potential filing of a biologics license application and potential approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2018, we also received positive
feedback from the FDA regarding our clinical development plans for AB-PA01 for the treatment of <I>P. aeruginosa </I>infections.
Resistant <I>P. aeruginosa</I> is designated as &lsquo;Priority 1: Critical&rsquo; pathogen on the World Health Organization&rsquo;s
Priority Pathogens List and as &lsquo;Serious Threat&rsquo; by the U.S. Centers for Disease Control and Prevention. The FDA expressed
general agreement with our proposed clinical trial designs and, based on the current FDA feedback, no additional clinical or nonclinical
data are required to proceed with two proposed randomized clinical trials. The first such clinical trial would be a Phase 1/2 randomized,
controlled clinical trial to evaluate the safety and efficacy of AB-PA01, administered intravenously with the best available antibiotic
therapy, compared to placebo plus best available antibiotic therapy, in approximately 100 patients with hospital-acquired and ventilator-associated
pneumonia due to <I>P. aeruginosa</I>. The second clinical trial would be a Phase 1/2 randomized, controlled clinical trial to
evaluate the safety and efficacy of AB-PA01, administered intravenously with the best available antibiotic therapy, compared to
placebo plus best available antibiotic therapy, in approximately 100 patients with P. aeruginosa bacteremia. We intend to seek
non-dilutive financing and explore other opportunities to conduct these clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, in September 2018 we provided updated topline clinical
results for our ongoing single-patient expanded access program. 84% of patients achieved treatment success (physician&rsquo;s assessment)
at the end of bacteriophage therapy, defined as complete resolution or significant improvement of baseline signs and symptoms.
We have now received clinical outcome results for 21 of the patients provided with our investigational bacteriophage therapeutics,
across seven hospitals, and with serious or life-threatening infections not responding to antibiotic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On October 16, 2018, we completed an underwritten
public offering in which we sold 14,875,000 shares of common stock and 2,125,000 pre-funded warrants to purchase common stock,
and common warrants to purchase 17,500,000 shares of common stock. The combined price to the public for each share of common stock
and accompanying common warrant was $0.40. The combined price to the public for each pre-funded warrant and accompanying common
warrant was $0.39. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.01 per share.
The common warrants are exercisable at a price of $0.40 per share of common stock, and will expire five years from the date of
issuance. We received aggregate gross proceeds from the offering of $6.8 million, before deducting the underwriting discount and
commissions and other offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of three and nine months ended September 30, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July 2018, we received tax incentive
payments of approximately $1.2 million from the Australian tax authority. Such tax incentive payments were based on eligible research
and development expenditures incurred by our Australian subsidiary in 2017. In September 2017, we received tax incentive payments
of approximately $2.0 million from the Australian tax authority, based on eligible research and development expenditures incurred
by our Australian subsidiary in 2016. The tax incentive payments were recorded as an offset to research and development expense,
resulting in net expense of $0.4 million for the three months ended September 30, 2018 and a net benefit of $0.8 million for the
three months ended September 30, 2017. Research and development expenses, excluding any benefit from tax incentive payments, for
the three months ended September 30, 2018 and 2017 were $1.6 million and $1.2 million, respectively. The increase of $0.4 million
was primarily attributable to a $0.3 million increase in clinical costs and a $0.1 million increase in payroll-related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development expenses for the
nine months ended September 30, 2018 were $3.5 million, net of approximately $1.2 million of incentive tax payments received from
the Australian tax authority. Research and development expenses for the nine months ended September 30, 2017 were $1.8 million,
net of approximately $2.0 million of incentive tax payments received from the Australian tax authority. Research and development
expenses, excluding any benefit from tax incentive payments, for the nine months ended September 30, 2018 and 2017 were $4.7 million
and $3.8 million, respectively. The increase of $0.9 million was primarily related to a $0.7 million increase in clinical costs,
a $0.1 million increase in professional and consulting fees, and a $0.1 million increase in payroll-related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>General and Administrative</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses for
the three months ended September 30, 2018 and 2017 were $1.3 million and $1.6 million, respectively. The decrease of $0.3 million
was related to a $0.1 million decrease in professional fees. The decrease was also attributable to a $0.1 million non-cash charge
during the three months ended September 30, 2017 related to the fair value of 523,210 shares of our common stock issued pursuant
to the First Amendment of the Common Stock Issuance Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses for
the nine months ended September 30, 2018 and 2017 were $4.2 million and $6.3 million, respectively. The decrease of $2.1 million
was primarily related to a $0.6 million decrease in payroll-related costs, a $0.5 million decrease in professional fees and a $0.2
million decrease in non-cash stock-based compensation expense. The decrease was also attributable to a $0.5 million non-cash charge
during the nine months ended September 30, 2017 related to the fair value of 523,210 shares of our common stock issued pursuant
to the First Amendment of the Common Stock Issuance Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Impairment Charges</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There were no impairment charges during the three and nine months
ended September 30, 2018. During the nine months ended September 30, 2017, we recorded a $5.8 million impairment charge, offset
by a related income tax benefit of $1.3 million, relating to our IPR&amp;D assets originally capitalized as a result of prior acquisitions
of know-how and phage libraries. As of June 30, 2017, we assessed the fair value of our IPR&amp;D assets and determined that the
IPR&amp;D assets were impaired. The impairment was due to an increase in our discount rate as compared to previous assessments
due to the significant difference between our net assets and our market capitalization as of June 30, 2017. Due to this impairment,
we recorded an impairment charge of $5.8 million, offset by a related income tax benefit of $1.3 million, in the second quarter
of 2017. The IPR&amp;D assets had a remaining book value of $4.7 million after the impairment charge, $2.8 million and $1.9 million
for our Staphylococcal and Pseudomonas programs, respectively. We assessed the qualitative indicators for impairment as of September
30, 2018 and concluded that there were no negative operations indicators that would necessitate an interim impairment test for
our research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Other Income (Expense)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recorded a loss of $46,000, net, for
the nine months ended September 30, 2018, which was primarily related to a loss of $60,000 from the change in fair value of our
derivative liability for warrants issued in November 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We recorded a gain of $2.0 million for
the nine months ended September 30, 2017, which was primarily related to a gain of $1.7 million from the change in fair value of
our derivative liability for warrants issued in November 2016 and was attributable to a decrease in our stock price and downward
adjustments in the exercise price during 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There was no income tax benefit for the
three and nine months ended September 30, 2018 or for the three months ended September 30, 2017. The income tax benefit of $1.3
million for the nine months ended September 30, 2017 is related to a reduction of the existing deferred tax liability during the
second quarter of 2017 as a result of a $5.8 million impairment charge for our IPR&amp;D asset discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Liquidity, Capital Resources and Financial Condition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have prepared the accompanying consolidated
financial statements on a going concern basis, which assumes that we will realize our assets and satisfy our liabilities in the
normal course of business. However, since our inception we have incurred net losses and had negative operating cash flows, and
our accumulated deficit was $402.0 million as of September 30, 2018, $86.5 million of which has been accumulated since January
of 2011 when we began our focus on bacteriophage development. These circumstances raise substantial doubt about our ability to
continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future
effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from
the outcome of the uncertainty concerning our ability to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We had cash and cash equivalents of $4.5
million at September 30, 2018. In October 2018, we completed an underwritten public offering of common stock, pre-funded warrants
and common warrants, resulting in aggregate gross proceeds to us of $6.8 million. We believe our existing cash resources, after
taking into account the net proceeds from our October 2018 public offering, will be sufficient to fund our planned operations until
mid-2019. However, we cannot provide assurances that our plans will not change or that changed circumstances will not result in
the depletion of our capital resources more rapidly than we currently anticipate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Operating activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in operating activities for
the nine months ended September 30, 2018 was $7.0 million, as compared to $6.8 million for the nine months ended September 30,
2017. The increase of $0.2 million was due to an increase in payments related to research and development costs, net of incentive
tax payments received from the Australian tax authority, offset by a decrease in payments related to general and administrative
costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Investing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in investing activities was
$41,000 and $40,000 for the nine months ended September 30, 2018 and 2017, respectively, and was attributable to purchases of property
and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Financing activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by financing activities
for the nine months ended September 30, 2018 was comprised of net cash proceeds of $6.2 million from our January 2018 and March
2018 offerings of common stock, after deducting offering costs paid of approximately $0.9 million. Net cash provided by financing
activities also included cash proceeds of $0.2 million from the exercise of warrants for common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash provided by financing activities
for the nine months ended September 30, 2017 was comprised of net cash proceeds of $9.4 million from our May 2017 underwritten
public offering of common stock, pre-funded warrants and common warrants to purchase common stock, after deducting the underwriting
discount and commissions and other expenses paid related to the offering of approximately $1.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Future Capital Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We will need to raise additional capital
in the future to continue to fund our operations. Our future funding requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of our research and development activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress and cost of our clinical trials and other research and
development activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">manufacturing costs associated with our targeted phage therapies strategy
and other research and development activities;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms and timing of any collaborative, licensing, acquisition
or other arrangements that we may establish;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether and when we receive future Australian tax rebates, if any;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of seeking regulatory approvals;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of filing, prosecuting and enforcing any patent applications,
claims, patents and other intellectual property rights; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of lawsuits involving us or our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may seek funds through arrangements
with collaborators or others that may require us to relinquish rights to the product candidates that we might otherwise seek to
develop or commercialize independently. We cannot be certain that we will be able to enter into any such arrangements on reasonable
terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may seek to raise capital through a
variety of sources, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the public equity market;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">private equity financings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">collaborative arrangements or strategic financings;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">licensing arrangements; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">public or private debt.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any additional fundraising efforts may
divert our management team from their day to day activities, which may adversely affect our ability to develop and commercialize
our product candidates. Our ability to raise additional funds will depend, in part, on the success of our product development activities,
including our targeted phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify
and enter into in-licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects,
as well as factors related to financial, economic and market conditions, many of which are beyond our control. We cannot be certain
that sufficient funds will be available to us when required or on acceptable terms. If we are unable to secure additional funds
on a timely basis or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure,
curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition
of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements
that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy
or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and
results of operations. Moreover, if we are unable to obtain additional funds on a timely basis, there will be substantial doubt
about our ability to continue as a going concern and increased risk of insolvency and loss of investment by our stockholders. To
the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of such securities
could result in dilution to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Off-Balance Sheet Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of September 30, 2018, we did not have
off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Refer to <I>Note 3</I> of the condensed
consolidated notes to the consolidated financial statements contained elsewhere in this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_006"></A><B>Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a smaller reporting company as defined
by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information
required under this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_007"></A><B>Item 4. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Disclosure Controls and Procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We carried out an evaluation, under the
supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of
the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e)
under the Exchange Act, as of the end of the period covered by this quarterly report on Form 10Q. In designing and evaluating the
disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated,
can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies
its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable
assurance level as of September 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Changes in Internal Control over Financial Reporting</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An evaluation was also performed under
the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer,
of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.&nbsp;That evaluation did
not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has
materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_008"></A><B>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_009"></A><B>Item 1. Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time, we are a party to certain litigation that
is either judged to be not material or that arises in the ordinary course of business. We intend to vigorously defend our interests
in these matters. We expect that the resolution of these matters will not have a material adverse effect on our business, financial
condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the
outcome of these proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.25in"><A NAME="a_010"></A><B>Item 1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>You should consider carefully the following
information about the risks described below, together with the other information contained in this Quarterly Report and in our
other public filings in evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain
changes to the similarly titled risk factors included in, Item 1A of our Annual Report on Form 10-K for the year ended December
31, 2017 as filed with the SEC. If any of the following risks actually occur, our business, financial condition, results of operations,
and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our
common stock would likely decline.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Financial Condition and Need for Additional
Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is substantial doubt about our ability to continue
as a going concern, which may affect our ability to obtain future financing and may require us to curtail our operations. We will
need to raise additional capital to support our operations.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">Our Annual Report on Form 10-K for the
year ended December 31, 2017 includes disclosures and an opinion from our independent registered public accounting firm stating
that our recurring losses and negative cash flows from operations raise substantial doubt about our ability to continue as a going
concern. Our financial statements as of December 31, 2017 and September 30, 2018 were prepared under the assumption that we will
continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. At September
30, 2018, we had cash and cash equivalents of $4.5 million, and we have had recurring losses from operations and negative operating
cash flows since inception. In October 2018, we completed an underwritten public offering of common stock, pre-funded warrants
and common warrants, resulting in aggregate gross proceeds to us of $6.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">We will need to raise additional capital
to support our operations and product development activities. In the near term, we expect to continue to fund our operations, if
at all, primarily through equity and debt financings in the future. We may also seek funds through arrangements with collaborators
or others that may require us to relinquish rights to the product candidates that we might otherwise seek to develop or commercialize
independently. If additional capital is not available to us when needed or on acceptable terms, we may not be able to continue
to operate our business pursuant to our business plan or we may have to discontinue our operations entirely. While we believe that
our existing resources will be sufficient to fund our planned operations until mid-2019, we cannot provide assurances that our
estimates are accurate, that our plans will not change or that changed circumstances will not result in the depletion of our capital
resources more rapidly than we currently anticipate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">Developing drugs and conducting clinical
trials is expensive. Our future funding requirements will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of our research and development activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the progress and cost of our clinical trials and other research and
development activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">manufacturing costs associated with our targeted phage therapies strategy
and other research and development activities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the terms and timing of any collaborative, licensing, acquisition
or other arrangements that we may establish;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">whether and when we receive future Australian tax rebates, if any;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of seeking regulatory approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of filing, prosecuting, defending and enforcing any patent
applications, claims, patents and other intellectual property rights; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of lawsuits involving us or our product candidates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">We may seek to raise capital through a
variety of sources, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the public equity market;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">private equity financings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">collaborative arrangements or strategic financings;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">licensing arrangements; and/or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">public or private debt.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Raising additional capital through the
sale of securities could cause significant dilution to our stockholders. Any additional fundraising efforts may divert our management
from their day to day activities, which may adversely affect our ability to develop and commercialize our product candidates. Our
ability to raise additional funds will depend, in part, on the success of our product development activities, including our targeted
phage therapies strategy and any clinical trials we initiate, regulatory events, our ability to identify and enter into in-licensing
or other strategic arrangements, and other events or conditions that may affect our value or prospects, as well as factors related
to financial, economic and market conditions, many of which are beyond our control. There can be no assurances that sufficient
funds will be available to us when required or on acceptable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to secure additional funds
when needed or on acceptable terms, we may be required to defer, reduce or eliminate significant planned expenditures, restructure,
curtail or eliminate some or all of our development programs or other operations, dispose of technology or assets, pursue an acquisition
of our company by a third party at a price that may result in a loss on investment for our stockholders, enter into arrangements
that may require us to relinquish rights to certain of our product candidates, technologies or potential markets, file for bankruptcy
or cease operations altogether. Any of these events could have a material adverse effect on our business, financial condition and
results of operations. Moreover, if we are unable to obtain additional funds on a timely basis, there will be substantial doubt
about our ability to continue as a going concern and increased risk of insolvency and up to a total loss of investment by our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have incurred losses since our inception and anticipate
that we will continue to incur significant losses for the foreseeable future, and our future profitability is uncertain.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have incurred losses in each year since
our inception in 1992. As of September 30, 2018, our accumulated deficit was $402.0 million, $86.5 million of which has been accumulated
since January of 2011, when we began our focus on bacteriophage development, and we expect to incur losses for the foreseeable
future. We have devoted, and will continue to devote for the foreseeable future, substantially all of our resources to research
and development of our product candidates. For the nine months ended September 30, 2018 and 2017, we had losses from operations
of $7.7 million and $13.8 million, respectively. Additional information regarding our results of operations may be found in our
consolidated financial statements and in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations&rdquo; included in Item 2 in this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Clinical trials and activities associated
with discovery research are costly. We do not expect to generate any revenue from the commercial sales of our product candidates
in the near term, and we expect to continue to have significant losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To attain ongoing profitability, we will
need to develop products that receive regulatory approval, and market and sell such products effectively, or rely on other parties
to do so. We cannot predict when we will achieve ongoing profitability, if at all. We have never generated revenue from product
sales and there is no guarantee that we will be able to do so in the future. If we fail to become profitable, or if we are unable
to fund our continuing losses, our business, financial condition and results of operations may be materially adversely impacted
and our stock price could decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have never generated any revenue from product sales
and may never be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ability to generate meaningful revenue
and achieve profitability depends on our ability, and the ability of any third party with which we may partner, to successfully
complete the development of, and obtain the regulatory approvals necessary to, commercialize our product candidates. We do not
anticipate generating revenues from product sales for the foreseeable future, if ever. If any of our product candidates fail in
clinical trials or if any of our product candidates do not gain regulatory approval, or if any of our product candidates, if approved,
fail to achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be
able to sustain profitability in subsequent periods. Our ability to generate future revenues from product sales depends heavily
on our success in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">completing research and preclinical and clinical development of our
product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">seeking and obtaining regulatory and marketing approvals for product
candidates for which we complete clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">developing a sustainable, scalable, reproducible, and transferable
manufacturing process for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">launching and commercializing product candidates for which we obtain
regulatory and marketing approval, either by establishing a sales force, marketing and distribution infrastructure, or by collaborating
with a partner;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">obtaining market acceptance of any approved products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">addressing any competing technological and market developments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">implementing additional internal systems and infrastructure, as needed;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">identifying and validating new product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">negotiating favorable terms in any collaboration, licensing or other
arrangements into which we may enter;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">maintaining, protecting and expanding our portfolio of intellectual
property rights, including patents, trade secrets and know-how; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">attracting, hiring and retaining qualified personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even if one or more of the product candidates
that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any
approved product. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration,
or FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities to perform clinical trials and other studies
in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products,
we may not become profitable and may need to obtain additional funding to continue operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The recently passed comprehensive tax reform bill could
adversely affect our business and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On December&nbsp;22, 2017, President Trump
signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended.&nbsp;The newly enacted
federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate
tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of
adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current
year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless
of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense
over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain
clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions).&nbsp;Notwithstanding the reduction
in the corporate income tax rate, the overall impact of the new federal tax law is uncertain and our business and financial condition
could be adversely affected.&nbsp;In addition, it is uncertain if and to what extent various states will conform to the newly enacted
federal tax law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Taxing authorities could reallocate our taxable income
among our subsidiaries, which could increase our overall tax liability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are organized in the United States,
and we currently have subsidiaries in the United Kingdom, Australia and Slovenia. If we succeed in growing our business, we expect
to conduct increased operations through our subsidiaries in various tax jurisdictions pursuant to transfer pricing arrangements
between us and our subsidiaries. If two or more affiliated companies are located in different countries, the tax laws or regulations
of each country generally will require that transfer prices be the same as those between unrelated companies dealing at arm&rsquo;s
length and that appropriate documentation is maintained to support the transfer prices. While we believe that we operate in compliance
with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable
tax authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If tax authorities in any of these countries
were to successfully challenge our transfer prices as not reflecting arm&rsquo;s length transactions, they could require us to
adjust our transfer prices and thereby reallocate our income to reflect these revised transfer prices, which could result in a
higher tax liability to us. In addition, if the country from which the income is reallocated does not agree with the reallocation,
both countries could tax the same income, resulting in double taxation. If tax authorities were to allocate income to a higher
tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax
liability, which could adversely affect our financial condition, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our ability to use our net operating tax loss carryforwards
and certain other tax attributes may be limited.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2017, we had federal
net operating loss carryforwards of approximately $198.1 million, of which $7.3 million will expire in 2018 unless utilized, and
the remaining carryforwards will expire in taxable years 2019 through 2037. These net operating loss carryforwards could expire
unused and be unavailable to offset future income tax liabilities. Under the newly enacted federal income tax law, federal net
operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal
net operating losses is limited.&nbsp; It is uncertain if and to what extent various states will conform to the newly enacted federal
tax law. &nbsp;In addition, under Section 382 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of
state law, if a corporation undergoes an &ldquo;ownership change,&rdquo; which is generally defined as a greater than 50% change,
by value, in its equity ownership over a three-year period, the corporation&rsquo;s ability to use its pre-change net operating
loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We believe we
have experienced ownership changes in the past, including in connection with our November 2016, May 2017, January 2018 and March
2018 offerings, and we may experience additional ownership changes in the future as a result of subsequent shifts in our stock
ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating
loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B><I>If we fail to maintain proper and
effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could
be impaired and our public reporting may be unreliable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are required to maintain internal control
over financial reporting adequate to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of our consolidated financial statements in accordance with generally accepted accounting principles. We do not expect that our
internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed
and operated, can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. Further,
the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or
more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions
or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective
control system, misstatements due to error or fraud may occur and not be detected. Material weaknesses in our internal controls
have been identified in the past, and we cannot assure you that significant deficiencies or material weaknesses in our internal
control over financial reporting will not be identified in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to maintain effective
controls and procedures, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be
adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic
reports and we may experience a loss of public confidence, which could have an adverse effect on our business, financial condition
and the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We incur significant costs as a result of operating as
a public company, and our management is required to devote substantial time to compliance initiatives.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a public company, we incur significant
legal, accounting and other expenses. We are subject to the reporting requirements of the Exchange Act, which require, among other
things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In
addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the NYSE American to implement provisions
of the Sarbanes-Oxley Act, imposes significant requirements on public companies, including requiring establishment and maintenance
of effective disclosure and financial controls and changes in corporate governance practices. These expenses will likely increase
in the future, particularly after we cease to be an &ldquo;emerging growth company&rdquo; if we are also no longer a &ldquo;smaller
reporting company&rdquo; as a result of additional corporate governance and disclosure requirements under the Sarbanes-Oxley Act,
the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and SEC rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect the rules and regulations applicable
to public companies to result in us continuing to incur substantial legal and financial compliance costs. These costs will decrease
our net income or increase our net loss, and may require us to reduce costs in other areas of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Results from preclinical studies and Phase 1 or 2 clinical
trials of our product candidates or from single-patient expanded access treatments may not be predictive of the results of later
stage clinical trials.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Preclinical studies, including studies
of our product candidates in animal disease models, may not accurately predict the result of human clinical trials of those product
candidates. In particular, promising animal studies suggesting the efficacy of prototype phage products in the treatment of bacterial
infections, such as<I>&nbsp;P. aeruginosa&nbsp;</I>and<I>&nbsp;S. aureus,</I> may not predict the ability of these products to
treat similar infections in humans. Despite promising data in our completed Phase 1 clinical trials, our phage technology may be
found not to be efficacious in treating bacterial infections alone or in combination with other agents, when studied in later-stage
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we have used and plan to continue
to use our bacteriophage technology in the area of targeted medicine under single-patient expanded access guidelines, which permit
the use of phage therapy outside of clinical trials, beginning in the United States and Australia and then potentially expanding
to other countries. Despite prior single-patient expanded access successes, no assurance can be given that we will have similar
single-patient expanded access treatment successes in the future. Single-patient expanded access is a term that is used to refer
to the use of an investigational drug or therapy outside of a clinical trial to treat a patient with a serious or immediately life-threatening
disease or condition who has no comparable or satisfactory alternative treatment options. Regulators often allow single-patient
expanded access on a case-by-case basis for an individual patient or for defined groups of patients with similar treatment needs.
In some countries, such as Australia, the treating physician can administer treatment under single-patient expanded access guidelines
without pre-approval from the applicable regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September 2018, we received the official
minutes from our August&nbsp;2018 Type B pre-IND meeting with the FDA regarding our AB-SA01 bacteriophage therapy product candidate.
The FDA expressed general agreement with our proposed clinical trial designs and, based on the current FDA feedback, no additional
clinical or nonclinical data are required to proceed with two proposed randomized clinical trials. The first such clinical trial
would be a Phase&nbsp;1/2 randomized, controlled clinical trial to evaluate the safety and efficacy of AB-SA01, administered intravenously
with the best available antibiotic therapy, compared to placebo plus best available antibiotic therapy, in approximately 100 patients
with&nbsp;<I>S. aureus</I>&nbsp;bacteremia. The second such clinical trial would be a Phase&nbsp;1/2 randomized, controlled clinical
trial to evaluate the safety and efficacy of AB-SA01, administered by intra-articular injection and then intravenously with the
best available antibiotic therapy, compared to placebo plus the best available antibiotic therapy, in approximately 100 patients
with a hip or knee prosthetic joint infection due to&nbsp;<I>S.&nbsp;aureus</I>&nbsp;as an adjunct to surgical treatment. We are
actively seeking and intend to continue to seek non-dilutive financing and explore other opportunities to conduct these clinical
trials of AB-SA01. We intend to initiate the randomized clinical trial of AB-SA01 for <I>S. aureus</I> bacteremia in 2019. However,
there can be no assurance that we will be able to obtain sufficient capital for such bacteremia trial, or that non-dilutive financing
or other opportunities will be available to us, on a timely basis, on favorable terms, or at all. We may also choose to conduct
one or more smaller-scale clinical trials of similar design as an alternative to conducting the approximately 100 patient clinical
trials described above in an effort to reduce clinical trial expenditures. It is possible that results from such smaller-scale
clinical trials may not be viewed by the FDA or other regulatory agencies as sufficient for the advancement of AB-SA01 into Phase
2 trials, including potentially registrational Phase 2 trials, due to the smaller trial populations even if the trial results
are otherwise positive, which in turn could result in the FDA or other regulatory agencies requiring us to conduct additional
studies beyond those that would have been required if we had conducted trials of approximately 100 patients as proposed in our
August 2018 Type B pre-IND meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September&nbsp;2018, we received positive feedback, via written
response, from the FDA regarding our development plans for AB-PA01, without the need for a Type B pre-IND meeting. The FDA expressed
general agreement with our proposed clinical trial designs and, based on the current FDA feedback, no additional clinical or nonclinical
data are required to proceed with two proposed randomized clinical trials. The first such clinical trial would be a Phase&nbsp;1/2
randomized, controlled clinical trial to evaluate the safety and efficacy of AB-PA01, administered intravenously with the best
available antibiotic therapy, compared to placebo plus best available antibiotic therapy, in approximately 100 patients with hospital-acquired
and ventilator-associated pneumonia (HAP/VAP) due to&nbsp;<I>P. aeruginosa</I>. The second clinical trial would be a Phase&nbsp;1/2
randomized, controlled clinical trial to evaluate the safety and efficacy of AB-PA01, administered intravenously with the best
available antibiotic therapy, compared to placebo plus best available antibiotic therapy, in approximately 100 patients with&nbsp;<I>P.
aeruginosa</I>&nbsp;bacteremia. We intend to seek non-dilutive financing and explore other opportunities to conduct these clinical
trials. However, there can be no assurance that such non-dilutive financing or other opportunities will be available to us on a
timely basis, on favorable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To satisfy FDA or foreign regulatory approval
standards for the commercial sale of our product candidates, we must demonstrate in adequate and controlled clinical trials that
our product candidates are safe and effective. Success in early clinical trials, including Phase 1 and Phase 2 trials, or in our
single-patient expanded access program does not ensure that later clinical trials will be successful. Our initial results from
early stage clinical trials or our single-patient expanded access program also may not be confirmed by later analysis or subsequent
larger clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical
trials, even after obtaining promising results in earlier clinical trials and most product candidates that commence clinical trials
are never approved for commercial sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our single-patient expanded access strategy may not be
successful, which in turn could adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our targeted phage therapies strategy involves
providing phage therapy under single-patient expanded access guidelines to patients outside of clinical trials with antibiotic-resistant
infections who have few or no other therapeutic options. We believe this strategic approach will not only provide potential benefit
to patients to whom we are able to provide targeted phage therapies under the single-patient expanded access guidelines, but also
provide the clinical data from these single-patient expanded access cases that we expect to support the potential validation of
the clinical utility of phage therapy and inform our future discussions with the FDA in 2018 or later on defining a potential path
to market approval. However, this program is subject to numerous risks and uncertainties, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We have not established a cost reimbursement structure or otherwise
entered into an arrangement that would at least offset our manufacturing costs for our phage therapies that may be administered
to patients under single-patient expanded access guidelines. Increasing demand for our phage therapies in single-patient expanded
access cases could result in significant costs to us.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Responding to single-patient expanded access requests could divert
attention of our personnel and use manufacturing resources that could otherwise be deployed in other development program activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Single-patient expanded access treatment data may not establish proof-of-concept,
and the FDA or other regulatory authorities may not accept single-patient expanded access data as sufficient clinical validation
in support of our regulatory approval efforts, which could materially delay and increase the costs of our product development and
commercialization activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Patient access to phage therapy will be provided on an individual
basis where physicians will make an application or post-treatment notification to the applicable regulatory authorities on a patient-by-patient
basis. This can impose a significant administrative burden on participating physicians, who may be resistant to navigating a process
with which they are unfamiliar. We may be unable to identify in a timely manner a sufficient number of patients who are eligible
for expanded access emergency treatment&nbsp;and we may be unable to identify in a timely manner a sufficient number of physicians
who are interested in providing experimental therapy to such patients, which may limit our ability to provide bacteriophage therapeutics
under our expanded access program and to collect data from such cases.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are seeking to develop antibacterial agents using bacteriophage
technology, a novel approach, which makes it difficult to predict the time and cost of development. No bacteriophage products have
been approved in the United States or elsewhere.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing our product candidates
with bacteriophage technology. We have not, nor to our knowledge has any other company, received regulatory approval from the FDA
or equivalent foreign agencies for a pharmaceutical drug based on this approach. While <I>in vitro</I> studies have characterized
the behavior of bacteriophages in cell cultures and there exists a body of literature regarding the use of phage therapy in humans,
the safety and efficacy of phage therapy in humans has not been extensively studied in well-controlled modern clinical trials.
Most of the prior research on phage-based therapy was conducted in the former Soviet Union prior to and immediately after World
War II and lacked appropriate control group design or lacked control groups at all. Furthermore, the standard of care has changed
substantially during the ensuing decades since those studies were performed, diminishing the relevance of prior claims of improved
cure rates. We cannot be certain that our approach will lead to the development of approvable or marketable drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Developing phage-based therapies on a commercial
scale will also require developing new manufacturing processes and techniques. We and our third-party collaborators may experience
delays in developing manufacturing capabilities for our product candidates, and may not be able to do so at the scale required
to efficiently conduct the clinical trials required to obtain regulatory approval of our product candidates, or to manufacture
commercial quantities of our products, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, the FDA or other regulatory
agencies may lack experience in evaluating the safety and efficacy of drugs based on these approaches, which could lengthen the
regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delays in our clinical trials could result in us not achieving
anticipated developmental milestones when expected, increased costs and delay our ability to obtain regulatory approval for and
commercialize our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Delays in our ability to commence or enroll
patients for our clinical trials could result in us not meeting anticipated clinical milestones and could materially impact our
product development costs and delay regulatory approval of our product candidates. Planned clinical trials may not be commenced
or completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.7pt; text-indent: -14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in the development of manufacturing capabilities for our product
candidates to enable their consistent production at clinical trial scale;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">failures in our internal manufacturing operations that result in our
inability to consistently and timely produce bacteriophages in sufficient quantities to support our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the availability of financial resources to commence and complete our
planned clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in reaching a consensus with clinical investigators on study
design;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in reaching a consensus with regulatory agencies on trial design
or in obtaining regulatory approval to commence a trial;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in obtaining clinical materials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">slower than expected patient recruitment for participation in clinical
trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">failure by clinical trial sites, other third parties, or us to adhere
to clinical trial agreements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delays in reaching agreement on acceptable clinical trial agreement
terms with prospective sites or obtaining institutional review board approval; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adverse safety events experienced during our clinical trials.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we do not successfully commence or complete
our clinical trials on schedule, the price of our common stock may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Completion of clinical trials depends,
among other things, on our ability to enroll a sufficient number of patients, which is a function of many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the therapeutic endpoints chosen for evaluation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the eligibility criteria defined in the
protocol;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the perceived benefit of the product candidate
under study;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the size of the patient population required
for analysis of the clinical trial&rsquo;s therapeutic endpoints;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to recruit clinical trial
investigators and sites with the appropriate competencies and experience;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to obtain and maintain patient
consents; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">competition for patients from clinical
trials for other treatments.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may experience difficulties in enrolling
patients in our clinical trials, which could increase the costs or affect the timing or outcome of these clinical trials. This
is particularly true with respect to diseases with relatively small patient populations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have not completed formulation development of our product
candidates</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The development of our bacteriophage product
candidates requires that we isolate, select and combine a number of bacteriophages that target the desired bacteria for that product
candidate. The selection of bacteriophages for any of our product candidates is based on a variety of factors, including without
limitation the ability of the selected phages, in combination, to successfully kill the targeted bacteria, the degree of cross-reactivity
of the individual phages with the same part of the bacterial targets, the ability of the combined phages to satisfy regulatory
requirements, our ability to manufacture sufficient quantities of the phages, intellectual property rights of third parties, and
other factors. While we have selected initial formulations of AB-SA01 for the treatment of <I>S. aureus</I> infections and AB-PA01
for the treatment of <I>P. aeruginosa </I>infections, there can be no assurance that these initial formulations will be the final
formulations of AB-SA01 and AB-PA01 for commercialization if approved. If we are unable to complete formulation development of
our product candidates in the time frame that we have anticipated, then our product development timelines, and the regulatory approval
of our product candidates, could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our product candidates must undergo rigorous clinical
testing, such clinical testing may fail to demonstrate safety and efficacy and any of our product candidates could cause undesirable
side effects, which would substantially delay or prevent regulatory approval or commercialization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Before we can obtain regulatory approval
for a product candidate, we must undertake extensive clinical testing in humans to demonstrate safety and efficacy to the satisfaction
of the FDA or other regulatory agencies. Clinical trials of new drug candidates sufficient to obtain regulatory marketing approval
are expensive and take years to complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We cannot be certain of successfully completing
clinical testing within the time frame we have planned, or at all. We may experience numerous unforeseen events during, or as a
result of, the clinical trial process that could delay or prevent us from receiving regulatory approval or commercializing our
product candidates, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our clinical trials may produce negative or inconclusive results,
and we may decide, or regulators may require us, to conduct additional clinical and/or preclinical testing or to abandon programs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the results obtained in earlier stage clinical testing may not be
indicative of results in future clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">clinical trial results may not meet the level of statistical significance
required by the FDA or other regulatory agencies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we, or regulators, may suspend or terminate our clinical trials if
the participating patients are being exposed to unacceptable health risks; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our product candidates may have unintended or undesirable effects
on patients that may delay or preclude regulatory approval of our product candidates or limit their commercial use, if approved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We must continue to develop manufacturing processes for
our product candidates and any delay in or our inability to do so would result in delays in our clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing novel manufacturing processes
for our product candidates at our facility in Ljubljana, Slovenia. The manufacturing processes for our product candidates, and
the scale up of such processes for clinical trials, is novel, and there can be no assurance that we will be able to complete this
work in a timely manner, if at all. Any delay in the development or scale up of these manufacturing processes could delay the start
of clinical trials and harm our business. Our facility in Slovenia must also undergo ongoing inspections by JAZMP, the agency that
regulates and supervises pharmaceutical products in Slovenia, for compliance with their and the EMA&rsquo;s, current good manufacturing
practice regulations, or cGMP regulations, before the respective product candidates can be approved for use in clinical trials
or commercialization. In the event these facilities do not receive a satisfactory cGMP inspection for the manufacture of our product
candidates, we may need to fund additional modifications to our manufacturing process, conduct additional validation studies, or
find alternative manufacturing facilities, any of which would result in significant cost to us as well as a delay of up to several
years in obtaining approval for such product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our manufacturing facility will be subject
to ongoing periodic inspection by the European regulatory authorities, including JAZMP, and the FDA for compliance with European
and FDA cGMP regulations. Compliance with these regulations and standards is complex and costly, and there can be no assurance
that we will be able to comply. Any failure to comply with applicable regulations could result in sanctions being imposed (including
fines, injunctions and civil penalties), failure of regulatory authorities to grant marketing approval of our product candidates,
delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating
restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may conduct clinical trials for our products or product
candidates outside the United States and the FDA may not accept data from such trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We completed an investigator-sponsored
clinical trial of AB-SA01 at the University of Adelaide in Australia for CRS in December 2016. Although the FDA may accept data
from clinical trials conducted outside the United States, acceptance of such study data by the FDA is subject to certain conditions.
For example, the study must be well designed and conducted and performed by qualified investigators in accordance with ethical
principles. The study population must also adequately represent the U.S. population, and the data must be applicable to the U.S.
population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any
clinical studies conducted outside of the United States must be representative of the population for whom we intend to label the
product in the United States. In addition, such studies would be subject to the applicable local laws and FDA acceptance of the
data would be dependent upon its determination that the studies also complied with all applicable U.S. laws and regulations. There
can be no assurance the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept any
such data, it would likely result in the need for additional trials, which would be costly and time consuming and delay aspects
of our business plan. Despite the positive feedback we received from the FDA in April 2017 regarding our proposal to commence a
Phase 2 clinical trial of AB-SA01 in the United States, there can be no assurances that the FDA would ultimately support any decision
by us to pursue a Phase 2 clinical trial based on data we currently have available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may need to license additional intellectual property
rights.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The development and commercialization of
phage-based antibacterial agents may require us to obtain rights to intellectual property from third parties. For example, pursuant
to our Collaborative Research and Development Agreement with the United States Army Medical Research and Materiel Command and the
Walter Reed Army Institute of Research, we are currently focusing on developing bacteriophage therapeutics to treat <I>S. aureus</I>
infections. To the extent the intellectual property is generated from the United States Army Medical Research and Materiel Command
or Walter Reed Army Institute of Research that is used in a commercial product, we may be obligated to make payments such as royalties,
licensing fees and milestone payments. We may also determine that it is necessary or advisable to license other intellectual property
from third parties. There can be no assurance that such intellectual property rights would be available on commercially reasonable
terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are subject to significant regulatory approval requirements,
which could delay, prevent or limit our ability to market our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our research and development activities,
preclinical studies, clinical trials and the anticipated manufacturing and marketing of our product candidates are subject to extensive
regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in Europe and elsewhere.
There can be no assurance that our manufacturing facilities will satisfy the requirements of the FDA or comparable foreign authorities.
We require the approval of the relevant regulatory authorities before we may commence commercial sales of our product candidates
in a given market. The regulatory approval process is expensive and time-consuming, and the timing of receipt of regulatory approval
is difficult to predict. Our product candidates could require a significantly longer time to gain regulatory approval than expected,
or may never gain approval. We cannot be certain that, even after expending substantial time and financial resources, we will obtain
regulatory approval for any of our product candidates. A delay or denial of regulatory approval could delay or prevent our ability
to generate product revenues and to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Changes in regulatory approval policies
during the development period of any of our product candidates, changes in, or the enactment of, additional regulations or statutes,
or changes in regulatory review practices for a submitted product application may cause a delay in obtaining approval or result
in the rejection of an application for regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Regulatory approval, if obtained, may be
made subject to limitations on the indicated uses for which we may market a product. These limitations could adversely affect our
potential product revenues. Regulatory approval may also require costly post-marketing follow-up studies. In addition, the labeling,
packaging, adverse event reporting, storage, advertising, promotion and record-keeping related to the product will be subject to
extensive ongoing regulatory requirements. Furthermore, for any marketed product, its manufacturer and its manufacturing facilities
will be subject to continual review and periodic inspections by the FDA or other regulatory authorities. Failure to comply with
applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls,
product seizures, operating restrictions and criminal prosecution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A variety of risks associated with our international operations
could materially adversely affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition to our U.S. operations, we
have operations and subsidiaries in the United Kingdom, Australia and Slovenia. We face risks associated with our international
operations, including possible unfavorable regulatory, pricing and reimbursement, political, tax and labor conditions, which could
harm our business. We are subject to numerous risks associated with international business activities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">compliance with differing or unexpected regulatory requirements for
the development, manufacture and, if approved, commercialization of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">difficulties in staffing and managing foreign operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">foreign government taxes, regulations and permit requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S. and foreign government tariffs, trade restrictions, price and
exchange controls and other regulatory requirements;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">anti-corruption laws, including the Foreign Corrupt Practices Act,
or the FCPA;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">economic weakness, including inflation, natural disasters, war, events
of terrorism or political instability in particular foreign countries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">fluctuations in currency exchange rates, which could result in increased
operating expenses and reduced revenues, and other obligations related to doing business in another country;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">compliance with tax, employment, immigration and labor laws, regulations
and restrictions for employees living or traveling abroad;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">workforce uncertainty in countries where labor unrest is more common
than in the United States;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">production shortages resulting from any events affecting raw material
supply or manufacturing capabilities abroad;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in diplomatic and trade relationships; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">challenges in enforcing our contractual and intellectual property
rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as
the United States.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">These and other risks associated with our
international operations may materially adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not have a sales force and do not currently have
plans to develop one.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The commercial success of any of our product
candidates will depend upon the strength of sales and marketing efforts for them. We do not have a sales force and have no experience
in sales, marketing or distribution. To successfully commercialize our product candidates, we will need to develop such a capability
ourselves or seek assistance from a third party with a large distribution system and a large direct sales force. We may be unable
to put such a plan in place. In addition, if we arrange for others to market and sell our products, our revenues will depend upon
the efforts of those parties. Such arrangements may not succeed. Even if one or more of our product candidates is approved for
marketing, if we fail to establish adequate sales, marketing and distribution capabilities, independently or with others, our business
will be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our success depends in part on attracting, retaining and
motivating our personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our success depends on our continued ability
to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and
maintain important relationships with leading academic institutions, clinicians and scientists. Our success will depend on our
ability to retain and motivate personnel and hire additional qualified personnel when required. Competition for qualified personnel
in the biotechnology field is intense. We face competition for personnel from other biotechnology and pharmaceutical companies,
universities, public and private research institutions and other organizations. We also face competition from other more well-funded
and well-established businesses and we may also be viewed as a riskier choice from a job stability perspective due to our relative
newer status than longer existing biotech and pharmaceutical companies. We may not be able to attract and retain qualified personnel
on acceptable terms given the competition for such personnel. If we are unsuccessful in our retention, motivation and recruitment
efforts, we may be unable to execute our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We must manage a geographically dispersed organization.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While we are a small company, we currently
have operations in the United States, Australia and Slovenia. In the future, we may also locate facilities in other locations based
on proximity to personnel with the expertise needed to research, develop and manufacture phage-based therapeutics, costs of operations
or other factors. Managing our organization across multiple locations and multiple time zones may reduce our efficiency, increase
our expenses and increase the risk of operational difficulties in the execution of our plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our business and operations might be adversely affected
by security breaches, including any cybersecurity incidents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We depend on the efficient and uninterrupted
operation of our computer and communications systems, which we use for, among other things, sensitive company data, including our
financial data, intellectual property and other proprietary business information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While certain of our operations have business
continuity and disaster recovery plans and other security measures intended to prevent and minimize the impact of IT-related interruptions,
our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are vulnerable to damage from cyberattacks,
computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic events. We could experience
failures in our information systems and computer servers, which could result in an interruption of our normal business operations
and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security
breaches can cause interruptions in our operations and can result in a material disruption of our targeted phage therapies, bacteriophage
product candidates and other business operations. The loss of data from completed or future studies or clinical trials could result
in delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce
the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the development of our product
candidates could be delayed or otherwise adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Even though we believe we carry commercially
reasonable business interruption and liability insurance, we might suffer losses as a result of business interruptions that exceed
the coverage available under our insurance policies or for which we do not have coverage. For example, we are not insured against
terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative impact on our operations
and financial results. Moreover, any such event could delay the development of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Reliance on Third Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely on third parties for aspects of product development.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely on third parties such as the U.S.
Army for certain aspects of product development. We have worked with the U.S. Army for research and development of product candidates
to treat <I>S. aureus</I> infections. Because we rely on third parties to conduct these activities, we have less control over the
success of these programs than we would if we were conducting them on our own. Factors beyond our control that could impact the
success of these programs include the amount of resources devoted to the programs by the applicable third party, the staffing of
those projects by third-party personnel, and the amount of time such personnel devote to our programs compared to other programs.
Failure of our third-party collaborators to successfully complete the projects that we are working on with them could result in
delays in product development and the need to expend additional resources, increasing our expenses beyond current expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will rely on third parties to conduct our clinical
trials, and their failure to perform their obligations in a timely or competent manner may delay development and commercialization
of our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect to use third parties, such as
clinical research organizations or the U.S. Army, to assist in conducting our clinical trials. However, we may face delays outside
of our control if these parties do not perform their obligations in a timely or competent fashion or if we are forced to change
service providers. This risk is heightened for clinical trials conducted outside of the United States, where it may be more difficult
to ensure that clinical trials are conducted in compliance with FDA requirements. Any third party that we hire to conduct clinical
trials may also provide services to our competitors, which could compromise the performance of their obligations to us. If we experience
significant delays in the progress of our clinical trials and in our plans to submit Biologics License Applications, the commercial
prospects for product candidates could be harmed and our ability to generate product revenue would be delayed or prevented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are dependent on patents and proprietary technology.
If we fail to adequately protect this intellectual property or if we otherwise do not have exclusivity for the marketing of our
products, our ability to commercialize products could suffer.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our commercial success will depend in part
on our ability to obtain and maintain patent protection sufficient to prevent others from marketing our product candidates, as
well as to defend and enforce these patents against infringement and to operate without infringing the proprietary rights of others.
Protection of our product candidates from unauthorized use by third parties will depend on having valid and enforceable patents
cover our product candidates or their manufacture or use, or having effective trade secret protection. If our patent applications
do not result in issued patents, or if our patents are found to be invalid, we will lose the ability to exclude others from making,
using or selling the inventions claimed therein. We have a limited number of patents and pending patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The patent positions of biotechnology companies
can be uncertain and involve complex legal and factual questions. This is due to inconsistent application of policy and changes
in policy relating to examination and enforcement of biotechnology patents to date on a global scale. The laws of some countries
may not protect intellectual property rights to the same extent as the laws of countries having well-established patent systems,
and those countries may lack adequate rules and procedures for defending our intellectual property rights. Also, changes in either
patent laws or in interpretations of patent laws may diminish the value of our intellectual property. We are not able to guarantee
that all of our patent applications will result in the issuance of patents and we cannot predict the breadth of claims that may
be allowed in our patent applications or in the patent applications we may license from others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Central provisions of The Leahy-Smith America
Invents Act, or the America Invents Act went into effect on September 16, 2012 and on March 16, 2013. The America Invents Act includes
a number of significant changes to U.S. patent law. These changes include provisions that affect the way patent applications are
being filed, prosecuted and litigated. For example, the America Invents Act enacted proceedings involving post-issuance patent
review procedures, such as inter partes review, or IPR, and post-grant review, that allow third parties to challenge the validity
of an issued patent in front of the United States Patent and Trademark Office (&ldquo;U.S. PTO&rdquo;) Patent Trial and Appeal
Board. Each proceeding has different eligibility criteria and different patentability challenges that can be raised. IPRs permit
any person (except a party who has been litigating the patent for more than a year) to challenge the validity of the patent on
the grounds that it was anticipated or made obvious by prior art. Patents covering pharmaceutical products have been subject to
attack in IPRs from generic drug companies and from hedge funds. If it is within nine months of the issuance of the challenged
patent, a third party can petition the U.S. PTO for post-grant review, which can be based on any invalidity grounds and is not
limited to prior art patents or printed publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In post-issuance proceedings, U.S. PTO
rules and regulations generally tend to favor patent challengers over patent owners. For example, unlike in district court litigation,
claims challenged in post-issuance proceedings are given their broadest reasonable meaning, which increases the chance a claim
might be invalidated by prior art or lack support in the patent specification. As another example, unlike in district court litigation,
there is no presumption of validity for an issued patent, and thus, a challenger&rsquo;s burden to prove invalidity is by a preponderance
of the evidence, as opposed to the heightened clear and convincing evidence standard. As a result of these rules and others, statistics
released by the U.S. PTO show a high percentage of claims being invalidated in post-issuance proceedings. Moreover, with few exceptions,
there is no standing requirement to petition the U.S. PTO for inter partes review or post-grant review. In other words, companies
that have not been charged with infringement or that lack commercial interest in the patented subject matter can still petition
the U.S. PTO for review of an issued patent. Thus, even where we have issued patents, our rights under those patents may be challenged
and ultimately not provide us with sufficient protection against competitive products or processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The degree of future protection for our
proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or
permit us to gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we might not be the first to file patent applications for our inventions;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">others may independently develop similar or alternative product candidates
to any of our product candidates that fall outside the scope of our patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our pending patent applications may not result in issued patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our issued patents may not provide a basis for commercially viable
products or may not provide us with any competitive advantages or may be challenged by third parties;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">others may design around our patent claims to produce competitive
products that fall outside the scope of our patents;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we may not develop additional patentable proprietary technologies
related to our product candidates; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">we are dependent upon the diligence of our appointed agents in national
jurisdictions, acting for and on our behalf, which control the prosecution of pending domestic and foreign patent applications
and maintain granted domestic and foreign patents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">An issued patent does not guarantee us
the right to practice the patented technology or commercialize the patented product. Third parties may have blocking patents that
could be used to prevent us from commercializing our patented products and practicing our patented technology. Our issued patents
and those that may be issued in the future may be challenged, invalidated or circumvented, which could limit our ability to prevent
competitors from marketing the same or related product candidates or could limit the length of the term of patent protection of
our product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential
product, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain
in force for only a short period following commercialization, thereby reducing any advantage of the patent. Patent term extensions
may not be available for these patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We rely on trade secrets and other forms of non-patent
intellectual property protection. If we are unable to protect our trade secrets, other companies may be able to compete more effectively
against us.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We rely on trade secrets to protect certain
aspects of our technology, including our proprietary processes for manufacturing and purifying bacteriophages. Trade secrets are
difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public
during the regulatory approval process. Although we use reasonable efforts to protect our trade secrets, our employees, consultants,
contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors.
Enforcing a claim that a third party illegally obtained and is using our trade secret information is expensive and time-consuming,
and the outcome is unpredictable. In addition, courts outside the United States may be less willing to or may not protect trade
secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are sued for infringing intellectual property rights
of third parties or if we are forced to engage in an interference proceeding, it will be costly and time-consuming, and an unfavorable
outcome in that litigation or interference would have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ability to commercialize our product
candidates depends on our ability to develop, manufacture, market and sell our product candidates without infringing the proprietary
rights of third parties. Numerous United States and foreign patents and patent applications, which are owned by third parties,
exist in the general field of anti-infective products or in fields that otherwise may relate to our product candidates. If we are
shown to infringe, we could be enjoined from use or sale of the claimed invention if we are unable to prove that the patent is
invalid. In addition, because patent applications can take many years to issue, there may be currently pending patent applications,
unknown to us, which may later result in issued patents that our product candidates may infringe, or which may trigger an interference
proceeding regarding one of our owned or licensed patents or applications. There could also be existing patents of which we are
not aware that our product candidates may inadvertently infringe or which may become involved in an interference proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The biotechnology and pharmaceutical industries
are characterized by the existence of a large number of patents and frequent litigation based on allegations of patent infringement.
For so long as our product candidates are in clinical trials, we believe our clinical activities fall within the scope of the exemptions
provided by 35 U.S.C. Section 271(e) in the United States, which exempts from patent infringement liability activities reasonably
related to the development and submission of information to the FDA. As our clinical investigational drug product candidates progress
toward commercialization, the possibility of a patent infringement claim against us increases. While we attempt to ensure that
our active clinical investigational drugs and the methods we employ to manufacture them, as well as the methods for their use we
intend to promote, do not infringe other parties&rsquo; patents and other proprietary rights, we cannot be certain they do not,
and competitors or other parties may assert that we infringe their proprietary rights in any event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We may be exposed to future litigation
based on claims that our product candidates, or the methods we employ to manufacture them, or the uses for which we intend to promote
them, infringe the intellectual property rights of others. Our ability to manufacture and commercialize our product candidates
may depend on our ability to demonstrate that the manufacturing processes we employ and the use of our product candidates do not
infringe third-party patents. If third-party patents were found to cover our product candidates or their use or manufacture, we
could be required to pay damages or be enjoined and therefore unable to commercialize our product candidates, unless we obtained
a license. A license may not be available to us on acceptable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Industry</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our competitors are able to develop and market products
that are more effective, safer or more affordable than ours, or obtain marketing approval before we do, our commercial opportunities
may be limited.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Competition in the biotechnology and pharmaceutical
industries is intense and continues to increase. Some companies that are larger and have significantly more resources than we do
are aggressively pursuing antibacterial development programs, including traditional therapies and therapies with novel mechanisms
of action. In addition, other companies are developing phage-based products for non-therapeutic uses, and may elect to use their
expertise in phage development and manufacturing to try to develop products that would compete with ours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We also face potential competition from
academic institutions, government agencies and private and public research institutions engaged in the discovery and development
of drugs and therapies. Many of our competitors have significantly greater financial resources and expertise in research and development,
preclinical testing, conducting clinical trials, obtaining regulatory approvals, manufacturing, sales and marketing than we do.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our competitors may succeed in developing
products that are more effective, have fewer side effects and are safer or more affordable than our product candidates, which would
render our product candidates less competitive or noncompetitive. These competitors also compete with us to recruit and retain
qualified scientific and management personnel, establish clinical trial sites and patient registration for clinical trials, as
well as to acquire technologies and technology licenses complementary to our programs or advantageous to our business. Moreover,
competitors that are able to achieve patent protection, obtain regulatory approvals and commence commercial sales of their products
before we do, and competitors that have already done so, may enjoy a significant competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Generating Antibiotics Incentives Now
Act is intended to provide incentives for the development of new, qualified infectious disease products. These incentives may result
in more competition in the market for new antibiotics, and may cause pharmaceutical and biotechnology companies with more resources
than we have to shift their efforts towards the development of products that could be competitive with our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>There is a substantial risk of product liability claims
in our business. If we do not obtain sufficient liability insurance, a product liability claim could result in substantial liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our business exposes us to significant
potential product liability risks that are inherent in the development, manufacturing and marketing of human therapeutic products.
Regardless of merit or eventual outcome, product liability claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">delay or failure to complete our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">withdrawal of clinical trial participants;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">decreased demand for our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">injury to our reputation;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">litigation costs;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">substantial monetary awards against us; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">diversion of management or other resources from key aspects of our
operations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we succeed in marketing products, product
liability claims could result in an FDA investigation of the safety or efficacy of our products, our manufacturing processes and
facilities or our marketing programs. An FDA investigation could also potentially lead to a recall of our products or more serious
enforcement actions, or limitations on the indications, for which they may be used, or suspension or withdrawal of approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have product liability insurance that
covers our clinical trials up to a $10.0 million annual per claim and aggregate limit. We intend to expand our insurance coverage
to include the sale of commercial products if marketing approval is obtained for our product candidates or any other compound that
we may develop. However, insurance coverage is expensive and we may not be able to maintain insurance coverage at a reasonable
cost or at all, and the insurance coverage that we obtain may not be adequate to cover potential claims or losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Even if we receive regulatory approval to market our product
candidates, the market may not be receptive to our product candidates upon their commercial introduction, which would negatively
affect our ability to achieve profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our product candidates may not gain market
acceptance among physicians, patients, healthcare payors and the medical community. The degree of market acceptance of any approved
products will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the effectiveness of the product;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the prevalence and severity of any side effects;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">potential advantages or disadvantages over alternative treatments;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">relative convenience and ease of administration;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the strength of marketing and distribution support;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the price of the product, both in absolute terms and relative to alternative
treatments; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Symbol; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">sufficient third-party coverage or reimbursement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If our product candidates receive regulatory
approval but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate
product revenues sufficient to attain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Foreign governments tend to impose strict price controls,
which may adversely affect our future profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">In some foreign countries, particularly
in the European Union, prescription drug pricing is subject to governmental control. In these countries, pricing negotiations with
governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement
or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our
product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount,
or if pricing is set at unsatisfactory levels, our profitability will be negatively affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may incur significant costs complying with environmental
laws and regulations, and failure to comply with these laws and regulations could expose us to significant liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our research and development activities
use biological and hazardous materials that are dangerous to human health and safety or the environment. We are subject to a variety
of federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of
these materials and wastes resulting from these materials. We are also subject to regulation by the Occupational Safety and Health
Administration, or OSHA, state and federal environmental protection agencies and to regulation under the Toxic Substances Control
Act. OSHA, state governments or federal Environmental Protection Agency, or EPA, may adopt regulations that may affect our research
and development programs. We are unable to predict whether any agency will adopt any regulations that could have a material adverse
effect on our operations. We have incurred, and will continue to incur, capital and operating expenditures and other costs in the
ordinary course of our business in complying with these laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we believe our safety procedures
for handling and disposing of these materials comply with federal, state and local laws and regulations, we cannot entirely eliminate
the risk of accidental injury or contamination from the use, storage, handling or disposal of hazardous materials. In the event
of contamination or injury, we could be held liable for any resulting damages, and any liability could significantly exceed our
insurance coverage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The price of our common stock has been and may continue
to be volatile.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The stock markets in general, the markets
for biotechnology stocks and, in particular, the stock price of our common stock, have experienced extreme volatility. The market
for our common stock is characterized by significant price volatility when compared to the shares of larger, more established companies
that trade on a national securities exchange and have large public floats, and we expect that our share price will continue to
be more volatile than the shares of such larger, more established companies for the indefinite future. The volatility in our share
price is attributable to a number of factors. Our common shares are, compared to the shares of such larger, more established companies,
sporadically and thinly traded. As a consequence of this limited liquidity, the trading of relatively small quantities of shares
by our stockholders may disproportionately influence the price of those shares in either direction. The price for our shares could,
for example, decline precipitously in the event that a large number of shares of our common stock are sold on the market without
commensurate demand. We are also a speculative or &ldquo;risky&rdquo; investment due to the early stage of our drug development
programs and our lack of profits to date, and uncertainty of future market acceptance for our potential products and our ability
to continue as a going concern. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing
all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the
market more quickly and at greater discounts than would be the case with the stock of a larger, more established company that has
a large public float and broader stockholder base. Many of these factors are beyond our control and may decrease the market price
of our common stock, regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing
market price for our common shares will be at any time, including as to whether our common stock will sustain their current market
prices, or as to what effect that the sale of shares or the availability of common stock for sale at any time will have on the
prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Price declines in our common stock could
also result from general market and economic conditions and a variety of other factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adverse results or delays in our clinical trials;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">adverse actions taken by regulatory agencies with respect to our product
candidates, clinical trials or the manufacturing processes of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">announcements of technological innovations, patents or new products
by our competitors;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">regulatory developments in the United States and foreign countries;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any lawsuit involving us or our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">announcements concerning our competitors, or the biotechnology or
pharmaceutical industries in general;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">developments concerning any strategic alliances or acquisitions we
may enter into;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">actual or anticipated variations in our operating results;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">changes in recommendations by securities analysts or lack of analyst
coverage;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">deviations in our operating results from the estimates of analysts;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">our inability, or the perception by investors that we will be unable,
to continue to meet all applicable requirements for continued listing of our common stock on the NYSE American, and the possible
delisting of our common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">sales of our common stock by our executive officers, directors and
principal stockholders or sales of substantial amounts of common stock; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">loss of any of our key scientific or management personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the past, following periods of volatility
in the market price of a particular company&rsquo;s securities, litigation has often been brought against that company. Any such
lawsuit could consume resources and management time and attention, which could adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>A significant number of shares of our common stock are
subject to issuance upon exercise of outstanding warrants and options, which upon such exercise may result in dilution to our security
holders.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of September 30, 2018, we had outstanding
common warrants to purchase an aggregate of 8,294,827 shares of our common stock at a weighted-average exercise price of $2.76
per share, and outstanding options to exercise 1,149,164 shares of our common stock at a weighted-average exercise price of $3.08
per share. Following the completion of our underwritten public offering in October 2018 in which we sold shares of our common stock
at a price of $0.39 per share, the exercise price of warrants outstanding at September 30, 2018 and exercisable for 168,498 shares
of our common stock was reduced from $0.57 per share to $0.39 per share in accordance with an exercise price adjustment feature
contained in such warrants. The exercise price of such warrants is subject to further reduction in the future in connection with
certain circumstances, including certain issuances of securities at a price less than the then-current exercise price, subdivisions
and stock splits. After giving effect to the exercise price reduction resulting from our October 2018 public offering, the adjusted
weighted-average exercise price of the common warrants outstanding as of September 30, 2018 is $2.75 per share. As of October 31,
2018, we had outstanding common warrants to purchase an aggregate of 25,794,827 shares of our common stock at a weighted-average
exercise price of $1.16 per share, which includes the common warrants to purchase 17,500,000 shares of our common stock at an exercise
price of $0.40 per share sold in our October 2018 public offering. As of October 31, 2018, there were also 1,175,000 pre-funded
warrants outstanding, each exercisable for one share of our common stock at an aggregate purchase price per share of $0.39, of
which $0.38 per share was pre-funded at the closing of our October 2018 public offering. Although we cannot determine when these
warrants or options will ultimately be exercised, it is reasonable to assume that such warrants and options will be exercised only
if the exercise price is below the market price of our common stock. To the extent any of our outstanding warrants or options are
exercised, additional shares of our common stock will be issued that will generally be eligible for resale in the public market
(subject to limitations under Rule 144 under the Securities Act for certain of our warrants and with respect to shares held by
our affiliates), which will result in dilution to our security holders. The issuance of additional securities could also have an
adverse effect on the market price of our common stock.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>We have a limited number of unreserved
shares available for future issuance, which may impair our ability to conduct future financing and other transactions.*</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">Our amended and restated articles of incorporation
currently authorize us to issue up to 67,000,000 shares of common stock and 10,000,000 shares of preferred stock. As of October
31, 2018, we had a total of approximately 6,093,402 shares of common stock that were authorized, not reserved and available for
future issuance. <FONT STYLE="background-color: white">As described in our preliminary proxy statement filed with the SEC on October
26, 2018, our board of directors has approved an amendment to our amended and restated articles of incorporation to increase the
number of our authorized shares of common stock from 67,000,000 to 217,000,000, and we are seeking approval of such amendment at
our annual meeting of shareholders to be held on December 17, 2018. There is no guarantee that this amendment will be approved
by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If we are unable to enter into new arrangements
to issue shares of our common stock or securities convertible or exercisable into shares of our common stock, our ability to complete
equity-based financings or other transactions that involve the potential issuance of our common stock or securities convertible
or exercisable into our common stock, will be limited. In lieu of issuing common stock or securities convertible into our common
stock in any future equity financing transactions, we may need to issue some or all of our authorized but unissued shares of preferred
stock, which would likely have superior rights, preferences and privileges to those of our common stock, or we may need to issue
debt that is not convertible into shares of our common stock, which may require us to grant security interests in our assets and
property and/or impose covenants upon us that restrict our business. If we are unable to issue additional shares of common stock
or securities convertible or exercisable into our common stock, our ability to enter into strategic transactions such as acquisitions
of companies or technologies, may also be limited. If we are unable to complete financing, strategic or other transactions due
to our inability to issue additional shares of common stock or securities convertible or exercisable into our common stock, our
financial condition and business prospects may be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Provisions of Washington law and our current articles
of incorporation and bylaws may discourage another company from acquiring us and may prevent attempts by our stockholders to replace
or remove our current management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Provisions of Washington law and our current
articles of incorporation and bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable,
including transactions in which you might otherwise receive a premium for your shares. In addition, these provisions may frustrate
or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders
to replace or remove our board of directors. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 14.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">authorizing the issuance of &ldquo;blank check&rdquo; preferred stock
without any need for action by stockholders;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">providing for a classified board of directors with staggered terms;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">requiring supermajority stockholder voting to effect certain amendments
to our articles of incorporation and bylaws; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing advance notice requirements for nominations for election
to our board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 12.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, because we are incorporated
in Washington, we are governed by the provisions of Chapter 23B.19 of the Washington Business Corporation Act, which, among other
things, restricts the ability of stockholders owning 10% or more of our outstanding voting stock from merging or combining with
us. These provisions could discourage potential acquisition attempts and could reduce the price that investors might be willing
to pay for shares of our common stock in the future and result in the market price being lower than it would without these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.2pt; text-indent: 12.95pt"></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although we believe these provisions collectively
provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they
would apply even if an offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or
prevent any attempts by our stockholders to replace or remove our current management by making it difficult for stockholders to
replace members of our board of directors, which is responsible for appointing the members of our management</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have never paid dividends on our common stock, and
we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have never declared or paid cash dividends
on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. We currently
intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital
appreciation, if any, of our common stock will be our stockholders&rsquo; sole source of gain for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Maintaining and improving our financial controls and the
requirements of being a public company may strain our resources, divert management&rsquo;s attention and affect our ability to
attract and retain qualified board members.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a public company, we are subject to
the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules of the NYSE American. The requirements of
these rules and regulations increase our legal and financial compliance costs, make some activities more difficult, time-consuming
or costly and place strain on our personnel, systems and resources. The Exchange Act requires, among other things, that we file
annual, quarterly and current reports with respect to our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Sarbanes-Oxley Act requires, among
other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. Ensuring
that we have adequate internal financial and accounting controls and procedures in place is a costly and time-consuming effort
that needs to be re-evaluated frequently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently do not have an internal audit
group, and we may need to hire additional accounting and financial staff with appropriate public company experience and technical
accounting knowledge. Implementing any appropriate changes to our internal controls may require specific compliance training for
our directors, officers and employees, entail substantial costs to modify our existing accounting systems, and take a significant
period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal controls, and
any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could
increase our operating costs and could materially impair our ability to operate our business. Moreover, effective internal controls
are necessary for us to produce reliable financial reports and are important to help prevent fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In accordance with NYSE American rules,
we are required to maintain a majority independent board of directors. The various rules and regulations applicable to public companies
make it more difficult and more expensive for us to maintain directors&rsquo; and officers&rsquo; liability insurance, and we may
be required to accept reduced coverage or incur substantially higher costs to maintain coverage. If we are unable to maintain adequate
directors&rsquo; and officers&rsquo; insurance, our ability to recruit and retain qualified officers and directors will be significantly
curtailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts do not publish research
or publish unfavorable research about our business, our stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The trading market for our common stock
will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently
have two securities analysts and may never obtain additional research coverage by other securities and industry analysts. If no
additional securities or industry analysts commence coverage of our company, the trading price for our stock could be negatively
impacted. If we obtain additional securities or industry analyst coverage and if one or more of the analysts who covers us downgrades
our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more
of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our stock could decrease, which
could cause our stock price and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt"><B><I>We are an &ldquo;emerging growth
company&rdquo; and we cannot be certain if the reduced disclosure requirements applicable to &ldquo;emerging growth companies&rdquo;
will make our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are an &ldquo;emerging growth company,&rdquo;
as defined under the JOBS Act. For so long as we are an &ldquo;emerging growth company,&rdquo; we intend to take advantage of certain
exemptions from reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including, but not limited to, compliance with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We could be an &ldquo;emerging growth company&rdquo;
for up to five years, although we may lose such status earlier, depending on the occurrence of certain events. We will remain an
&ldquo;emerging growth company&rdquo; until the earliest to occur of (i) the last day of the fiscal year (a) following the fifth
anniversary of our initial public offering conducted after we became a reporting company under the Exchange Act pursuant to our
registration statement on Form 10 (File No. 000-23930), (b) in which we have total annual gross revenue of at least $1.07 billion
or (c) in which we are deemed to be a &ldquo;large accelerated filer&rdquo; under the Exchange Act, which means that the market
value of our common stock that is held by non-affiliates exceeds $700 million as of June 30th of the prior year, and (ii) the date
on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We cannot predict if investors will find
our common stock less attractive or our company less comparable to certain other public companies because we will rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for
our common stock and our stock price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the JOBS Act, &ldquo;emerging growth
companies&rdquo; can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until
such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from
new or revised accounting standards, and, therefore, will be subject to the same new or revised accounting standards as other public
companies that are not &ldquo;emerging growth companies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Sales of a substantial number of shares of our common
stock in the public market by our existing stockholders could cause our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Sales of a substantial number of shares
of our common stock in the public market or the perception that these sales might occur, could depress the market price of our
common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict
the effect that sales may have on the prevailing market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Future sales and issuances of our common stock or rights
to purchase common stock by us, including pursuant to our equity incentive plans, could result in additional dilution of the percentage
ownership of our stockholders and could cause our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are generally not restricted from issuing
additional common stock, including any securities that are convertible into or exchangeable for, or that represent the right to
receive, common stock. The market price of our common stock could decline as a result of sales of common stock or securities that
are convertible into or exchangeable for, or that represent the right to receive, common stock or the perception that such sales
could occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect that significant additional capital
will be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts,
expanded research and development activities and costs associated with operating as a public company. To the extent we raise additional
capital by issuing equity or convertible securities, our stockholders may experience substantial dilution. We may sell common stock,
convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time
to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may
be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new
investors could gain rights superior to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 13.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to our 2016 Equity Incentive Plan, or the 2016 Plan,
our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants.
The number of shares available for future grant under the 2016 Plan will automatically increase on January 1st of each year by
up to 5% of all shares of our capital stock outstanding as of December&nbsp;31st of the preceding calendar year, subject to the
ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, we may grant
or provide for the grant of rights to purchase shares of our common stock pursuant to our Employee Stock Purchase Plan, or ESPP.
The number of shares of our common stock reserved for issuance under the ESPP will automatically increase on January&nbsp;1st of
each calendar year by the lessor of 1% of the total number of shares of our common stock outstanding on December&nbsp;31st of the
preceding calendar year and 30,000 shares, subject to the ability of our board of directors to take action to reduce the size of
the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the
2016 Plan and ESPP each year. Increases in the number of shares available for future grant or purchase may result in additional
dilution, which could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_011"></A><B>Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_012"></A><B>Item 3. Defaults upon Senior Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_013"></A><B>Item 4. Mine Safety Disclosures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_014"></A><B>Item 5. Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_015"></A><B>Item 6. Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Articles of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q, filed on November 16, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Amendment to Amended and Restated Articles of Incorporation of the Registrant.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415066161/v421749_ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of the Registrant, as amended (incorporated by reference to Exhibit 3.2 to the Quarterly Report on Form 10-Q, filed on November 16, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reference is made to Exhibits 3.1, 3.2 and 3.3.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420417023433/v465550_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420417023433/v465550_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form S-8 (File No. 333-217563), filed on May 1, 2017). </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Shares of Common Stock issued to purchasers in June 2013, July 2013 and December 2013 in connection with private placements (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement to Purchase Series B Preferred Stock and Common Stock Warrants, dated June 26, 2013 (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated December 16, 2013, by and among the Registrant and certain purchasers of the Registrant&rsquo;s Common Stock (incorporated by reference to Exhibit 4.4 to the Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex4-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement to Purchase Common Stock and Warrants, dated December 16, 2013 (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form 10 (File No. 000-23930), filed December 16, 2013, as amended).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement to Purchase Common Stock and Warrants, dated March 10, 2015 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed March 19, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of&nbsp;Common Stock Warrant issued to purchasers in March 2015 private placement (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K, filed March 19, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420413067533/v358053_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated March 10, 2015, by and among the Registrant and certain purchasers of the Registrant&rsquo;s Common Stock (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K, filed March 19, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415030985/v410779_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420415030985/v410779_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amendment to Warrants to Purchase Shares of Common Stock issued to purchasers in June 2013, July 2013 and December 2013 in connection with private placements (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed on May 15, 2015).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Shares of Common Stock issued in connection with the Registrant&rsquo;s acquisition of Biocontrol Ltd in December 2011 (incorporated by reference to Exhibit 4.11 to the Annual Report on Form 10-K, filed on March 30, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Shares of Common Stock issued in connection with the issuance of convertible notes of the Registrant in February 2013, March 2013, April 2013 and May 2013 (incorporated by reference to Exhibit 4.12 to the Annual Report on Form 10-K, filed on March 30, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416091546/v429366_ex4-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Shares of Common Stock issued in connection with the Registrant&rsquo;s acquisition of certain assets of Novolytics Limited in February 2016 (incorporated by reference to Exhibit 4.13 to the Annual Report on Form 10-K, filed on March 30, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416106103/v441440_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416106103/v441440_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock issued to purchasers in May 2016 registered direct offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed on June 1, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416106103/v441440_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416106103/v441440_ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 99.3 to the Current Report on Form 8-K, filed on June 1, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416135207/v453396_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420416135207/v453396_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock issued to purchasers in November 2016 registered direct offering (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, filed on November 17, 2016).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420417023490/v465628_ex4-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420417023490/v465628_ex4-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock issued to purchasers in May 2017 (incorporated by reference to Exhibit 4.18 to the Registrant&rsquo;s Registration Statement on Form S-1 (File No. 333-217169)).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420418052848/tv503028_ex4-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420418052848/tv503028_ex4-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant issued to purchasers in October 2018 underwritten public offering (incorporated by reference to Exhibit 4.18 to the Registrant Registration Statement on Form S-1 (File No. 333-226959)). </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420418052848/tv503028_ex4-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/921114/000114420418052848/tv503028_ex4-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock issued to purchasers in October 2018 underwritten public offering (incorporated by reference to Exhibit 4.19 to the Registrant Registration Statement on Form S-1 (File No. 333-226959)). </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex31-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex31-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex32-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Executive Officer Required by Rule 13a-14(b)&nbsp;or Rule 15d-14(b) and 18 U.S.C. 1350.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv505699_ex32-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Principal Financial Officer Required by Rule 13a-14(b)&nbsp;or Rule 15d-14(b) and 18 U.S.C. 1350.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Schema Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AMPLIPHI BIOSCIENCES CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: November 8, 2018</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(Principal Executive Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>tv505699_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STATEMENT OF CORRECTION TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMENDMENT TO AMENDED AND
RESTATED ARTICLES OF INCORPORATION OF </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMPLIPHI BIOSCIENCES CORPORATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Washington corporation)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the provisions
of the Washington Business Corporation Act, RCW 23B.01.240 and RCW 23.95.220, the undersigned corporation hereby submits a Statement
of Correction for the purpose of correcting a record filed with the Secretary of State of the State of Washington.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the corporation is AmpliPhi Biosciences Corporation (the &ldquo;Corporation&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Articles
of Amendment to Amended and Restated Articles of Incorporation of the Corporation were filed with the Secretary of State of the
State of Washington on April 24, 2017 (the &ldquo;Articles of Amendment&rdquo;), which Articles of Amendment contain an inaccurate
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
inaccuracy in said Articles of Amendment is as follows: Article Third of the Articles of Amendment stated that <I>Article 4</I>
of the Amended Articles are amended and restated in their entirety (emphasis added). Said Article Third should have stated that
<I>Section 4.1 of Article 4</I> of the Amended Articles are amended and restated in their entirety (emphasis added).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Article
Third of the Articles of Amendment is hereby corrected to read in its entirety as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 0.5in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>Third:</B></FONT>&nbsp;Effective
as of the effective time of 5:00 p.m., Pacific time, on April 24, 2017 (the &ldquo;Effective Time&rdquo;), Section 4.1 of Article
4 of the Amended Articles be, and it hereby is, amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 58.5pt; text-align: justify; text-indent: 13.5pt"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized
Capital</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 58.5pt; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 58.5pt; text-align: justify; text-indent: 13.5pt">The
total authorized stock of this corporation shall consist of 67,000,000 shares of Common Stock, par value $0.01 per share, and 10,000,000
shares of Preferred Stock, par value $.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 58.5pt; text-align: justify; text-indent: 13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in 0pt 58.5pt; text-align: justify; text-indent: 13.5pt">Effective
as of the Effective Time, each ten (10) shares of the Corporation&rsquo;s Common Stock, par value $0.01 per share, issued and outstanding
immediately prior to the Effective Time shall, automatically and without any action on the part of the Corporation or the respective
holders thereof, be combined into one (1) share of Common Stock without increasing or decreasing the par value of each share of
Common Stock (the &ldquo;Reverse Split&rdquo;);&nbsp;<I>provided, however</I>, no fractional shares of Common Stock shall be issued
as a result of the Reverse Split and, in lieu thereof, upon receipt after the Effective Time by the exchange agent selected by
the Corporation of a properly completed and duly executed transmittal letter and, where shares are held in certificated form, the
surrender of the stock certificate(s) formerly representing shares of pre-Reverse Split Common Stock, any shareholder who would
otherwise be entitled to a fractional share of post-Reverse Split Common Stock as a result of the Reverse Split, following the
Effective Time (after taking into account all fractional shares of post-Reverse Split Common Stock otherwise issuable to such shareholder),
shall be entitled to receive a cash payment (without interest) equal to the fractional share of post-Reverse Split Common Stock
to which such shareholder would otherwise be entitled multiplied by the average of the closing sales prices of a share of the Corporation&rsquo;s
Common Stock (as adjusted to give effect to the Reverse Split) on the NYSE MKT during regular trading hours for the five (5) consecutive
trading days immediately preceding the date these Articles of Amendment are filed with the Secretary of State of the State of Washington.
Each stock certificate that, immediately prior to the Effective Time, represented shares of pre-Reverse Split Common Stock shall,
from and after the Effective Time, automatically and without any action on the part of the Corporation or the respective holders
thereof, represent that number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common
Stock represented by such certificate shall have been combined (as well as the right to receive cash in lieu of any fractional
shares of post-Reverse Split Common Stock as set forth above; provided, however, that each holder of record of a certificate that
represented shares of pre-Reverse Split Common Stock shall receive, upon surrender of such certificate, a new certificate representing
the number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common Stock represented
by such certificate shall have been combined pursuant to the Reverse Split, as well as any cash in lieu of fractional shares of
post-Reverse Split Common Stock to which such holder may be entitled as set forth above. The Reverse Split shall be effected on
a record holder-by-record holder basis, such that any fractional shares of post-Reverse Split Common Stock resulting from the Reverse
Split and held by a single record holder shall be aggregated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">* * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B>,</FONT> this Statement of Correction to Articles of Amendment to Amended and Restated Articles of Incorporation
have been executed by a duly authorized officer of the Corporation on this 7<SUP>th</SUP> day of November, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AMPLIPHI BIOSCIENCES CORPORATION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLES OF AMENDMENT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED ARTICLES OF INCORPORATION
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMPLIPHI BIOSCIENCES CORPORATION<BR>
(a Washington corporation)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the provisions
of the Washington Business Corporation Act, RCW 23B.10.020 and RCW 23B.10.060, the undersigned corporation hereby submits these
Articles of Amendment for filing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>First:</B></FONT>
The name of the corporation is AmpliPhi Biosciences Corporation (the &ldquo;Corporation&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>Second:</B></FONT>
This amendment to the Corporations Amended and Restated Articles of Incorporation (&ldquo;Amended Articles&rdquo;) was adopted
by the Board of Directors of the Corporation on April 14, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>Third:</B></FONT>
Effective as of the effective time of 5:00 p.m., Pacific time, on April 24, 2017 (the &ldquo;Effective Time&rdquo;), Article 4
of the Amended Articles be, and it hereby is, amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE 4. CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><B>4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized
Capital</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">The total authorized stock of
this corporation shall consist of 67,000,000 shares of Common Stock, par value $0.01 per share, and 10,000,000 shares of Preferred
Stock, par value $.01 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Effective as of the Effective
Time, each ten (10) shares of the Corporation&rsquo;s Common Stock, par value $0.01 per share, issued and outstanding immediately
prior to the Effective Time shall, automatically and without any action on the part of the Corporation or the respective holders
thereof, be combined into one (1) share of Common Stock without increasing or decreasing the par value of each share of Common
Stock (the &ldquo;Reverse Split&rdquo;); <I>provided, however</I>, no fractional shares of Common Stock shall be issued as a result
of the Reverse Split and, in lieu thereof, upon receipt after the Effective Time by the exchange agent selected by the Corporation
of a properly completed and duly executed transmittal letter and, where shares are held in certificated form, the surrender of
the stock certificate(s) formerly representing shares of pre-Reverse Split Common Stock, any shareholder who would otherwise be
entitled to a fractional share of post-Reverse Split Common Stock as a result of the Reverse Split, following the Effective Time
(after taking into account all fractional shares of post-Reverse Split Common Stock otherwise issuable to such shareholder), shall
be entitled to receive a cash payment (without interest) equal to the fractional share of post-Reverse Split Common Stock to which
such shareholder would otherwise be entitled multiplied by the average of the closing sales prices of a share of the Corporation&rsquo;s
Common Stock (as adjusted to give effect to the Reverse Split) on the NYSE MKT during regular trading hours for the five (5) consecutive
trading days immediately preceding the date these Articles of Amendment are filed with the Secretary of State of the State of Washington.
Each stock certificate that, immediately prior to the Effective Time, represented shares of pre-Reverse Split Common Stock shall,
from and after the Effective Time, automatically and without any action on the part of the Corporation or the respective holders
thereof, represent that number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common
Stock represented by such certificate shall have been combined (as well as the right to receive cash in lieu of any fractional
shares of post-Reverse Split Common Stock as set forth above; provided, however, that each holder of record of a certificate that
represented shares of pre-Reverse Split Common Stock shall receive, upon surrender of such certificate, a new certificate representing
the number of whole shares of post-Reverse Split Common Stock into which the shares of pre-Reverse Split Common Stock represented
by such certificate shall have been combined pursuant to the Reverse Split, as well as any cash in lieu of fractional shares of
post-Reverse Split Common Stock to which such holder may be entitled as set forth above. The Reverse Split shall be effected on
a record holder-by-record holder basis, such that any fractional shares of post-Reverse Split Common Stock resulting from the Reverse
Split and held by a single record holder shall be aggregated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B>,</FONT> AmpliPhi Biosciences Corporation has caused these Articles of Amendment to be executed by its duly
authorized officer on April 21, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>AMPLIPHI BIOSCIENCES CORPORATION</B></FONT><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;/s/ M. Scott Salka</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">M. Scott Salka</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75in; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>tv505699_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: center"><B><U>CERTIFICATION OF PRINCIPAL
EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I, Paul C. Grint, M.D., certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 4%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.15pt; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: November 8, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>tv505699_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: center"><B><U>CERTIFICATION OF PRINCIPAL
FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">I, Steve R. Martin, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q of AmpliPhi Biosciences Corporation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 92%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.15pt; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.15pt; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.15pt; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.15pt; text-indent: -28.1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="width: 92%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: November 8, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>tv505699_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PURSUANT TO 18 U.S.C. SECTION 1350,</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AS ADOPTED PURSUANT TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of AmpliPhi Biosciences
Corporation (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange
Commission (the &ldquo;Report&rdquo;), I, Paul C. Grint, M.D., Chief Executive Officer of the Company, hereby certify as of the
date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 9%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.35pt; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 9%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 88%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the
electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Certification has not been, and shall not be deemed, &ldquo;filed&rdquo;
with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 8, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>tv505699_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PURSUANT TO 18 U.S.C. SECTION 1350,</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>AS ADOPTED PURSUANT TO</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the quarterly report
of AmpliPhi Biosciences Corporation (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended September 30, 2018 as filed with
the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Steve R. Martin, Chief Financial Officer of the Company,
hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that
to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 88%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 88%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A signed original of this written statement
required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed
form within the electronic version of this written statement required by Section 906, has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Certification has not been, and shall
not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 8, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve R. Martin</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>aphb-20180930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:14 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:aphb="http://www.ampliphibio.com/20180930" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="aphb-20180930.xsd" />
  <!--Context Section-->
  <context id="Duration_9_19_2017_To_9_19_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementSecondIssuanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-09-19</startDate>
      <endDate>2017-09-19</endDate>
    </period>
  </context>
  <context id="Duration_6_27_2017_To_6_27_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-27</startDate>
      <endDate>2017-06-27</endDate>
    </period>
  </context>
  <context id="As_Of_9_19_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementSecondIssuanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-19</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">aphb:EquityIncentivePlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">aphb:EquityIncentivePlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aphb:OneFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-22</instant>
    </period>
  </context>
  <context id="As_Of_3_22_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2018-03-22</instant>
    </period>
  </context>
  <context id="As_Of_1_12_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2018-01-12</instant>
    </period>
  </context>
  <context id="Duration_3_22_2018_To_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aphb:OneFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-22</startDate>
      <endDate>2018-03-22</endDate>
    </period>
  </context>
  <context id="Duration_3_22_2018_To_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsManagementLimitedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aphb:OneFundsManagementLimitedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-22</startDate>
      <endDate>2018-03-22</endDate>
    </period>
  </context>
  <context id="Duration_5_10_2017_To_5_10_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2017-05-10</startDate>
      <endDate>2017-05-10</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">aphb:EquityIncentivePlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:June2016OfferingLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:PreFundedWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-16</instant>
    </period>
  </context>
  <context id="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:CommonWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-16</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice82.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice82.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice40.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice40.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice22.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice22.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice120.00IMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice120.00IiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice107.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice107.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice1.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice1.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice0.57Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice0.57Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:PreFundedWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-10</instant>
    </period>
  </context>
  <context id="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:CommonWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-10</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_11_5_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <instant>2018-11-05</instant>
    </period>
  </context>
  <context id="Duration_10_16_2018_To_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:CommonWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-16</startDate>
      <endDate>2018-10-16</endDate>
    </period>
  </context>
  <context id="Duration_5_10_2017_To_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:CommonWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-10</startDate>
      <endDate>2017-05-10</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice82.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice82.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice40.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice40.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice22.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice22.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice120.00IMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice120.00IiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice107.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice107.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice1.50Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice1.50Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice0.57Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:ExercisePrice0.57Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_10_16_2018_To_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">aphb:PreFundedWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-16</startDate>
      <endDate>2018-10-16</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_10_16_2018_To_10_16_2018_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-16</startDate>
      <endDate>2018-10-16</endDate>
    </period>
  </context>
  <context id="Duration_3_22_2018_To_3_22_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2018-03-22</startDate>
      <endDate>2018-03-22</endDate>
    </period>
  </context>
  <context id="Duration_1_12_2018_To_1_12_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2018-01-12</startDate>
      <endDate>2018-01-12</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_9_30_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-07-01</startDate>
      <endDate>2018-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">aphb:November2016WarrantDerivativeLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_1_1_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">aphb:EquityIncentivePlan2016Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-01</instant>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementSecondIssuanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementSecondIssuanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2018_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000921114</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aphb:CommonStockIssuanceAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-09-30</instant>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit13">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit12">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:USD</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <aphb:CapitalRaisedLimitForPriceProtectionObligation id="Item-39" contextRef="As_Of_9_30_2018_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementMember" unitRef="Unit1" decimals="-5">10000000</aphb:CapitalRaisedLimitForPriceProtectionObligation>
  <aphb:ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense id="Item-67" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember" unitRef="Unit1" decimals="0">519000</aphb:ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense>
  <aphb:ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense id="Item-201" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember" unitRef="Unit1" decimals="0">111000</aphb:ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense>
  <aphb:IncreaseInSharesReservedForFutureIssuance id="Item-206" contextRef="As_Of_1_1_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member" unitRef="Unit12" decimals="0">474946</aphb:IncreaseInSharesReservedForFutureIssuance>
  <aphb:LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment id="Item-46" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">-1546000</aphb:LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment>
  <aphb:LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment id="Item-45" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">-21000</aphb:LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment>
  <aphb:OfferingCostsIncludedInAccountsPayable id="Item-133" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">277000</aphb:OfferingCostsIncludedInAccountsPayable>
  <aphb:ProceedsFromEquityOfferingsGross id="Item-225" contextRef="Duration_1_12_2018_To_1_12_2018" unitRef="Unit1" decimals="-5">4000000</aphb:ProceedsFromEquityOfferingsGross>
  <aphb:ProceedsFromEquityOfferingsGross id="Item-204" contextRef="Duration_3_22_2018_To_3_22_2018" unitRef="Unit1" decimals="-5">3000000</aphb:ProceedsFromEquityOfferingsGross>
  <aphb:ProceedsFromEquityOfferingsGross id="Item-320" contextRef="Duration_10_16_2018_To_10_16_2018_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="-5">6800000</aphb:ProceedsFromEquityOfferingsGross>
  <aphb:ProceedsFromSaleAndExerciseOfWarrants id="Item-119" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">9353000</aphb:ProceedsFromSaleAndExerciseOfWarrants>
  <aphb:ProceedsFromSaleAndExerciseOfWarrants id="Item-118" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">6159000</aphb:ProceedsFromSaleAndExerciseOfWarrants>
  <aphb:ResearchAndDevelopmentBenefit id="Item-252" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">829000</aphb:ResearchAndDevelopmentBenefit>
  <aphb:SaleOfWarrantPricePerWarrant id="Item-323" contextRef="Duration_10_16_2018_To_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">0.39</aphb:SaleOfWarrantPricePerWarrant>
  <aphb:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock id="Item-308" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company had reserved shares of its common stock for future issuance as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares Reserved&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Employee stock purchase plan &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;47,172&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Available for future grants under the 2016 Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;447,127&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,294,827&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total shares reserved&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,938,290&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</aphb:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
  <aphb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi id="Item-162" contextRef="Duration_1_1_2018_To_9_30_2018">P8Y3M11D</aphb:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi>
  <aphb:SharesIssuedPursuantToAgreementFairValue id="Item-100" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">519000</aphb:SharesIssuedPursuantToAgreementFairValue>
  <aphb:WarrantExpirationDate id="Item-344" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice0.57Member">2021-11-22</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-347" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice1.50Member">2022-05-10</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-335" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice107.50Member">2020-03-16</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-332" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IiMember">2019-03-01</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-329" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IMember">2018-12-31</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-341" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice22.50Member">2021-06-03</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-338" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice40.50Member">2021-03-31</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationDate id="Item-326" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice82.50Member">2018-12-23</aphb:WarrantExpirationDate>
  <aphb:WarrantExpirationTermFollowingExercisableDate id="Item-89" contextRef="Duration_5_10_2017_To_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember">P5Y</aphb:WarrantExpirationTermFollowingExercisableDate>
  <aphb:WarrantExpirationTermFollowingExercisableDate id="Item-350" contextRef="Duration_10_16_2018_To_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P5Y</aphb:WarrantExpirationTermFollowingExercisableDate>
  <aphb:WarrantsExercisedDuringPeriod id="Item-221" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">217400</aphb:WarrantsExercisedDuringPeriod>
  <aphb:WarrantsExpiredDuringPeriod id="Item-224" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">19691</aphb:WarrantsExpiredDuringPeriod>
  <aphb:WarrantsPolicyTextBlock id="Item-200" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; Warrants are accounted for in accordance with the applicable accounting guidance provided in ASC 815 - &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; as either derivative liabilities or as equity instruments depending on the specific terms of the warrants. Liability-classified instruments are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations (see Note 4).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</aphb:WarrantsPolicyTextBlock>
  <dei:AmendmentFlag id="Item-358" contextRef="Duration_1_1_2018_To_9_30_2018">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Item-357" contextRef="Duration_1_1_2018_To_9_30_2018">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="Item-356" contextRef="Duration_1_1_2018_To_9_30_2018">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="Item-355" contextRef="Duration_1_1_2018_To_9_30_2018">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="Item-354" contextRef="Duration_1_1_2018_To_9_30_2018">2018-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="Item-353" contextRef="Duration_1_1_2018_To_9_30_2018">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="Item-359" contextRef="Duration_1_1_2018_To_9_30_2018">0000921114</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="Item-241" contextRef="As_Of_11_5_2018" unitRef="Unit12" decimals="INF">32293308</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="Item-361" contextRef="Duration_1_1_2018_To_9_30_2018">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="Item-360" contextRef="Duration_1_1_2018_To_9_30_2018">AmpliPhi Biosciences Corp</dei:EntityRegistrantName>
  <dei:TradingSymbol id="Item-362" contextRef="Duration_1_1_2018_To_9_30_2018">APHB</dei:TradingSymbol>
  <us-gaap:AccountsPayableCurrent id="Item-18" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">578000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="Item-17" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">714000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Item-20" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">1390000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="Item-19" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">1751000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital id="Item-32" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">401842000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="Item-31" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">408684000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-238" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">568000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-234" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="0">435000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-230" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="0">133000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-236" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">98000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-232" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="0">66000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-228" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="0">32000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-237" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">366000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-233" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="0">253000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-229" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="0">113000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-235" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">120000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-231" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit1" decimals="0">82000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Item-227" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit1" decimals="0">38000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfIntangibleAssets id="Item-104" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">23000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AmortizationOfIntangibleAssets id="Item-103" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">23000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-147" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">9872031</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-143" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">523210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-137" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">1116765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-141" contextRef="Duration_1_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="0">8232056</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-145" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">10352195</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-142" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">523210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-135" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">1116765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-139" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="0">8712220</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-146" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">9443991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-136" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">1149164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-140" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="0">8294827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-144" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">9275493</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-134" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="Unit12" decimals="0">1149164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Item-138" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="0">8126329</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AssetImpairmentCharges id="Item-106" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">5800000</us-gaap:AssetImpairmentCharges>
  <us-gaap:Assets id="Item-16" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">11138000</us-gaap:Assets>
  <us-gaap:Assets id="Item-15" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">10619000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="Item-8" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">5385000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Item-7" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">5114000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="Item-150" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; included in the Company&amp;#x2019;s Annual Report on Form&amp;nbsp;10&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8209;K, filed with the SEC. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&amp;#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-130" contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="0">5711000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-132" contextRef="As_Of_9_30_2017" unitRef="Unit1" decimals="0">7725000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-129" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">5132000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Item-131" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">4499000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Item-128" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">2014000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Item-127" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-633000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-316" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember" unitRef="Unit13" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-86" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember" unitRef="Unit13" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-245" contextRef="As_Of_9_30_2018" unitRef="Unit13" decimals="2">2.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-343" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice0.57Member" unitRef="Unit13" decimals="2">0.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-346" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice1.50Member" unitRef="Unit13" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-334" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice107.50Member" unitRef="Unit13" decimals="2">107.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-331" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IiMember" unitRef="Unit13" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-328" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IMember" unitRef="Unit13" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-340" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice22.50Member" unitRef="Unit13" decimals="2">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-337" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice40.50Member" unitRef="Unit13" decimals="2">40.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-325" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice82.50Member" unitRef="Unit13" decimals="2">82.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-216" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Item-317" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Item-84" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember" unitRef="Unit12" decimals="0">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="Item-305" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Item-311" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember" unitRef="Unit12" decimals="0">8000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Item-1" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember" unitRef="Unit12" decimals="0">4483334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Item-222" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">17500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Item-209" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">2125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-348" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">8294827</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-342" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice0.57Member" unitRef="Unit12" decimals="0">168498</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-345" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice1.50Member" unitRef="Unit12" decimals="0">7920933</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-333" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice107.50Member" unitRef="Unit12" decimals="0">41872</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-330" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IiMember" unitRef="Unit12" decimals="0">8492</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-327" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice120.00IMember" unitRef="Unit12" decimals="0">8492</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-339" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice22.50Member" unitRef="Unit12" decimals="0">106381</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-336" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice40.50Member" unitRef="Unit12" decimals="0">31519</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Item-324" contextRef="As_Of_9_30_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_ExercisePrice82.50Member" unitRef="Unit12" decimals="0">8640</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Item-215" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;8.&amp;nbsp;&amp;nbsp;Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&amp;#x2019;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&amp;#x2019;s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management&amp;#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Item-214" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">9938290</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Item-82" contextRef="As_Of_12_31_2017" unitRef="Unit13" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Item-83" contextRef="As_Of_9_30_2018" unitRef="Unit13" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Item-152" contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="INF">67000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="Item-151" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="INF">67000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Item-203" contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="INF">9498928</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Item-248" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="INF">16468308</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="Item-239" contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="INF">9498928</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Item-148" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="INF">16468308</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue id="Item-30" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">95000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="Item-29" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">165000</us-gaap:CommonStockValue>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="Item-107" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-1302000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="Item-26" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">1147000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent id="Item-25" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">1147000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Depreciation id="Item-102" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">255000</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Item-101" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">268000</us-gaap:Depreciation>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-195" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">292000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-187" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember" unitRef="Unit1" decimals="0">32000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-191" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">260000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-192" contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-193" contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-194" contextRef="As_Of_12_31_2017_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">292000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-184" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-185" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-186" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">32000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-188" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-189" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-190" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">260000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-183" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">154000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-175" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember" unitRef="Unit1" decimals="0">18000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-179" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">136000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-180" contextRef="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-181" contextRef="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-182" contextRef="As_Of_9_30_2018_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">154000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-172" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-173" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-174" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">18000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-176" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability xsi:nil="true" id="Item-177" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="Unit1" />
  <us-gaap:DerivativeFairValueOfDerivativeLiability id="Item-178" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="Unit1" decimals="0">136000</us-gaap:DerivativeFairValueOfDerivativeLiability>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="Item-271" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">1997000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="Item-269" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-37000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="Item-270" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-46000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DerivativeGainLossOnDerivativeNet id="Item-268" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">31000</us-gaap:DerivativeGainLossOnDerivativeNet>
  <us-gaap:DerivativeLiabilities id="Item-70" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">292000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Item-68" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember" unitRef="Unit1" decimals="0">32000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Item-69" contextRef="As_Of_12_31_2017_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">260000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Item-78" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">154000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Item-76" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember" unitRef="Unit1" decimals="0">18000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Item-77" contextRef="As_Of_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">136000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativesAndFairValueTextBlock id="Item-310" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;4. Fair Value Measurements&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The guidance regarding fair value measurements prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:12pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:13.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Symbol;font-size:10pt;"&gt;&amp;#xF0B7;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:544.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Level&amp;nbsp;1&amp;#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:12pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:13.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Symbol;font-size:10pt;"&gt;&amp;#xF0B7;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:544.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Level&amp;nbsp;2&amp;#x2014;Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:12pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:13.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Symbol;font-size:10pt;"&gt;&amp;#xF0B7;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:544.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Level&amp;nbsp;3&amp;#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company estimates the fair values of derivative liabilities utilizing Level 3 inputs. No derivative liabilities have been transferred between the classification levels. Estimating the fair values of derivative liabilities requires the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; The recurring fair value measurements of the Company&amp;#x2019;s derivative liabilities at September 30, 2018 and December 31, 2017 consisted of the following: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Quoted&amp;nbsp;Prices&amp;nbsp;in&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Active&amp;nbsp;Markets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Significant&amp;nbsp;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Significant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;for&amp;nbsp;Identical&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Observable&amp;nbsp;Inputs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Unobservable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Items&amp;nbsp;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Inputs&amp;nbsp;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following table sets forth a summary of changes in the fair value of the Company's derivative liabilities:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;June 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;November 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt; Offering&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Offering&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt; Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Changes in estimated fair value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(14,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;46,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Exercised warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(184,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(184,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company estimates the fair value of the June 2016 offering warrant liability at each reporting date using the Black-Scholes valuation model. Inputs used in this valuation model include the Company&amp;#x2019;s stock price volatility, risk-free interest rates and expected term of the warrants. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Historically, the Company estimated the fair value of the November 2016 offering warrant liability at each reporting date using the Monte Carlo valuation model. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Inputs used in the Monte Carlo valuation model included the Company&amp;#x2019;s stock price volatility, risk-free interest rates and expected term of the warrants. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Effective March 31, 2018, due primarily to the significant decrease in the number of warrants outstanding, the Company simplified the method used and changed to the Black Scholes valuation model, which approximates the Monte Carlo valuation model.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DerivativesAndFairValueTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="Item-304" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;7. Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Stock Option Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In June 2016, the Company&amp;#x2019;s stockholders approved the 2016 Equity Incentive Plan (the &amp;#x201C;2016 Plan&amp;#x201D;). The 2016 Plan provides for the issuance of incentive awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&amp;#x2019;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; years from the date of grant and generally vest and typically become exercisable over a &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;-year period following the date of grant. Upon the exercise of stock options, the Company issues the resulting shares from shares reserved for issuance under the 2016 Plan. With the approval of the 2016 Plan, the remaining unallocated shares under the Company&amp;#x2019;s 2013 Stock Incentive Plan were allocated to the 2016 Plan and an additional &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;100,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; new shares were added to the authorized share reserve under the 2016 Plan. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;beginning January 1, 2017 and through January 1, 2026. On January 1, 2018, the number of shares of common stock authorized for future issuance was automatically increased by &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;474,946&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Share-based Compensation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite service period. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;background-color:lime;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The table below summarizes the total stock-based compensation expense included in the Company&amp;#x2019;s consolidated statements of operations for the periods presented: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Three Months Ended September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Nine Months Ended September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;38,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;133,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;82,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;66,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;253,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;435,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;98,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;366,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;568,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock option transactions during the nine months ended September 30, 2018 are presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;(Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,115,865&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.17&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.98&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;36,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Forfeited/Cancelled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3,201)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;11.02&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Outstanding at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.08&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.28&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;118,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vested and expected to vest at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;864,051&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.80&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.03&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;90,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Exercisable at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;361,773&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6.20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6.77&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;39,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15.1pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The aggregate intrinsic value of options at September 30, 2018 is based on the Company&amp;#x2019;s closing stock price on that date of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.01&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share. As of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$0.7&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;million of total unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over the weighted average remaining period of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Shares Reserved For Future Issuance&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company had reserved shares of its common stock for future issuance as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares Reserved&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock options outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Employee stock purchase plan &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;47,172&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Available for future grants under the 2016 Plan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;447,127&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,294,827&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total shares reserved&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,938,290&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasic id="Item-290" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit13" decimals="2">-1.97</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="Item-288" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit13" decimals="2">-0.09</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="Item-289" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">-0.51</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic id="Item-287" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">-0.10</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted id="Item-298" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit13" decimals="2">-2.18</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="Item-296" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit13" decimals="2">-0.09</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="Item-297" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">-0.51</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted id="Item-295" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">-0.10</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareTextBlock id="Item-149" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;5. Net Loss per Share &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Nine Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Basic and diluted net loss per share calculation:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,606,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(779,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7,790,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(10,486,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Change in fair value of November 2016 warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(21,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,546,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,627,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(779,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7,790,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(12,032,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Weighted average shares outstanding, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16,468,308&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,874,813&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15,418,146&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,326,139&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss per share, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.10)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.09)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.51)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1.97)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Weighted average&amp;nbsp;&amp;nbsp;shares outstanding, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16,496,957&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,874,813&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15,418,146&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,518,847&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.10)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.09)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.51)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2.18)
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following outstanding securities at &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; have been excluded from the computation of diluted weighted average shares outstanding for the three and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;nine months&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, as they would have been anti-dilutive: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Nine Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,116,765&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,116,765&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,126,329&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,712,220&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,294,827&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,232,056&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Common stock (Note 6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;523,210&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;523,210&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,275,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10,352,195&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,443,991&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,872,031&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Item-352" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="Item-91" contextRef="As_Of_9_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="-5">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares id="Item-211" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">47172</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares>
  <us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP id="Item-88" contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member" unitRef="Unit12" decimals="0">100000</us-gaap:EmployeeStockOwnershipPlanESOPSharesContributedToESOP>
  <us-gaap:FairValueAdjustmentOfWarrants id="Item-75" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">184000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants id="Item-74" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">184000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock id="Item-226" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following table sets forth a summary of changes in the fair value of the Company's derivative liabilities:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;June 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;November 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt; Offering&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Offering&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt; Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, December&amp;nbsp;31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Changes in estimated fair value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(14,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;46,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Exercised warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(184,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(184,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="Item-14" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">276000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet id="Item-13" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">253000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-258" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">6295000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-256" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">1613000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-257" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">4227000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-255" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">1276000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Item-281" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-11788000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Item-279" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Item-280" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-7790000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="Item-278" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-1606000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="Item-218" contextRef="Duration_7_1_2017_To_9_30_2017_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember" unitRef="Unit1" decimals="-5">2000000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:IncomeTaxCreditsAndAdjustments id="Item-81" contextRef="Duration_7_1_2018_To_9_30_2018_us-gaap_IncomeTaxAuthorityNameAxis_us-gaap_AustralianTaxationOfficeMember" unitRef="Unit1" decimals="-5">1200000</us-gaap:IncomeTaxCreditsAndAdjustments>
  <us-gaap:IncomeTaxExpenseBenefit id="Item-282" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-1302000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Item-109" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-595000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="Item-108" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">218000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Item-111" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-370000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Item-110" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">85000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="Item-12" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">4661000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="Item-11" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">4661000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:Liabilities id="Item-28" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">3407000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Item-27" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">3766000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Item-38" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">11138000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Item-37" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">10619000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="Item-22" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">1968000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Item-21" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">2465000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesFairValueAdjustment id="Item-73" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">46000</us-gaap:LiabilitiesFairValueAdjustment>
  <us-gaap:LiabilitiesFairValueAdjustment id="Item-71" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_June2016OfferingLiabilityMember" unitRef="Unit1" decimals="0">-14000</us-gaap:LiabilitiesFairValueAdjustment>
  <us-gaap:LiabilitiesFairValueAdjustment id="Item-72" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_DerivativeInstrumentRiskAxis_aphb_November2016WarrantDerivativeLiabilityMember" unitRef="Unit1" decimals="0">60000</us-gaap:LiabilitiesFairValueAdjustment>
  <us-gaap:LicenseAndServicesRevenue id="Item-250" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">95000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="Item-249" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">38000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Item-126" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">8877000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="Item-125" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">6362000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Item-117" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-40000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="Item-116" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-41000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Item-113" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-6823000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="Item-112" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-6954000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="Item-286" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-10486000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Item-284" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-779000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Item-285" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-7790000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Item-283" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-1606000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAttributableToParentDiluted id="Item-50" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-12032000</us-gaap:NetIncomeLossAttributableToParentDiluted>
  <us-gaap:NetIncomeLossAttributableToParentDiluted id="Item-48" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-779000</us-gaap:NetIncomeLossAttributableToParentDiluted>
  <us-gaap:NetIncomeLossAttributableToParentDiluted id="Item-49" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-7790000</us-gaap:NetIncomeLossAttributableToParentDiluted>
  <us-gaap:NetIncomeLossAttributableToParentDiluted id="Item-47" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-1627000</us-gaap:NetIncomeLossAttributableToParentDiluted>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Item-205" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In February 2015, the FASB issued ASU No. 2016-02,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Leases (Topic 842)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and mandates a modified retrospective transition method. The Company plans to adopt this ASU on January 1, 2019. While the Company is still evaluating the timing and impact of the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase in the assets and liabilities recorded on its consolidated balance sheet. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;.&amp;nbsp;&amp;nbsp;ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&amp;#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively, and is effective for calendar year end companies in 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. Adoption of this ASU is not expected to have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;. The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted this ASU as of January 1, 2018 using the modified retrospective approach. As of January 1, 2018, the Company had no revenue contracts and therefore the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;Cash Flow Statements, Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, which addresses eight specific cash flow classification issues with the objective of reducing diversity in practice. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification.&amp;nbsp;&amp;nbsp;Part I of ASU No. 2017-11, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Accounting for Certain Financial Instruments with Down Round Features&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company elected to early adopt this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements.&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#FFFFFF;font-size:1pt;"&gt;a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;Nonemployee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU as &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;of June 30, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingExpenses id="Item-263" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">13886000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Item-261" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">784000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Item-262" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">7744000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Item-260" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">1637000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Item-267" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-13791000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Item-265" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-746000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Item-266" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-7744000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Item-264" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-1637000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Item-85" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;1. Organization and Description of the Business&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;AmpliPhi Biosciences Corporation (the &amp;#x201C;Company&amp;#x201D;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company is dedicated to developing novel antibacterial therapies called bacteriophage (phage). Phages are naturally occurring viruses that preferentially bind to and kill their bacterial targets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherNoncashExpense id="Item-105" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">22000</us-gaap:OtherNoncashExpense>
  <us-gaap:OtherNonoperatingIncome id="Item-273" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">6000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncome id="Item-272" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">4000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:OtherNonoperatingIncomeExpense id="Item-277" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">2003000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="Item-275" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">-33000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="Item-276" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">-46000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="Item-274" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">31000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonrecurringExpense id="Item-259" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">5800000</us-gaap:OtherNonrecurringExpense>
  <us-gaap:PaymentsOfStockIssuanceCosts id="Item-2" contextRef="Duration_5_10_2017_To_5_10_2017" unitRef="Unit1" decimals="-5">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Item-115" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Item-114" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">41000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Item-6" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">253000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Item-5" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">615000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="Item-123" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">3000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions id="Item-122" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">5000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="Item-349" contextRef="Duration_5_10_2017_To_5_10_2017" unitRef="Unit1" decimals="-5">9400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="Item-313" contextRef="Duration_1_12_2018_To_1_12_2018" unitRef="Unit1" decimals="-5">3400000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity id="Item-93" contextRef="Duration_3_22_2018_To_3_22_2018" unitRef="Unit1" decimals="-5">2800000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromWarrantExercises id="Item-121" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">31000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises id="Item-306" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">198000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentNet id="Item-10" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">816000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Item-9" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">591000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="Item-351" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;9. Related Party &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;On March 22, 2018, the Company completed a registered direct offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;2,743,640&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; per share, including &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;181,820&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares sold to One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II (&amp;#x201C;One Funds&amp;#x201D;). Two members of the Company&amp;#x2019;s board of directors are affiliated with One Funds.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfNotesPayable id="Item-124" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">510000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-254" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">1791000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-253" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">3517000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-251" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">361000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="Item-309" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Research and Development Expenses &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian tax authority (&amp;#x201C;AU Tax Rebates&amp;#x201D;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty of receipt. The Company received AU Tax Rebates of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$2.0&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million during the three months ended September 30, 2018 and 2017, respectively.&amp;nbsp;&amp;nbsp;AU Tax Rebates of $1.2 million have been recorded as an offset to research and development expense in the Company&amp;#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2018. AU Tax Rebates of $2.0 million have been recorded as an offset to research and development expense in the Company&amp;#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Item-34" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">-394206000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Item-33" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">-401996000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-207" contextRef="Duration_5_10_2017_To_5_10_2017" unitRef="Unit12" decimals="0">2584085</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-199" contextRef="Duration_1_12_2018_To_1_12_2018" unitRef="Unit12" decimals="0">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-90" contextRef="Duration_3_22_2018_To_3_22_2018" unitRef="Unit12" decimals="0">2743640</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-247" contextRef="Duration_3_22_2018_To_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsManagementLimitedMember" unitRef="Unit12" decimals="0">181820</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-312" contextRef="Duration_3_22_2018_To_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsMember" unitRef="Unit12" decimals="0">2743640</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction id="Item-223" contextRef="Duration_10_16_2018_To_10_16_2018_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">14875000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockPricePerShare id="Item-92" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember" unitRef="Unit13" decimals="2">1.50</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-202" contextRef="As_Of_5_10_2017_us-gaap_ClassOfWarrantOrRightAxis_aphb_PreFundedWarrantMember" unitRef="Unit13" decimals="2">1.49</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-197" contextRef="As_Of_1_12_2018" unitRef="Unit13" decimals="2">1.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-307" contextRef="As_Of_3_22_2018" unitRef="Unit13" decimals="2">1.10</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-40" contextRef="As_Of_3_22_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_aphb_OneFundsMember" unitRef="Unit13" decimals="2">1.10</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare id="Item-246" contextRef="As_Of_10_16_2018_us-gaap_ClassOfWarrantOrRightAxis_aphb_CommonWarrantMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="2">0.40</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="Item-303" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following outstanding securities at &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; have been excluded from the computation of diluted weighted average shares outstanding for the three and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;nine months&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, as they would have been anti-dilutive: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Nine Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,116,765&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,116,765&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,126,329&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,712,220&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,294,827&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,232,056&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Common stock (Note 6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;523,210&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;523,210&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,275,493&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10,352,195&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,443,991&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,872,031&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock id="Item-87" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The recurring fair value measurements of the Company&amp;#x2019;s derivative liabilities at September 30, 2018 and December 31, 2017 consisted of the following: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Quoted&amp;nbsp;Prices&amp;nbsp;in&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Active&amp;nbsp;Markets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Significant&amp;nbsp;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Significant&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;for&amp;nbsp;Identical&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Observable&amp;nbsp;Inputs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Unobservable&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Items&amp;nbsp;(Level&amp;nbsp;1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;(Level&amp;nbsp;2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Inputs&amp;nbsp;(Level&amp;nbsp;3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;18,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;136,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;154,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 2016 offering warrant liability&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;260,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;292,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="Item-220" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Nine Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Basic and diluted net loss per share calculation:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,606,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(779,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7,790,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(10,486,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Change in fair value of November 2016 warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(21,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,546,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,627,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(779,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(7,790,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(12,032,000)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Weighted average shares outstanding, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16,468,308&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,874,813&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15,418,146&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,326,139&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss per share, basic &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.10)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.09)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.51)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1.97)
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Weighted average&amp;nbsp;&amp;nbsp;shares outstanding, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16,496,957&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,874,813&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15,418,146&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,518,847&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Net loss per share, diluted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.10)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.09)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.51)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2.18)
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Item-198" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The table below summarizes the total stock-based compensation expense included in the Company&amp;#x2019;s consolidated statements of operations for the periods presented: &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Three Months Ended September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Nine Months Ended September 30, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;38,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;32,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;133,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;82,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;66,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;253,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;435,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;98,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;366,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;568,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="Item-318" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock option transactions during the nine months ended September 30, 2018 are presented below:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Term&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;(Years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,115,865&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.17&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.98&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;36,500&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Forfeited/Cancelled&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3,201)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;11.02&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Outstanding at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,149,164&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.08&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.28&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;118,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vested and expected to vest at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;864,051&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3.80&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8.03&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;90,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Exercisable at September 30, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;361,773&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6.20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;6.77&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;39,000&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Item-322" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;At September 30, 2018, outstanding warrants to purchase shares of common stock, accounted for as equity or liabilities, are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares Underlying&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,640&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;82.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 23, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 41,872&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;107.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 16, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 31,519&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;40.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 106,381&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 3, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 168,498&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.57&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; (1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 22, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 7,920,933&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;May 10, 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,294,827&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensation id="Item-99" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit1" decimals="0">568000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Item-98" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit1" decimals="0">366000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="Item-196" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="Item-219" contextRef="Duration_1_1_2018_To_9_30_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Item-212" contextRef="As_Of_9_30_2018_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_aphb_EquityIncentivePlan2016Member" unitRef="Unit12" decimals="0">447127</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="Item-171" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">39000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="Item-168" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">361773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="Item-169" contextRef="As_Of_9_30_2018" unitRef="Unit13" decimals="2">6.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="Item-170" contextRef="Duration_1_1_2018_To_9_30_2018">P6Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="Item-158" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">3201</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="Item-156" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">36500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="Item-163" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">118000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Item-153" contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="0">1115865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="Item-210" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">1149164</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Item-154" contextRef="As_Of_12_31_2017" unitRef="Unit13" decimals="2">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="Item-161" contextRef="As_Of_9_30_2018" unitRef="Unit13" decimals="2">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="Item-155" contextRef="Duration_1_1_2017_To_12_31_2017">P8Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="Item-167" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="Item-164" contextRef="As_Of_9_30_2018" unitRef="Unit12" decimals="0">864051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="Item-165" contextRef="As_Of_9_30_2018" unitRef="Unit13" decimals="2">3.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="Item-166" contextRef="Duration_1_1_2018_To_9_30_2018">P8Y11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="Item-159" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">11.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="Item-157" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit13" decimals="2">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharePrice id="Item-314" contextRef="As_Of_9_19_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember" unitRef="Unit13" decimals="2">0.99</us-gaap:SharePrice>
  <us-gaap:SharePrice id="Item-242" contextRef="As_Of_9_30_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="2">1.01</us-gaap:SharePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Item-315" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;3. Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company&amp;#x2019;s significant accounting policies are described in Note 3 to the consolidated financial statements included in the Company&amp;#x2019;s Annual Report on Form 10-K for the year ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, filed with the Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;). Since the date of those financial statements, there have been no material changes to the Company&amp;#x2019;s significant accounting policies. The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited, Ampliphi &lt;/font&gt;&lt;font style="display: inline;font-family:Times-Roman;font-size:10pt;"&gt;Biotehnolo&amp;#x161;ke Raziskave in Razvoj&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying unaudited consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; included in the Company&amp;#x2019;s Annual Report on Form&amp;nbsp;10&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8209;K, filed with the SEC. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&amp;#x201C;U.S. GAAP&amp;#x201D;) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&amp;#x201C;ASC&amp;#x201D;) and Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) of the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&amp;#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#x2019;s estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Research and Development Expenses &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian tax authority (&amp;#x201C;AU Tax Rebates&amp;#x201D;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty of receipt. The Company received AU Tax Rebates of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$2.0&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million during the three months ended September 30, 2018 and 2017, respectively.&amp;nbsp;&amp;nbsp;AU Tax Rebates of $1.2 million have been recorded as an offset to research and development expense in the Company&amp;#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2018. AU Tax Rebates of $2.0 million have been recorded as an offset to research and development expense in the Company&amp;#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; Warrants are accounted for in accordance with the applicable accounting guidance provided in ASC 815 - &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; as either derivative liabilities or as equity instruments depending on the specific terms of the warrants. Liability-classified instruments are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations (see Note 4).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In February 2015, the FASB issued ASU No. 2016-02,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Leases (Topic 842)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and mandates a modified retrospective transition method. The Company plans to adopt this ASU on January 1, 2019. While the Company is still evaluating the timing and impact of the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase in the assets and liabilities recorded on its consolidated balance sheet. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;.&amp;nbsp;&amp;nbsp;ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&amp;#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively, and is effective for calendar year end companies in 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. Adoption of this ASU is not expected to have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Recently Adopted Accounting Standards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt; Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;. The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted this ASU as of January 1, 2018 using the modified retrospective approach. As of January 1, 2018, the Company had no revenue contracts and therefore the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;Cash Flow Statements, Classification of Certain Cash Receipts and Cash Payments&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, which addresses eight specific cash flow classification issues with the objective of reducing diversity in practice. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification.&amp;nbsp;&amp;nbsp;Part I of ASU No. 2017-11, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Accounting for Certain Financial Instruments with Down Round Features&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company elected to early adopt this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements.&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#FFFFFF;font-size:1pt;"&gt;a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;In June 2018, the FASB issued ASU No. 2018-07, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;Nonemployee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU as &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;of June 30, 2018 and the adoption did not have an impact on the Company&amp;#x2019;s consolidated financial statements&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="Item-36" contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="0">7731000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Item-35" contextRef="As_Of_9_30_2018" unitRef="Unit1" decimals="0">6853000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Item-321" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;6.&amp;nbsp;&amp;nbsp;Stockholders&amp;#x2019; Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Underwritten Public Offering of Common Stock, Pre-funded Warrants and Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;On May 10, 2017, the Company completed an underwritten public offering and sold &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2,584,085&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of its common stock and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;4,483,334&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; pre-funded warrants to purchase common stock in lieu of additional shares of common stock, and common warrants to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;8,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of common stock. All of the pre-funded warrants were exercised during the year ended December 31, 2017. The combined price to the public for each share of common stock and accompanying common warrant was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.50.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; The combined price to the public for each pre-funded warrant and accompanying common warrant was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.49&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&amp;nbsp;&amp;nbsp;Each pre-funded warrant was exercisable for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; share of common stock at an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share. The common warrants are exercisable at a price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.50&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share of common stock, and will expire &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; years from the date of issuance. The Company received net proceeds from the offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;approximately $9.4&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million, after deducting &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million in offering costs including the underwriting discount and commissions and other offering expenses payable by the Company. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company evaluated the pre-funded warrants and common warrants issued in the May 2017 offering and determined that the warrants should be classified as equity instruments. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;"&gt;Registered Offerings of Common Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;On January 12, 2018, the Company completed a registered public offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;4,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares of its common stock at an offering price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$1.00&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; per share, for aggregate gross proceeds of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$4.0&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million. The Company received net proceeds from the offering of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$3.4&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million, after deducting placement agent fees and other offering expenses payable by the Company. On March 22, 2018, the Company completed a registered direct offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;2,743,640&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares of its common stock at an offering price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$1.10&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; per share, for aggregate gross proceeds of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$3.0&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million. The Company received net proceeds from the offering of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$2.8&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; million, after deducting placement agent fees and other offering expenses payable by the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Common Stock Issuance Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;On April 8, 2016, the Company entered into the Common Stock Issuance Agreement (the &amp;#x201C;CSIA&amp;#x201D;) with certain former holders of the Company&amp;#x2019;s Series B redeemable convertible preferred stock (the &amp;#x201C;Holders&amp;#x201D;). Pursuant to terms of the CSIA, the Company agreed to issue a formula-based number of shares of its common stock to the Holders for no additional consideration upon completion of one or more bona fide equity financings in which the Company sells shares of its common stock below a specified price (a &amp;#x201C;Dilutive Issuance&amp;#x201D;) in a transaction that occurs prior to the earlier of June 30, 2018 or such time as the Company has raised, following the date of the CSIA, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$10.0&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million in the aggregate (the &amp;#x201C;Price Protection Obligations&amp;#x201D;). In each of June 2016, November 2016 and May 2017, the Company completed offerings of its common stock that constituted Dilutive Issuances under the CSIA. Due in part to limitations on the number of shares issuable to the Holders under the rules of the NYSE American, no additional shares of common stock were issued to the holders in connection with the November 2016 and May 2017 offerings prior to June 2017.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;On June 27, 2017, the Company and the Holders entered into an amendment to the CSIA (the &amp;#x201C;Amendment&amp;#x201D;) to, among other things, terminate the Price Protection Obligations. In consideration for the termination of the Price Protection Obligations and a release of claims by the Holders, the Company agreed to (i) issue to the Holders, within five business days of the Amendment, an aggregate of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;28,684&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of its common stock (the &amp;#x201C;First Issuance&amp;#x201D;), which, under the rules of the NYSE American, was the maximum number of shares the Company was permitted to issue to the Holders pursuant to the CSIA without further shareholder approval, and (ii) issue to the Holders in a subsequent closing an aggregate &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;523,210&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of common stock (the &amp;#x201C;Second Issuance&amp;#x201D;), subject to obtaining shareholder approval of the Second Issuance at the Company&amp;#x2019;s 2017 Annual Meeting of Shareholders and the Company&amp;#x2019;s receipt of a release of claims from the Holders at the time of the Second Issuance. On September 7, 2017 the Company&amp;#x2019;s shareholders approved the Second Issuance. The Company received a release of claims from each of the Holders and issued &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;523,210&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of common stock on September 19, 2017. The shares were valued at &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$519,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; as of September 19, 2017 based on the closing price of the Company&amp;#x2019;s common stock of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$0.99&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share at September 19, 2017 multiplied by the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;523,210&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of common stock issued to the Holders. The related charges of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$111,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$519,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; were included as a component of general and administrative expense in the Company&amp;#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Warrants &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;At September 30, 2018, outstanding warrants to purchase shares of common stock, accounted for as equity or liabilities, are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Shares Underlying&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;Date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,640&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;82.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 23, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;120.00&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 41,872&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;107.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 16, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 31,519&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;40.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 31, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 106,381&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 3, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 168,498&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.57&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; (1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;November 22, 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 7,920,933&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.50&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;May 10, 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; 8,294,827&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:12pt;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;p style="width:36pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 100%;text-indent:0pt;"&gt;
			&lt;p style="line-height:12pt;font-family:Calibri;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;line-height:12pt;font-family:Calibri;font-size:10pt;;;padding:0pt 25pt 0pt 0pt;"&gt; (1)&lt;/font&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The exercise price of the warrants is subject to adjustment upon future dilutive issuances of the Company&amp;#x2019;s common stock and stock combination events as defined in an exercise price adjustment provision in the warrant agreements&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The exercise price will be adjusted downward due to an event subsequent to September 30, 2018 (see Note 10).&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 36pt;line-height:12pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the nine months ended September 30, 2018, warrants to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;217,400&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of the Company&amp;#x2019;s common stock, originally issued in connection with the November 2016 and May 2017 public offerings, were exercised for proceeds to the Company of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$198,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. During the nine months ended September 30, 2018, warrants to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;19,691&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of the Company&amp;#x2019;s common stock expired. The weighted average exercise price of outstanding warrants to purchase common stock at September 30, 2018 was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2.76&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="Item-80" contextRef="Duration_6_27_2017_To_6_27_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementMember" unitRef="Unit12" decimals="0">28684</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesOther id="Item-243" contextRef="Duration_9_19_2017_To_9_19_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember" unitRef="Unit12" decimals="0">523210</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther id="Item-79" contextRef="Duration_9_19_2017_To_9_19_2017_us-gaap_TypeOfArrangementAxis_aphb_CommonStockIssuanceAgreementSecondIssuanceMember" unitRef="Unit1" decimals="0">519000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:SubsequentEventsTextBlock id="Item-244" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;10. Subsequent Event&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;On &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;October 16&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;, the Company completed an underwritten public offering and sold &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;14,875,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares of its common stock and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;2,125,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; pre-funded warrants to purchase common stock&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;and common warrants&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;17,500,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; shares of common stock&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;. The combined price to the public for each share of common stock and accompanying common warrant was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$0.40&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; combined&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; price to the public for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;each pre-funded warrant and accompanying common warrant was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$0.39&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;. Each pre-funded warrant is exercisable for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; share of common stock at an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; per share. The common warrants are exercisable at a price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;0.40&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; per share of common stock, and will expire &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; years from the date of issuance. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company received aggregate gross proceeds from the offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$6.8&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million, before deducting the underwriting discount and commissions and other offering expenses payable by the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock id="Item-240" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2. Liquidity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 11pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&amp;#x2019;s ability to continue as a going concern.&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 11pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As of September 30, 2018, the Company had cash and cash equivalents of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$4.5&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; On October 16, 2018, the Company completed an underwritten public offering of common stock, pre-funded warrants and common warrants. The Company received aggregate gross proceeds from the offering of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$6.8&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; million, before deducting the underwriting discount and commissions and other offering expenses payable by the Company (see Note 10). &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Considering the Company&amp;#x2019;s current cash resources, including the net proceeds received from the public offering in October 2018, management believes the Company&amp;#x2019;s existing resources will be sufficient to fund the Company&amp;#x2019;s planned operations until mid-2019. For the foreseeable future, the Company&amp;#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:UseOfEstimates id="Item-217" contextRef="Duration_1_1_2018_To_9_30_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&amp;#x2019;s estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Item-302" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">5518847</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Item-300" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">8874813</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Item-301" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">15418146</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding id="Item-299" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">16496957</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Item-294" contextRef="Duration_1_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">5326139</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Item-292" contextRef="Duration_7_1_2017_To_9_30_2017" unitRef="Unit12" decimals="0">8874813</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Item-293" contextRef="Duration_1_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">15418146</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="Item-291" contextRef="Duration_7_1_2018_To_9_30_2018" unitRef="Unit12" decimals="0">16468308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <!--Extensible List Section-->
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>aphb-20180930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:22 PM-->
<!--Modified on: 11/8/2018 1:27:22 PM-->
<schema targetNamespace="http://www.ampliphibio.com/20180930" elementFormDefault="qualified" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:aphb="http://www.ampliphibio.com/20180930">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" id="DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails">
        <link:definition>40705 - Disclosure - Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00050 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00150 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" id="DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureLiquidity" id="DisclosureLiquidity">
        <link:definition>10201 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10501 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10701 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureRelatedParty" id="DisclosureRelatedParty">
        <link:definition>10901 - Disclosure - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>11001 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>30503 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30603 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30703 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails" id="DisclosureLiquidityNarrativeDetails">
        <link:definition>40201 - Disclosure - Liquidity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>40402 - Disclosure - Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" id="DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails">
        <link:definition>40403 - Disclosure - Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" id="DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails">
        <link:definition>40501 - Disclosure - Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" id="DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails">
        <link:definition>40502 - Disclosure - Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40601 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" id="DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails">
        <link:definition>40602 - Disclosure - Stockholders' Equity (Summary of Warrants Outstanding) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails" id="DisclosureStockBasedCompensationNarrativeDetails">
        <link:definition>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails">
        <link:definition>40703 - Disclosure - Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>40704 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails" id="DisclosureRelatedPartyDetails">
        <link:definition>40901 - Disclosure - Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails" id="DisclosureSubsequentEventDetails">
        <link:definition>41001 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="aphb-20180930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aphb-20180930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aphb-20180930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="aphb-20180930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aphb_DocumentAndEntityInformationAbstract" />
  <element id="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="DerivativesAndFairValueTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="aphb_DerivativesAndFairValueTable" />
  <element name="DerivativesAndFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aphb_DerivativesAndFairValueLineItems" />
  <element name="ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" />
  <element id="aphb_WarrantExpirationDate" name="WarrantExpirationDate" nillable="true" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_WarrantsExercisedDuringPeriod" name="WarrantsExercisedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_LiquidityAbstract" name="LiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="aphb_CommonStockIssuanceAgreementMember" name="CommonStockIssuanceAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_June2016OfferingLiabilityMember" name="June2016OfferingLiabilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_EquityIncentivePlan2016Member" name="EquityIncentivePlan2016Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_November2016WarrantDerivativeLiabilityMember" name="November2016WarrantDerivativeLiabilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ProceedsFromEquityOfferingsGross" name="ProceedsFromEquityOfferingsGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="aphb_WarrantExpirationTermFollowingExercisableDate" name="WarrantExpirationTermFollowingExercisableDate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_IncreaseInSharesReservedForFutureIssuance" name="IncreaseInSharesReservedForFutureIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="aphb_PreFundedWarrantMember" name="PreFundedWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_CommonWarrantMember" name="CommonWarrantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ProceedsFromSaleAndExerciseOfWarrants" name="ProceedsFromSaleAndExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="aphb_OfferingCostsIncludedInAccountsPayable" name="OfferingCostsIncludedInAccountsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="aphb_ExercisePrice82.50Member" name="ExercisePrice82.50Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice107.50Member" name="ExercisePrice107.50Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice40.50Member" name="ExercisePrice40.50Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice120.00IMember" name="ExercisePrice120.00IMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice120.00IiMember" name="ExercisePrice120.00IiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice22.50Member" name="ExercisePrice22.50Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice1.50Member" name="ExercisePrice1.50Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_CapitalRaisedLimitForPriceProtectionObligation" name="CapitalRaisedLimitForPriceProtectionObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" name="LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="aphb_CommonStockIssuanceAgreementSecondIssuanceMember" name="CommonStockIssuanceAgreementSecondIssuanceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ExercisePrice0.57Member" name="ExercisePrice0.57Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_OneFundsMember" name="OneFundsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_OneFundsManagementLimitedMember" name="OneFundsManagementLimitedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_WarrantsExpiredDuringPeriod" name="WarrantsExpiredDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_SharesIssuedPursuantToAgreementFairValue" name="SharesIssuedPursuantToAgreementFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" name="ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="aphb_SaleOfWarrantPricePerWarrant" name="SaleOfWarrantPricePerWarrant" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="aphb_ResearchAndDevelopmentBenefit" name="ResearchAndDevelopmentBenefit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>aphb-20180930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:22 PM-->
<!--Modified on: 11/8/2018 1:27:22 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquity" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" />
  <calculationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636772804417838875" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636772804417838875" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_636772804417838875" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636772804417838875" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636772804417838875" xlink:to="us-gaap_CommonStockValue_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636772804417838875" xlink:to="us-gaap_AdditionalPaidInCapital_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636772804417838875" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636772804417838875" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636772804417838875" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804417838875" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636772804417838875" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636772804417838875" xlink:to="us-gaap_LiabilitiesCurrent_636772804417838875" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636772804417838875" xlink:to="us-gaap_AccountsPayableCurrent_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636772804417838875" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636772804417838875" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636772804417838875" xlink:to="us-gaap_OperatingIncomeLoss_636772804417838875" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636772804417838875" xlink:to="us-gaap_LicenseAndServicesRevenue_636772804417838875" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636772804417838875" xlink:to="us-gaap_OperatingExpenses_636772804417838875" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636772804417838875" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636772804417838875" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ResearchAndDevelopmentBenefit" xlink:label="aphb_ResearchAndDevelopmentBenefit_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636772804417838875" xlink:to="aphb_ResearchAndDevelopmentBenefit_636772804417838875" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636772804417838875" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636772804417838875" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="us-gaap_OtherNonrecurringExpense_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636772804417838875" xlink:to="us-gaap_OtherNonrecurringExpense_636772804417838875" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636772804417838875" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636772804417838875" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_636772804417838875" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_636772804417838875" xlink:to="us-gaap_OtherNonoperatingIncome_636772804417838875" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636772804417838875" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636772804417838875" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_NetIncomeLoss_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_636772804417838875" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_ShareBasedCompensation_636772804417838875" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_AssetImpairmentCharges_636772804417838875" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_636772804417838875" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SharesIssuedPursuantToAgreementFairValue" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="aphb_SharesIssuedPursuantToAgreementFairValue_636772804417838875" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_AmortizationOfIntangibleAssets_636772804417838875" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_Depreciation_636772804417838875" order="8" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_OtherNoncashExpense_636772804417838875" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636772804417838875" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804417838875" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636772804417838875" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636772804417838875" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636772804417838875" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636772804417838875" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromSaleAndExerciseOfWarrants" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" xlink:to="aphb_ProceedsFromSaleAndExerciseOfWarrants_636772804417838875" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" xlink:to="us-gaap_ProceedsFromWarrantExercises_636772804417838875" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636772804417838875" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804417838875" xlink:to="us-gaap_RepaymentsOfNotesPayable_636772804417838875" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804417838875" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_636772804417838875" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636772804417838875" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636772804417838875" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636772804417838875" order="4" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>aphb-20180930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:22 PM-->
<!--Modified on: 11/8/2018 1:27:22 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureLiquidityNarrativeDetails" roleURI="http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureRelatedPartyDetails" roleURI="http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSubsequentEventDetails" roleURI="http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636772804417994587" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_636772804417994587" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="aphb_ProceedsFromEquityOfferingsGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_636772804417994587" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_636772804417994587" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueTable" xlink:label="aphb_DerivativesAndFairValueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="aphb_DerivativesAndFairValueTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804417994587" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804417994587" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="aphb_DerivativesAndFairValueTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_636772804417994587" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_636772804417994587" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_June2016OfferingLiabilityMember" xlink:label="aphb_June2016OfferingLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="aphb_June2016OfferingLiabilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:label="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:to="aphb_DerivativesAndFairValueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueTable" xlink:label="aphb_DerivativesAndFairValueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="aphb_DerivativesAndFairValueTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_June2016OfferingLiabilityMember" xlink:label="aphb_June2016OfferingLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="aphb_June2016OfferingLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueLineItems" xlink:label="aphb_DerivativesAndFairValueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="aphb_DerivativesAndFairValueLineItems" xlink:to="aphb_DerivativesAndFairValueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="aphb_DerivativesAndFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="aphb_DerivativesAndFairValueLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="aphb_DerivativesAndFairValueLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToParentDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418150299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418150299" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636772804418150299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636772804418150299" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_PreFundedWarrantMember" xlink:label="aphb_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_PreFundedWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonWarrantMember" xlink:label="aphb_CommonWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_CommonWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418150299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418150299" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementMember" xlink:label="aphb_CommonStockIssuanceAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aphb_CommonStockIssuanceAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementSecondIssuanceMember" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="aphb_CommonStockIssuanceAgreementSecondIssuanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636772804418150299" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636772804418150299" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationTermFollowingExercisableDate" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_WarrantExpirationTermFollowingExercisableDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_ProceedsFromEquityOfferingsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CapitalRaisedLimitForPriceProtectionObligation" xlink:label="aphb_CapitalRaisedLimitForPriceProtectionObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_CapitalRaisedLimitForPriceProtectionObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" xlink:label="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExercisedDuringPeriod" xlink:label="aphb_WarrantsExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_WarrantsExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExpiredDuringPeriod" xlink:label="aphb_WarrantsExpiredDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="aphb_WarrantsExpiredDuringPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders' Equity (Summary of Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice82.50Member" xlink:label="aphb_ExercisePrice82.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice82.50Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice107.50Member" xlink:label="aphb_ExercisePrice107.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice107.50Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice40.50Member" xlink:label="aphb_ExercisePrice40.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice40.50Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IMember" xlink:label="aphb_ExercisePrice120.00IMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice120.00IMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IiMember" xlink:label="aphb_ExercisePrice120.00IiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice120.00IiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice22.50Member" xlink:label="aphb_ExercisePrice22.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice22.50Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice0.57Member" xlink:label="aphb_ExercisePrice0.57Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice0.57Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice1.50Member" xlink:label="aphb_ExercisePrice1.50Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_ExercisePrice1.50Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationDate" xlink:label="aphb_WarrantExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="aphb_WarrantExpirationDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804418306011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804418306011" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_EquityIncentivePlan2016Member" xlink:label="aphb_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="aphb_EquityIncentivePlan2016Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636772804418306011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636772804418306011" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_IncreaseInSharesReservedForFutureIssuance" xlink:label="aphb_IncreaseInSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="aphb_IncreaseInSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_EquityIncentivePlan2016Member" xlink:label="aphb_EquityIncentivePlan2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="aphb_EquityIncentivePlan2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636772804418306011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_636772804418306011" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsMember" xlink:label="aphb_OneFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aphb_OneFundsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsManagementLimitedMember" xlink:label="aphb_OneFundsManagementLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="aphb_OneFundsManagementLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Subsequent Event (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_PreFundedWarrantMember" xlink:label="aphb_PreFundedWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_PreFundedWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonWarrantMember" xlink:label="aphb_CommonWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="aphb_CommonWarrantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SaleOfWarrantPricePerWarrant" xlink:label="aphb_SaleOfWarrantPricePerWarrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="aphb_SaleOfWarrantPricePerWarrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationTermFollowingExercisableDate" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="aphb_WarrantExpirationTermFollowingExercisableDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="aphb_ProceedsFromEquityOfferingsGross" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>aphb-20180930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:22 PM-->
<!--Modified on: 11/8/2018 1:27:22 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DocumentAndEntityInformationAbstract" xlink:label="aphb_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="aphb_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">In-process research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Acquired patents, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value; 67,000,000 shares authorized at September 30, 2018 and December 31, 2017; 16,468,308 and 9,498,928 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statement of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xml:lang="en-US">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development (benefit)</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ResearchAndDevelopmentBenefit" xlink:label="aphb_ResearchAndDevelopmentBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ResearchAndDevelopmentBenefit" xlink:to="aphb_ResearchAndDevelopmentBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ResearchAndDevelopmentBenefit_lbl" xml:lang="en-US">The aggregate benefit incurred during the reporting period as a result of research and development activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ResearchAndDevelopmentBenefit_lbl" xml:lang="en-US">Research and development benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aphb_ResearchAndDevelopmentBenefit_lbl" xml:lang="en-US">Research and development benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="us-gaap_OtherNonrecurringExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonrecurringExpense" xlink:to="us-gaap_OtherNonrecurringExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonrecurringExpense_lbl" xml:lang="en-US">Other Nonrecurring Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonrecurringExpense_lbl" xml:lang="en-US">Impairment charges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Basic and diluted net loss per common share calculation:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Per share information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SharesIssuedPursuantToAgreementFairValue" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_SharesIssuedPursuantToAgreementFairValue" xlink:to="aphb_SharesIssuedPursuantToAgreementFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue_lbl" xml:lang="en-US">Fair value of shares issued pursuant to agreements with certain shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue_lbl" xml:lang="en-US">Shares issued pursuant to agreement, fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue_lbl" xml:lang="en-US">Charge for common stock issuance (Note 6)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Other Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Other non-cash adjustments, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Financing activities:</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromSaleAndExerciseOfWarrants" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ProceedsFromSaleAndExerciseOfWarrants" xlink:to="aphb_ProceedsFromSaleAndExerciseOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants_lbl" xml:lang="en-US">Represents the cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) as well as the cash inflow associated with the amount received from holders exercising their stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from sale and exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from sale of common stock and related warrants, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercises of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Proceeds from stock issuance under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on note payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental schedule of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OfferingCostsIncludedInAccountsPayable" xlink:label="aphb_OfferingCostsIncludedInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_OfferingCostsIncludedInAccountsPayable" xlink:to="aphb_OfferingCostsIncludedInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_OfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Represents the portion of offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_OfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Offering costs included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of the Business [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of the Business</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiquidityAbstract" xlink:label="aphb_LiquidityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_LiquidityAbstract" xlink:to="aphb_LiquidityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_LiquidityAbstract_lbl" xml:lang="en-US">Liquidity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:to="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsPolicyTextBlock" xlink:label="aphb_WarrantsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_WarrantsPolicyTextBlock" xlink:to="aphb_WarrantsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy pertaining to warrants, in accordance with guidance provided in ASC 815 - Derivatives and Hedging, to determine whether a given instrument is clasified as a derivative liability or as an equity instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueTable" xlink:label="aphb_DerivativesAndFairValueTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_DerivativesAndFairValueTable" xlink:to="aphb_DerivativesAndFairValueTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_DerivativesAndFairValueTable_lbl" xml:lang="en-US">Derivatives And Fair Value [Table]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueLineItems" xlink:label="aphb_DerivativesAndFairValueLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_DerivativesAndFairValueLineItems" xlink:to="aphb_DerivativesAndFairValueLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_DerivativesAndFairValueLineItems_lbl" xml:lang="en-US">Derivatives And Fair Value [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Liabilities Measured at Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Changes in Fair Value of Derivative Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of Basic and Diluted Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of Warrant Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Allocation of Stock-Based Compensation Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Stock Option Activity</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of components of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US">Shares Reserved for Future Issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ProceedsFromEquityOfferingsGross" xlink:to="aphb_ProceedsFromEquityOfferingsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ProceedsFromEquityOfferingsGross_lbl" xml:lang="en-US">The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ProceedsFromEquityOfferingsGross_lbl" xml:lang="en-US">Proceeds from equity offerings, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian Taxation Office [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xml:lang="en-US">Australian Taxation Office [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Income Tax Credits and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_lbl" xml:lang="en-US">Tax rebates received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value Inputs Level2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_June2016OfferingLiabilityMember" xlink:label="aphb_June2016OfferingLiabilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_June2016OfferingLiabilityMember" xlink:to="aphb_June2016OfferingLiabilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_June2016OfferingLiabilityMember_lbl" xml:lang="en-US">June 2016 Offering Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_June2016OfferingLiabilityMember_lbl" xml:lang="en-US">June2016 Offering Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_June2016OfferingLiabilityMember_lbl" xml:lang="en-US">June 2016 Offering Liability [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_November2016WarrantDerivativeLiabilityMember" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_lbl" xml:lang="en-US">November 2016 Warrant Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_lbl" xml:lang="en-US">November2016 Warrant Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_lbl" xml:lang="en-US">November 2016 Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:label="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:to="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems_lbl" xml:lang="en-US">Schedule Of Derivative Liabilities At Fair Value [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Balance, derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Balance, derivative liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Changes in estimated fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Exercised warrants</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" xlink:to="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_lbl" xml:lang="en-US">Amount of addition (reduction) to the amount at whicha liability could be incurred (settled) in a current transaction between willing parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_lbl" xml:lang="en-US">Liabilities Fair Value Adjustment Including Exercise Price Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_lbl" xml:lang="en-US">Changes in estimated fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:to="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_lbl" xml:lang="en-US">Net loss, diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant Liability [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of diluted weighted shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_PreFundedWarrantMember" xlink:label="aphb_PreFundedWarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_PreFundedWarrantMember" xlink:to="aphb_PreFundedWarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre Funded Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_PreFundedWarrantMember_lbl" xml:lang="en-US">Pre-Funded Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonWarrantMember" xlink:label="aphb_CommonWarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_CommonWarrantMember" xlink:to="aphb_CommonWarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_CommonWarrantMember_lbl" xml:lang="en-US">Common Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_CommonWarrantMember_lbl" xml:lang="en-US">Common Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_CommonWarrantMember_lbl" xml:lang="en-US">Common Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementMember" xlink:label="aphb_CommonStockIssuanceAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_CommonStockIssuanceAgreementMember" xlink:to="aphb_CommonStockIssuanceAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_CommonStockIssuanceAgreementMember_lbl" xml:lang="en-US">Common Stock Issuance Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_CommonStockIssuanceAgreementMember_lbl" xml:lang="en-US">Common Stock Issuance Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_CommonStockIssuanceAgreementMember_lbl" xml:lang="en-US">Common Stock Issuance Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementSecondIssuanceMember" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_CommonStockIssuanceAgreementSecondIssuanceMember" xlink:to="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_lbl" xml:lang="en-US">Common Stock Issuance Agreement Second Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_lbl" xml:lang="en-US">Common Stock Issuance Agreement Second Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_lbl" xml:lang="en-US">CSIA Second Issuance [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock, number of shares issued in transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of securities called by warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of stock, price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Number of shares called by each warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationTermFollowingExercisableDate" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_WarrantExpirationTermFollowingExercisableDate" xlink:to="aphb_WarrantExpirationTermFollowingExercisableDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate_lbl" xml:lang="en-US">The expiration term of warrants issued, expressed as the period of time following the date of effectiveness of the warrants or initial date warrants become exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate_lbl" xml:lang="en-US">Warrant Expiration Term Following Exercisable Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate_lbl" xml:lang="en-US">Expiration term of warrants (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Net proceeds from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Offering costs</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CapitalRaisedLimitForPriceProtectionObligation" xlink:label="aphb_CapitalRaisedLimitForPriceProtectionObligation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_CapitalRaisedLimitForPriceProtectionObligation" xlink:to="aphb_CapitalRaisedLimitForPriceProtectionObligation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_CapitalRaisedLimitForPriceProtectionObligation_lbl" xml:lang="en-US">Represents the amount of capital that must be raised before the Price Protection Obligation ceases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_CapitalRaisedLimitForPriceProtectionObligation_lbl" xml:lang="en-US">Capital raised limit for Price Protection Obligation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued per agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Value of common stock issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Common stock closing price</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" xlink:label="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" xlink:to="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Represents charges related to common stock issued to parties and included in general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Charges related to common stock included in general and administrative expense</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExercisedDuringPeriod" xlink:label="aphb_WarrantsExercisedDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_WarrantsExercisedDuringPeriod" xlink:to="aphb_WarrantsExercisedDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_WarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Represents the number of securities called by warrants that were exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_WarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Shares, Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_WarrantsExercisedDuringPeriod_lbl" xml:lang="en-US">Warrants exercised during period</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExpiredDuringPeriod" xlink:label="aphb_WarrantsExpiredDuringPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_WarrantsExpiredDuringPeriod" xlink:to="aphb_WarrantsExpiredDuringPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_WarrantsExpiredDuringPeriod_lbl" xml:lang="en-US">Represents the number of warrants to purchase shares of stock that expired during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_WarrantsExpiredDuringPeriod_lbl" xml:lang="en-US">Warrants expired during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice82.50Member" xlink:label="aphb_ExercisePrice82.50Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice82.50Member" xlink:to="aphb_ExercisePrice82.50Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice82.50Member_lbl" xml:lang="en-US">Exercise Price 82.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice82.50Member_lbl" xml:lang="en-US">Exercise Price82.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice82.50Member_lbl" xml:lang="en-US">Exercise Price 82.50 [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice107.50Member" xlink:label="aphb_ExercisePrice107.50Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice107.50Member" xlink:to="aphb_ExercisePrice107.50Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice107.50Member_lbl" xml:lang="en-US">Exercise Price 107.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice107.50Member_lbl" xml:lang="en-US">Exercise Price107.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice107.50Member_lbl" xml:lang="en-US">Exercise Price 107.50 [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice40.50Member" xlink:label="aphb_ExercisePrice40.50Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice40.50Member" xlink:to="aphb_ExercisePrice40.50Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice40.50Member_lbl" xml:lang="en-US">Exercise Price 40.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice40.50Member_lbl" xml:lang="en-US">Exercise Price40.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice40.50Member_lbl" xml:lang="en-US">Exercise Price 40.50 [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IMember" xlink:label="aphb_ExercisePrice120.00IMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice120.00IMember" xlink:to="aphb_ExercisePrice120.00IMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice120.00IMember_lbl" xml:lang="en-US">Exercise Price 120.00 I [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice120.00IMember_lbl" xml:lang="en-US">Exercise Price120.00 I [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice120.00IMember_lbl" xml:lang="en-US">Exercise Price 120.00 I [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IiMember" xlink:label="aphb_ExercisePrice120.00IiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice120.00IiMember" xlink:to="aphb_ExercisePrice120.00IiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice120.00IiMember_lbl" xml:lang="en-US">Exercise Price 120.00 II [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice120.00IiMember_lbl" xml:lang="en-US">Exercise Price120.00 Ii [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice120.00IiMember_lbl" xml:lang="en-US">Exercise Price 120.00 II [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice22.50Member" xlink:label="aphb_ExercisePrice22.50Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice22.50Member" xlink:to="aphb_ExercisePrice22.50Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice22.50Member_lbl" xml:lang="en-US">Exercise Price 22.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice22.50Member_lbl" xml:lang="en-US">Exercise Price22.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice22.50Member_lbl" xml:lang="en-US">Exercise Price 22.50 [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice0.57Member" xlink:label="aphb_ExercisePrice0.57Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice0.57Member" xlink:to="aphb_ExercisePrice0.57Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice0.57Member_lbl" xml:lang="en-US">Exercise Price 0.57 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice0.57Member_lbl" xml:lang="en-US">Exercise Price0.57 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice0.57Member_lbl" xml:lang="en-US">Exercise Price 0.57 [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice1.50Member" xlink:label="aphb_ExercisePrice1.50Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_ExercisePrice1.50Member" xlink:to="aphb_ExercisePrice1.50Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_ExercisePrice1.50Member_lbl" xml:lang="en-US">Exercise Price 1.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_ExercisePrice1.50Member_lbl" xml:lang="en-US">Exercise Price1.50 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_ExercisePrice1.50Member_lbl" xml:lang="en-US">Exercise Price 1.50 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationDate" xlink:label="aphb_WarrantExpirationDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_WarrantExpirationDate" xlink:to="aphb_WarrantExpirationDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_WarrantExpirationDate_lbl" xml:lang="en-US">Represents the terms related with expiration of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_WarrantExpirationDate_lbl" xml:lang="en-US">Warrant Expiration Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan E S O P Plan [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_EquityIncentivePlan2016Member" xlink:label="aphb_EquityIncentivePlan2016Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_EquityIncentivePlan2016Member" xlink:to="aphb_EquityIncentivePlan2016Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_EquityIncentivePlan2016Member_lbl" xml:lang="en-US">Equity Incentive Plan 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period of share-based payment award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period of share-based compensation award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_lbl" xml:lang="en-US">Additional shares added to the Plan during period</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_IncreaseInSharesReservedForFutureIssuance" xlink:label="aphb_IncreaseInSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_IncreaseInSharesReservedForFutureIssuance" xlink:to="aphb_IncreaseInSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_IncreaseInSharesReservedForFutureIssuance_lbl" xml:lang="en-US">The increase in the number of shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_IncreaseInSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Increase in shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation cost related to unvested options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted-average remaining period for recognition of compensation costs related to unvested options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Balance at September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Balance at December 31, 2017</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Stock options outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Shares, Vested or expected to vest at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, Exercisable at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at December 31, 2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested or expected to vest at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Average Remaining Contractual Term (Years), Outstanding at December 31, 2017</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" xlink:label="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" xlink:to="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_lbl" xml:lang="en-US">Represents the weighted average remaining contractual term for options outstanding at end of reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_lbl" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term II</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_lbl" xml:lang="en-US">Average Remaining Contractual Term (Years), Outstanding at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Average Remaining Contractual Term (Years), Exercisable at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding at September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Outstanding at December 31, 2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Intrinsic Value, Vested or expected to vest at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic Value, Exercisable at September 30, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Committed-to-be-Released Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_lbl" xml:lang="en-US">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for future grants under the 2016 Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total shares reserved</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsMember" xlink:label="aphb_OneFundsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_OneFundsMember" xlink:to="aphb_OneFundsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_OneFundsMember_lbl" xml:lang="en-US">One Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_OneFundsMember_lbl" xml:lang="en-US">One Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_OneFundsMember_lbl" xml:lang="en-US">One Funds [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsManagementLimitedMember" xlink:label="aphb_OneFundsManagementLimitedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_OneFundsManagementLimitedMember" xlink:to="aphb_OneFundsManagementLimitedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_OneFundsManagementLimitedMember_lbl" xml:lang="en-US">One Funds Management Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_OneFundsManagementLimitedMember_lbl" xml:lang="en-US">One Funds Management Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="aphb_OneFundsManagementLimitedMember_lbl" xml:lang="en-US">One Funds Management Limited [Member]</label>
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SaleOfWarrantPricePerWarrant" xlink:label="aphb_SaleOfWarrantPricePerWarrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aphb_SaleOfWarrantPricePerWarrant" xlink:to="aphb_SaleOfWarrantPricePerWarrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aphb_SaleOfWarrantPricePerWarrant_lbl" xml:lang="en-US">Per warrant amount received for each warrant issued or sold in the transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aphb_SaleOfWarrantPricePerWarrant_lbl" xml:lang="en-US">Sale of warrant, price per warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>aphb-20180930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.23.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/8/2018 1:27:22 PM-->
<!--Modified on: 11/8/2018 1:27:22 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ampliphibio.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureOrganizationAndDescriptionOfBusiness" roleURI="http://www.ampliphibio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureLiquidity" roleURI="http://www.ampliphibio.com/role/DisclosureLiquidity" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurements" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurements" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerShare" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquity" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensation" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ampliphibio.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureRelatedParty" roleURI="http://www.ampliphibio.com/role/DisclosureRelatedParty" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSubsequentEvent" roleURI="http://www.ampliphibio.com/role/DisclosureSubsequentEvent" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerShareTables" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureLiquidityNarrativeDetails" roleURI="http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" roleURI="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" roleURI="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationNarrativeDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" roleURI="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureRelatedPartyDetails" roleURI="http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails" />
  <roleRef xlink:type="simple" xlink:href="aphb-20180930.xsd#DisclosureSubsequentEventDetails" roleURI="http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails" />
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00050 - Document - Document And Entity Information">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DocumentAndEntityInformationAbstract" xlink:label="aphb_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636772804418461723" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636772804418461723" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636772804418928859" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636772804418928859" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_636772804418928859" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636772804418928859" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_123" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_123" xlink:to="us-gaap_AssetsAbstract_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636772804418928859" xlink:to="us-gaap_AssetsCurrentAbstract_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636772804418928859" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636772804418928859" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636772804418928859" xlink:to="us-gaap_AssetsCurrent_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636772804418928859" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636772804418928859" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636772804418928859" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636772804418928859" xlink:to="us-gaap_Assets_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_123" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636772804418928859" xlink:to="us-gaap_AccountsPayableCurrent_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636772804418928859" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636772804418928859" xlink:to="us-gaap_LiabilitiesCurrent_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_Liabilities_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_StockholdersEquityAbstract_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_CommonStockValue_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_AdditionalPaidInCapital_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_StockholdersEquity_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636772804418928859" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00150 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_287" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesAuthorized_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesIssued_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_287" xlink:to="us-gaap_CommonStockSharesOutstanding_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_306" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_LicenseAndServicesRevenue_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OperatingExpensesAbstract_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636772804418928859" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ResearchAndDevelopmentBenefit" xlink:label="aphb_ResearchAndDevelopmentBenefit_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636772804418928859" xlink:to="aphb_ResearchAndDevelopmentBenefit_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636772804418928859" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="us-gaap_OtherNonrecurringExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636772804418928859" xlink:to="us-gaap_OtherNonrecurringExpense_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636772804418928859" xlink:to="us-gaap_OperatingExpenses_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OperatingIncomeLoss_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_OtherExpensesAbstract_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_636772804418928859" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_636772804418928859" xlink:to="us-gaap_OtherNonoperatingIncome_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract_636772804418928859" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_NetIncomeLoss_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636772804418928859" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_306" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_EarningsPerShareBasic_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_EarningsPerShareDiluted_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_372" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_NetIncomeLoss_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_ShareBasedCompensation_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SharesIssuedPursuantToAgreementFairValue" xlink:label="aphb_SharesIssuedPursuantToAgreementFairValue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="aphb_SharesIssuedPursuantToAgreementFairValue_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_Depreciation_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_AmortizationOfIntangibleAssets_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_OtherNoncashExpense_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_AssetImpairmentCharges_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_636772804418928859" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636772804418928859" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636772804418928859" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636772804418928859" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636772804418928859" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636772804418928859" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromSaleAndExerciseOfWarrants" xlink:label="aphb_ProceedsFromSaleAndExerciseOfWarrants_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="aphb_ProceedsFromSaleAndExerciseOfWarrants_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_ProceedsFromWarrantExercises_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_RepaymentsOfNotesPayable_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636772804418928859" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6367728044189288591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6367728044189288591" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_372" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OfferingCostsIncludedInAccountsPayable" xlink:label="aphb_OfferingCostsIncludedInAccountsPayable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636772804418928859" xlink:to="aphb_OfferingCostsIncludedInAccountsPayable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Description of the Business">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_440" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_440" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureLiquidity" xlink:type="extended" xlink:title="10201 - Disclosure - Liquidity">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiquidityAbstract" xlink:label="aphb_LiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_LiquidityAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_442" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_442" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_882" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_882" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10501 - Disclosure - Net Loss per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_684" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_684" xlink:to="us-gaap_EarningsPerShareTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10601 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10701 - Disclosure - Stock-Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_438" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_438" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureRelatedParty" xlink:type="extended" xlink:title="10901 - Disclosure - Related Party">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureSubsequentEvent" xlink:type="extended" xlink:title="11001 - Disclosure - Subsequent Event">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_467" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_467" xlink:to="us-gaap_SubsequentEventsTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_28" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28" xlink:to="us-gaap_UseOfEstimates_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsPolicyTextBlock" xlink:label="aphb_WarrantsPolicyTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28" xlink:to="aphb_WarrantsPolicyTextBlock_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_28" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_884" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_884" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_884" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="30503 - Disclosure - Net Loss per Share (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_687" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_687" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_687" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30603 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30703 - Disclosure - Stock-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_448" xlink:to="aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Liquidity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiquidityAbstract" xlink:label="aphb_LiquidityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_LiquidityAbstract" xlink:to="us-gaap_StatementTable_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_SubsequentEventTypeAxis_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636772804418928859" xlink:to="us-gaap_SubsequentEventTypeDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636772804418928859" xlink:to="us-gaap_SubsequentEventMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_StatementLineItems_636772804418928859" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804418928859" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804418928859" xlink:to="aphb_ProceedsFromEquityOfferingsGross_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Significant Accounting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis_636772804418928859" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain_636772804418928859" xlink:to="us-gaap_AustralianTaxationOfficeMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_StatementLineItems_636772804418928859" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxCreditsAndAdjustments" xlink:label="us-gaap_IncomeTaxCreditsAndAdjustments_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804418928859" xlink:to="us-gaap_IncomeTaxCreditsAndAdjustments_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_636772128789250618" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueTable" xlink:label="aphb_DerivativesAndFairValueTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_636772128789250618" xlink:to="aphb_DerivativesAndFairValueTable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueTable_636772804418928859" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_636772804418928859" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_636772804418928859" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804418928859" xlink:to="us-gaap_FairValueInputsLevel1Member_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804418928859" xlink:to="us-gaap_FairValueInputsLevel2Member_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636772804418928859" xlink:to="us-gaap_FairValueInputsLevel3Member_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueTable_636772804418928859" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" xlink:to="us-gaap_DerivativeContractTypeDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_June2016OfferingLiabilityMember" xlink:label="aphb_June2016OfferingLiabilityMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_636772804418928859" xlink:to="aphb_June2016OfferingLiabilityMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_636772804418928859" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems" xlink:label="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueTable_636772804418928859" xlink:to="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems_636772804418928859" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_917" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueTable" xlink:label="aphb_DerivativesAndFairValueTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract_917" xlink:to="aphb_DerivativesAndFairValueTable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueTable_636772804418928859" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" xlink:to="us-gaap_DerivativeContractTypeDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_June2016OfferingLiabilityMember" xlink:label="aphb_June2016OfferingLiabilityMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_636772804418928859" xlink:to="aphb_June2016OfferingLiabilityMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_636772804418928859" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_DerivativesAndFairValueLineItems" xlink:label="aphb_DerivativesAndFairValueLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueTable_636772804418928859" xlink:to="aphb_DerivativesAndFairValueLineItems_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueLineItems_636772804418928859" xlink:to="us-gaap_DerivativeLiabilities_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueLineItems_636772804418928859" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueLineItems_636772804418928859" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_6367728044189288591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="aphb_DerivativesAndFairValueLineItems_636772804418928859" xlink:to="us-gaap_DerivativeLiabilities_6367728044189288591" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1011" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1011" xlink:to="us-gaap_StatementTable_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_636772804418928859" xlink:to="us-gaap_DerivativeContractTypeDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_November2016WarrantDerivativeLiabilityMember" xlink:label="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_636772804418928859" xlink:to="aphb_November2016WarrantDerivativeLiabilityMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804418928859" xlink:to="us-gaap_StatementLineItems_636772804418928859" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804418928859" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_NetIncomeLoss_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment" xlink:label="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAttributableToParentDiluted" xlink:label="us-gaap_NetIncomeLossAttributableToParentDiluted_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_NetIncomeLossAttributableToParentDiluted_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_EarningsPerShareBasic_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636772804418928859" xlink:to="us-gaap_EarningsPerShareDiluted_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_690" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_690" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636772804418928859" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636772804418928859" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636772804418928859" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418928859" xlink:to="us-gaap_StockOptionMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418928859" xlink:to="us-gaap_WarrantMember_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636772804418928859" xlink:to="us-gaap_CommonStockMember_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636772804418928859" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636772804418928859" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_PreFundedWarrantMember" xlink:label="aphb_PreFundedWarrantMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_PreFundedWarrantMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonWarrantMember" xlink:label="aphb_CommonWarrantMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_CommonWarrantMember_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636772804418928859" xlink:to="us-gaap_TypeOfArrangementAxis_636772804418928859" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636772804418928859" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementMember" xlink:label="aphb_CommonStockIssuanceAgreementMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418928859" xlink:to="aphb_CommonStockIssuanceAgreementMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonStockIssuanceAgreementSecondIssuanceMember" xlink:label="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636772804418928859" xlink:to="aphb_CommonStockIssuanceAgreementSecondIssuanceMember_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636772804418928859" xlink:to="us-gaap_IncomeStatementLocationAxis_636772804418928859" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636772804418928859" xlink:to="us-gaap_IncomeStatementLocationDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636772804418928859" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember_636772804418928859" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636772804418928859" xlink:to="us-gaap_ClassOfStockLineItems_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_SaleOfStockPricePerShare_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationTermFollowingExercisableDate" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_WarrantExpirationTermFollowingExercisableDate_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636772804418928859" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_ProceedsFromEquityOfferingsGross_636772804418928859" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CapitalRaisedLimitForPriceProtectionObligation" xlink:label="aphb_CapitalRaisedLimitForPriceProtectionObligation_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_CapitalRaisedLimitForPriceProtectionObligation_636772804418928859" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_636772804418928859" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_636772804418928859" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_SharePrice_636772804418928859" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense" xlink:label="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense_636772804418928859" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExercisedDuringPeriod" xlink:label="aphb_WarrantsExercisedDuringPeriod_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_WarrantsExercisedDuringPeriod_636772804418928859" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="us-gaap_ProceedsFromWarrantExercises_636772804418928859" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantsExpiredDuringPeriod" xlink:label="aphb_WarrantsExpiredDuringPeriod_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636772804418928859" xlink:to="aphb_WarrantsExpiredDuringPeriod_636772804418928859" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Stockholders' Equity (Summary of Warrants Outstanding) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_831" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_831" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice82.50Member" xlink:label="aphb_ExercisePrice82.50Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice82.50Member_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice107.50Member" xlink:label="aphb_ExercisePrice107.50Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice107.50Member_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice40.50Member" xlink:label="aphb_ExercisePrice40.50Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice40.50Member_636772804418928859" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IMember" xlink:label="aphb_ExercisePrice120.00IMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice120.00IMember_636772804418928859" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice120.00IiMember" xlink:label="aphb_ExercisePrice120.00IiMember_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice120.00IiMember_636772804418928859" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice22.50Member" xlink:label="aphb_ExercisePrice22.50Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice22.50Member_636772804418928859" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice0.57Member" xlink:label="aphb_ExercisePrice0.57Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice0.57Member_636772804418928859" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ExercisePrice1.50Member" xlink:label="aphb_ExercisePrice1.50Member_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804418928859" xlink:to="aphb_ExercisePrice1.50Member_636772804418928859" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636772804418928859" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636772804418928859" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636772804418928859" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804418928859" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationDate" xlink:label="aphb_WarrantExpirationDate_636772804418928859" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636772804418928859" xlink:to="aphb_WarrantExpirationDate_636772804418928859" order="3" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_260" xlink:to="us-gaap_StatementTable_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_EquityIncentivePlan2016Member" xlink:label="aphb_EquityIncentivePlan2016Member_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" xlink:to="aphb_EquityIncentivePlan2016Member_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_AwardTypeAxis_636772804419084571" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636772804419084571" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636772804419084571" xlink:to="us-gaap_EmployeeStockOptionMember_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_StatementLineItems_636772804419084571" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP_636772804419084571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_IncreaseInSharesReservedForFutureIssuance" xlink:label="aphb_IncreaseInSharesReservedForFutureIssuance_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="aphb_IncreaseInSharesReservedForFutureIssuance_636772804419084571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SharePrice_636772804419084571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636772804419084571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636772804419084571" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_454" xlink:to="us-gaap_StatementTable_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_IncomeStatementLocationAxis_636772804419084571" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636772804419084571" xlink:to="us-gaap_IncomeStatementLocationDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636772804419084571" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636772804419084571" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636772804419084571" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40704 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636772804419084571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6367728044190845711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6367728044190845711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636772804419084571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636772804419084571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636772804419084571" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636772804419084571" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636772804419084571" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6367728044190845711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6367728044190845711" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636772804419084571" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636772804419084571" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636772804419084571" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi" xlink:label="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi_636772804419084571" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636772804419084571" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_636772804419084571" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636772804419084571" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6367728044190845711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6367728044190845711" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636772804419084571" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_220" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_636772804419084571" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails" xlink:type="extended" xlink:title="40705 - Disclosure - Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_247" xlink:to="us-gaap_StatementTable_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_EquityIncentivePlan2016Member" xlink:label="aphb_EquityIncentivePlan2016Member_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_636772804419084571" xlink:to="aphb_EquityIncentivePlan2016Member_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_StatementLineItems_636772804419084571" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636772804419084571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636772804419084571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_636772804419084571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_636616652293838334" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_636616652293838334" xlink:to="us-gaap_StatementTable_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636772804419084571" xlink:to="us-gaap_RelatedPartyDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsMember" xlink:label="aphb_OneFundsMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636772804419084571" xlink:to="aphb_OneFundsMember_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_OneFundsManagementLimitedMember" xlink:label="aphb_OneFundsManagementLimitedMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636772804419084571" xlink:to="aphb_OneFundsManagementLimitedMember_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_StatementLineItems_636772804419084571" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SaleOfStockPricePerShare_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Subsequent Event (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_StatementTable_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_SubsequentEventTypeAxis_636772804419084571" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636772804419084571" xlink:to="us-gaap_SubsequentEventTypeDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636772804419084571" xlink:to="us-gaap_SubsequentEventMember_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636772804419084571" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_PreFundedWarrantMember" xlink:label="aphb_PreFundedWarrantMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804419084571" xlink:to="aphb_PreFundedWarrantMember_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_CommonWarrantMember" xlink:label="aphb_CommonWarrantMember_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636772804419084571" xlink:to="aphb_CommonWarrantMember_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636772804419084571" xlink:to="us-gaap_StatementLineItems_636772804419084571" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636772804419084571" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636772804419084571" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636772804419084571" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_SaleOfStockPricePerShare_636772804419084571" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_SaleOfWarrantPricePerWarrant" xlink:label="aphb_SaleOfWarrantPricePerWarrant_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="aphb_SaleOfWarrantPricePerWarrant_636772804419084571" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636772804419084571" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_WarrantExpirationTermFollowingExercisableDate" xlink:label="aphb_WarrantExpirationTermFollowingExercisableDate_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="aphb_WarrantExpirationTermFollowingExercisableDate_636772804419084571" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="aphb-20180930.xsd#aphb_ProceedsFromEquityOfferingsGross" xlink:label="aphb_ProceedsFromEquityOfferingsGross_636772804419084571" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636772804419084571" xlink:to="aphb_ProceedsFromEquityOfferingsGross_636772804419084571" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795082960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Nov. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AmpliPhi Biosciences Corp<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000921114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APHB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,293,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795358464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,499,000<span></span>
</td>
<td class="nump">$ 5,132,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">615,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,114,000<span></span>
</td>
<td class="nump">5,385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">591,000<span></span>
</td>
<td class="nump">816,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research and development</a></td>
<td class="nump">4,661,000<span></span>
</td>
<td class="nump">4,661,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Acquired patents, net</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">10,619,000<span></span>
</td>
<td class="nump">11,138,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">714,000<span></span>
</td>
<td class="nump">578,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,751,000<span></span>
</td>
<td class="nump">1,390,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,465,000<span></span>
</td>
<td class="nump">1,968,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">1,147,000<span></span>
</td>
<td class="nump">1,147,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,766,000<span></span>
</td>
<td class="nump">3,407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 67,000,000 shares authorized at September 30, 2018 and December 31, 2017; 16,468,308 and 9,498,928 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">408,684,000<span></span>
</td>
<td class="nump">401,842,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(401,996,000)<span></span>
</td>
<td class="num">(394,206,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">6,853,000<span></span>
</td>
<td class="nump">7,731,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 10,619,000<span></span>
</td>
<td class="nump">$ 11,138,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795399824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,468,308<span></span>
</td>
<td class="nump">9,498,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,468,308<span></span>
</td>
<td class="nump">9,498,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795712256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statement of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (benefit)</a></td>
<td class="nump">$ 361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,517,000<span></span>
</td>
<td class="nump">1,791,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ResearchAndDevelopmentBenefit', window );">Research and development benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(829,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,276,000<span></span>
</td>
<td class="nump">1,613,000<span></span>
</td>
<td class="nump">4,227,000<span></span>
</td>
<td class="nump">6,295,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,637,000<span></span>
</td>
<td class="nump">784,000<span></span>
</td>
<td class="nump">7,744,000<span></span>
</td>
<td class="nump">13,886,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,637,000)<span></span>
</td>
<td class="num">(746,000)<span></span>
</td>
<td class="num">(7,744,000)<span></span>
</td>
<td class="num">(13,791,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="num">(37,000)<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="nump">1,997,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">31,000<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="num">(46,000)<span></span>
</td>
<td class="nump">2,003,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(1,606,000)<span></span>
</td>
<td class="num">(779,000)<span></span>
</td>
<td class="num">(7,790,000)<span></span>
</td>
<td class="num">(11,788,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,606,000)<span></span>
</td>
<td class="num">$ (779,000)<span></span>
</td>
<td class="num">$ (7,790,000)<span></span>
</td>
<td class="num">$ (10,486,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">16,468,308<span></span>
</td>
<td class="nump">8,874,813<span></span>
</td>
<td class="nump">15,418,146<span></span>
</td>
<td class="nump">5,326,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">16,496,957<span></span>
</td>
<td class="nump">8,874,813<span></span>
</td>
<td class="nump">15,418,146<span></span>
</td>
<td class="nump">5,518,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ResearchAndDevelopmentBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate benefit incurred during the reporting period as a result of research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ResearchAndDevelopmentBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64828382&amp;loc=d3e15138-107781<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795484592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,790,000)<span></span>
</td>
<td class="num">$ (10,486,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="num">(1,997,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="nump">568,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_SharesIssuedPursuantToAgreementFairValue', window );">Charge for common stock issuance (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">519,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">268,000<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patents</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Other non-cash adjustments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,302,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">218,000<span></span>
</td>
<td class="num">(595,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(85,000)<span></span>
</td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,954,000)<span></span>
</td>
<td class="num">(6,823,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromSaleAndExerciseOfWarrants', window );">Proceeds from sale of common stock and related warrants, net of offering costs</a></td>
<td class="nump">6,159,000<span></span>
</td>
<td class="nump">9,353,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of warrants</a></td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock issuance under employee stock purchase plan</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(510,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,362,000<span></span>
</td>
<td class="nump">8,877,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(633,000)<span></span>
</td>
<td class="nump">2,014,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">5,132,000<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">4,499,000<span></span>
</td>
<td class="nump">$ 7,725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_OfferingCostsIncludedInAccountsPayable', window );">Offering costs included in accounts payable</a></td>
<td class="nump">$ 277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_OfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_OfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ProceedsFromSaleAndExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt) as well as the cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ProceedsFromSaleAndExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_SharesIssuedPursuantToAgreementFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares issued pursuant to agreements with certain shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_SharesIssuedPursuantToAgreementFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based compensation arrangement. Issuance includes, but is not limited to, exercise of stock options and similar instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786503616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of the Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">1. Organization and Description of the Business</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">AmpliPhi Biosciences Corporation (the &#x201C;Company&#x201D;) was incorporated in the state of Washington in 1989 under the name Targeted Genetics Corporation. In February 2011, Targeted Genetics Corporation changed its name to AmpliPhi Biosciences Corporation. The Company is dedicated to developing novel antibacterial therapies called bacteriophage (phage). Phages are naturally occurring viruses that preferentially bind to and kill their bacterial targets.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617573840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2. Liquidity</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has prepared its consolidated financial statements on a going concern basis, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. However, the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company&#x2019;s ability to continue as a going concern.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As of September 30, 2018, the Company had cash and cash equivalents of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4.5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> On October 16, 2018, the Company completed an underwritten public offering of common stock, pre-funded warrants and common warrants. The Company received aggregate gross proceeds from the offering of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$6.8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million, before deducting the underwriting discount and commissions and other offering expenses payable by the Company (see Note 10). </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Considering the Company&#x2019;s current cash resources, including the net proceeds received from the public offering in October 2018, management believes the Company&#x2019;s existing resources will be sufficient to fund the Company&#x2019;s planned operations until mid-2019. For the foreseeable future, the Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786440592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">3. Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s significant accounting policies are described in Note 3 to the consolidated financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, filed with the Securities and Exchange Commission (&#x201C;SEC&#x201D;). Since the date of those financial statements, there have been no material changes to the Company&#x2019;s significant accounting policies. The interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries Biocontrol Limited, Ampliphi </font><font style="display: inline;font-family:Times-Roman;font-size:10pt;">Biotehnolo&#x161;ke Raziskave in Razvoj</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> d.o.o., and AmpliPhi Australia Pty Ltd. All significant intercompany accounts and transactions have been eliminated.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying unaudited consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included in the Company&#x2019;s Annual Report on Form&nbsp;10</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#8209;K, filed with the SEC. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201C;ASC&#x201D;) and Accounting Standards Update (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board (&#x201C;FASB&#x201D;).</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Research and Development Expenses </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian tax authority (&#x201C;AU Tax Rebates&#x201D;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty of receipt. The Company received AU Tax Rebates of approximately </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$1.2</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$2.0</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million during the three months ended September 30, 2018 and 2017, respectively.&nbsp;&nbsp;AU Tax Rebates of $1.2 million have been recorded as an offset to research and development expense in the Company&#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2018. AU Tax Rebates of $2.0 million have been recorded as an offset to research and development expense in the Company&#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Warrants </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> Warrants are accounted for in accordance with the applicable accounting guidance provided in ASC 815 - </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Derivatives and Hedging</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> as either derivative liabilities or as equity instruments depending on the specific terms of the warrants. Liability-classified instruments are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations (see Note 4).</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Recent Accounting Pronouncements Not Yet Adopted</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In February 2015, the FASB issued ASU No. 2016-02,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Leases (Topic 842)</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and mandates a modified retrospective transition method. The Company plans to adopt this ASU on January 1, 2019. While the Company is still evaluating the timing and impact of the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase in the assets and liabilities recorded on its consolidated balance sheet. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.&nbsp;&nbsp;ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively, and is effective for calendar year end companies in 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. Adoption of this ASU is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Recently Adopted Accounting Standards</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Revenue from Contracts with Customers (Topic 606)</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">. The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted this ASU as of January 1, 2018 using the modified retrospective approach. As of January 1, 2018, the Company had no revenue contracts and therefore the adoption did not have an impact on the Company&#x2019;s consolidated financial statements. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Cash Flow Statements, Classification of Certain Cash Receipts and Cash Payments</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which addresses eight specific cash flow classification issues with the objective of reducing diversity in practice. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification.&nbsp;&nbsp;Part I of ASU No. 2017-11, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Accounting for Certain Financial Instruments with Down Round Features</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company elected to early adopt this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements.&nbsp; </font><font style="display: inline;font-family:Times New Roman;color:#FFFFFF;font-size:1pt;">a</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Compensation - Stock Compensation (Topic 718): Improvements to </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Nonemployee Share-Based Payment Accounting</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU as </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">of June 30, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615860176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">4. Fair Value Measurements&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The guidance regarding fair value measurements prioritizes the inputs used in measuring fair value and establishes a three-tier value hierarchy that distinguishes among the following: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:18.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt">
						<font style="display: inline;font-family:Times New Roman;font-size:12pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:13.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Symbol;font-size:10pt;">&#xF0B7;</font></p>
				</td>
				<td valign="top" style="width:544.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Level&nbsp;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:18.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt">
						<font style="display: inline;font-family:Times New Roman;font-size:12pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:13.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Symbol;font-size:10pt;">&#xF0B7;</font></p>
				</td>
				<td valign="top" style="width:544.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Level&nbsp;2&#x2014;Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:18.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 12pt">
						<font style="display: inline;font-family:Times New Roman;font-size:12pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:13.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Symbol;font-size:10pt;">&#xF0B7;</font></p>
				</td>
				<td valign="top" style="width:544.50pt;padding:0pt;">
					<p style="margin:0pt 0.8pt 0pt 0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Level&nbsp;3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company estimates the fair values of derivative liabilities utilizing Level 3 inputs. No derivative liabilities have been transferred between the classification levels. Estimating the fair values of derivative liabilities requires the use of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The recurring fair value measurements of the Company&#x2019;s derivative liabilities at September 30, 2018 and December 31, 2017 consisted of the following: </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Quoted&nbsp;Prices&nbsp;in</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Active&nbsp;Markets</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Significant&nbsp;Other</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Significant</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">for&nbsp;Identical</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Observable&nbsp;Inputs</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Unobservable</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Items&nbsp;(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Inputs&nbsp;(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following table sets forth a summary of changes in the fair value of the Company's derivative liabilities:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">June 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">November 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> Offering</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Offering</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrant</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrant</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Derivative</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Changes in estimated fair value</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,000)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exercised warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(184,000)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(184,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company estimates the fair value of the June 2016 offering warrant liability at each reporting date using the Black-Scholes valuation model. Inputs used in this valuation model include the Company&#x2019;s stock price volatility, risk-free interest rates and expected term of the warrants. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Historically, the Company estimated the fair value of the November 2016 offering warrant liability at each reporting date using the Monte Carlo valuation model. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Inputs used in the Monte Carlo valuation model included the Company&#x2019;s stock price volatility, risk-free interest rates and expected term of the warrants. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Effective March 31, 2018, due primarily to the significant decrease in the number of warrants outstanding, the Company simplified the method used and changed to the Black Scholes valuation model, which approximates the Monte Carlo valuation model.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786487104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">5. Net Loss per Share </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Nine Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">September 30, </font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Basic and diluted net loss per share calculation:</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,606,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(779,000)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7,790,000)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,486,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Change in fair value of November 2016 warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(21,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,546,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,627,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(779,000)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7,790,000)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(12,032,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Weighted average shares outstanding, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16,468,308&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,874,813&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15,418,146&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,326,139&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss per share, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.10)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.09)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.51)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1.97)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Weighted average&nbsp;&nbsp;shares outstanding, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16,496,957&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,874,813&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15,418,146&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,518,847&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.10)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.09)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.51)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2.18)
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following outstanding securities at </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> have been excluded from the computation of diluted weighted average shares outstanding for the three and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">nine months</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, as they would have been anti-dilutive: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Nine Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, </font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,116,765&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,116,765&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,126,329&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,712,220&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,294,827&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,232,056&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Common stock (Note 6)</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">523,210&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">523,210&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,275,493&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,352,195&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,443,991&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,872,031&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615941216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">6.&nbsp;&nbsp;Stockholders&#x2019; Equity</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Underwritten Public Offering of Common Stock, Pre-funded Warrants and Warrants</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On May 10, 2017, the Company completed an underwritten public offering and sold </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2,584,085</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of its common stock and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,483,334</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> pre-funded warrants to purchase common stock in lieu of additional shares of common stock, and common warrants to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of common stock. All of the pre-funded warrants were exercised during the year ended December 31, 2017. The combined price to the public for each share of common stock and accompanying common warrant was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.50.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The combined price to the public for each pre-funded warrant and accompanying common warrant was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.49</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Each pre-funded warrant was exercisable for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">one</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> share of common stock at an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.01</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. The common warrants are exercisable at a price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.50</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share of common stock, and will expire </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years from the date of issuance. The Company received net proceeds from the offering of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">approximately $9.4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million, after deducting </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million in offering costs including the underwriting discount and commissions and other offering expenses payable by the Company. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company evaluated the pre-funded warrants and common warrants issued in the May 2017 offering and determined that the warrants should be classified as equity instruments. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Registered Offerings of Common Stock</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:12.95pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">On January 12, 2018, the Company completed a registered public offering of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">4,000,000</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares of its common stock at an offering price of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$1.00</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> per share, for aggregate gross proceeds of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$4.0</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million. The Company received net proceeds from the offering of approximately </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$3.4</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million, after deducting placement agent fees and other offering expenses payable by the Company. On March 22, 2018, the Company completed a registered direct offering of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">2,743,640</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares of its common stock at an offering price of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$1.10</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> per share, for aggregate gross proceeds of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$3.0</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million. The Company received net proceeds from the offering of approximately </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$2.8</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million, after deducting placement agent fees and other offering expenses payable by the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Common Stock Issuance Agreement</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On April 8, 2016, the Company entered into the Common Stock Issuance Agreement (the &#x201C;CSIA&#x201D;) with certain former holders of the Company&#x2019;s Series B redeemable convertible preferred stock (the &#x201C;Holders&#x201D;). Pursuant to terms of the CSIA, the Company agreed to issue a formula-based number of shares of its common stock to the Holders for no additional consideration upon completion of one or more bona fide equity financings in which the Company sells shares of its common stock below a specified price (a &#x201C;Dilutive Issuance&#x201D;) in a transaction that occurs prior to the earlier of June 30, 2018 or such time as the Company has raised, following the date of the CSIA, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$10.0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million in the aggregate (the &#x201C;Price Protection Obligations&#x201D;). In each of June 2016, November 2016 and May 2017, the Company completed offerings of its common stock that constituted Dilutive Issuances under the CSIA. Due in part to limitations on the number of shares issuable to the Holders under the rules of the NYSE American, no additional shares of common stock were issued to the holders in connection with the November 2016 and May 2017 offerings prior to June 2017.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On June 27, 2017, the Company and the Holders entered into an amendment to the CSIA (the &#x201C;Amendment&#x201D;) to, among other things, terminate the Price Protection Obligations. In consideration for the termination of the Price Protection Obligations and a release of claims by the Holders, the Company agreed to (i) issue to the Holders, within five business days of the Amendment, an aggregate of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">28,684</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of its common stock (the &#x201C;First Issuance&#x201D;), which, under the rules of the NYSE American, was the maximum number of shares the Company was permitted to issue to the Holders pursuant to the CSIA without further shareholder approval, and (ii) issue to the Holders in a subsequent closing an aggregate </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">523,210</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of common stock (the &#x201C;Second Issuance&#x201D;), subject to obtaining shareholder approval of the Second Issuance at the Company&#x2019;s 2017 Annual Meeting of Shareholders and the Company&#x2019;s receipt of a release of claims from the Holders at the time of the Second Issuance. On September 7, 2017 the Company&#x2019;s shareholders approved the Second Issuance. The Company received a release of claims from each of the Holders and issued </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">523,210</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of common stock on September 19, 2017. The shares were valued at </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$519,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as of September 19, 2017 based on the closing price of the Company&#x2019;s common stock of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.99</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share at September 19, 2017 multiplied by the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">523,210</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of common stock issued to the Holders. The related charges of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$111,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$519,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> were included as a component of general and administrative expense in the Company&#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Warrants </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">At September 30, 2018, outstanding warrants to purchase shares of common stock, accounted for as equity or liabilities, are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares Underlying</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Expiration</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,640</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 23, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,492</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120.00&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,492</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120.00&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 41,872</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">107.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 16, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 31,519</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 31, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 106,381</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 3, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 168,498</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.57&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 22, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 7,920,933</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">May 10, 2022</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,294,827</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:12pt;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 100%;text-indent:0pt;">
			<p style="line-height:12pt;font-family:Calibri;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;line-height:12pt;font-family:Calibri;font-size:10pt;;;padding:0pt 25pt 0pt 0pt;"> (1)</font>
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">The exercise price of the warrants is subject to adjustment upon future dilutive issuances of the Company&#x2019;s common stock and stock combination events as defined in an exercise price adjustment provision in the warrant agreements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> The exercise price will be adjusted downward due to an event subsequent to September 30, 2018 (see Note 10).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:12pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">During the nine months ended September 30, 2018, warrants to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">217,400</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of the Company&#x2019;s common stock, originally issued in connection with the November 2016 and May 2017 public offerings, were exercised for proceeds to the Company of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">$198,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">. During the nine months ended September 30, 2018, warrants to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">19,691</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of the Company&#x2019;s common stock expired. The weighted average exercise price of outstanding warrants to purchase common stock at September 30, 2018 was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">$2.76</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> per share.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786499488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">7. Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Stock Option Plan</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In June 2016, the Company&#x2019;s stockholders approved the 2016 Equity Incentive Plan (the &#x201C;2016 Plan&#x201D;). The 2016 Plan provides for the issuance of incentive awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&#x2019;s Board of Directors to its employees, directors and officers and to consultants, agents, advisors and independent contractors who provide services to the Company or to a subsidiary of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the date of grant. Stock options expire no later than </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ten</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years from the date of grant and generally vest and typically become exercisable over a </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">four</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-year period following the date of grant. Upon the exercise of stock options, the Company issues the resulting shares from shares reserved for issuance under the 2016 Plan. With the approval of the 2016 Plan, the remaining unallocated shares under the Company&#x2019;s 2013 Stock Incentive Plan were allocated to the 2016 Plan and an additional </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">100,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> new shares were added to the authorized share reserve under the 2016 Plan. Under the 2016 Plan, the number of shares authorized for issuance automatically increases annually </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">beginning January 1, 2017 and through January 1, 2026. On January 1, 2018, the number of shares of common stock authorized for future issuance was automatically increased by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">474,946</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Share-based Compensation </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company estimates the fair value of stock options with performance and service conditions using the Black-Scholes valuation model. Compensation expense related to stock options granted is measured at the grant date based on the estimated fair value of the award and is recognized on a straight-line basis over the requisite service period. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;background-color:lime;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The table below summarizes the total stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations for the periods presented: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Three Months Ended September 30, </font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Nine Months Ended September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">133,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">66,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">253,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">435,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">98,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">366,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">568,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock option transactions during the nine months ended September 30, 2018 are presented below:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Contractual</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Term</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">(Years)</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Outstanding at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,115,865&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.17&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.98&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">36,500&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.20&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Forfeited/Cancelled</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,201)
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">11.02&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Outstanding at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.08&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.28&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">118,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vested and expected to vest at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">864,051&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.80&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.03&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">90,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exercisable at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">361,773&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6.20&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6.77&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">39,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:15.1pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The aggregate intrinsic value of options at September 30, 2018 is based on the Company&#x2019;s closing stock price on that date of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.01</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. As of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, there was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">million of total unrecognized compensation expense related to unvested stock options, which the Company expects to recognize over the weighted average remaining period of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Shares Reserved For Future Issuance</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company had reserved shares of its common stock for future issuance as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares Reserved</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock options outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Employee stock purchase plan </font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">47,172&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Available for future grants under the 2016 Plan</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">447,127&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,294,827&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total shares reserved</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,938,290&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786441424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">8.&nbsp;&nbsp;Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business. Any of these claims could subject the Company to costly legal expenses and, while management generally believes that there is adequate insurance to cover many different types of liabilities, the Company&#x2019;s insurance carriers may deny coverage or policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company&#x2019;s reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would have a material adverse effect on our consolidated results of operations or financial position.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6633791344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">9. Related Party </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">On March 22, 2018, the Company completed a registered direct offering of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">2,743,640</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares of its common stock at a price of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$1.10</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> per share, including </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">181,820</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares sold to One Funds Management Limited as Trustee for Asia Pacific Healthcare Fund II (&#x201C;One Funds&#x201D;). Two members of the Company&#x2019;s board of directors are affiliated with One Funds.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786405888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">10. Subsequent Event</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">On </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">October 16</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, the Company completed an underwritten public offering and sold </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">14,875,000</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares of its common stock and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">2,125,000</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> pre-funded warrants to purchase common stock</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">and common warrants</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> to purchase </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">17,500,000</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> shares of common stock</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">. The combined price to the public for each share of common stock and accompanying common warrant was </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$0.40</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> combined</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> price to the public for </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">each pre-funded warrant and accompanying common warrant was </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$0.39</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">. Each pre-funded warrant is exercisable for </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">one</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> share of common stock at an exercise price of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$0.01</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> per share. The common warrants are exercisable at a price of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">0.40</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> per share of common stock, and will expire </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> years from the date of issuance. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company received aggregate gross proceeds from the offering of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$6.8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million, before deducting the underwriting discount and commissions and other offering expenses payable by the Company.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638500688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying unaudited consolidated financial statements of the Company should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included in the Company&#x2019;s Annual Report on Form&nbsp;10</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#8209;K, filed with the SEC. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201C;U.S. GAAP&#x201D;) for interim financial statements and in accordance with the instructions to Form 10-Q. Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201C;ASC&#x201D;) and Accounting Standards Update (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board (&#x201C;FASB&#x201D;).</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In the opinion of management, the accompanying consolidated financial statements include all adjustments that are of a normal and recurring nature and that are necessary for the fair presentation of the Company&#x2019;s financial position and the results of its operations and cash flows for the periods presented. Interim results are not necessarily indicative of results for the full year or any future period.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in its consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates these estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management&#x2019;s estimates.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Research and Development Expenses </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development expenses are charged to operations as incurred. Research and development expenses include, among other things, salaries, costs of outside collaborators and outside services, allocated facility, occupancy and utility expenses, which are partially offset by the benefit of tax incentive payments for qualified research and development expenditures from the Australian tax authority (&#x201C;AU Tax Rebates&#x201D;). The Company does not record AU Tax Rebates until payment is received due to the uncertainty of receipt. The Company received AU Tax Rebates of approximately </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$1.2</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$2.0</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> million during the three months ended September 30, 2018 and 2017, respectively.&nbsp;&nbsp;AU Tax Rebates of $1.2 million have been recorded as an offset to research and development expense in the Company&#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2018. AU Tax Rebates of $2.0 million have been recorded as an offset to research and development expense in the Company&#x2019;s consolidated statements of operations for the three and nine months ended September 30, 2017.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantsPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Warrants </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> Warrants are accounted for in accordance with the applicable accounting guidance provided in ASC 815 - </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Derivatives and Hedging</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> as either derivative liabilities or as equity instruments depending on the specific terms of the warrants. Liability-classified instruments are recorded at fair value at each reporting period with any change in fair value recognized as a component of change in fair value of derivative liabilities in the consolidated statements of operations (see Note 4).</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Recent Accounting Pronouncements Not Yet Adopted</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In February 2015, the FASB issued ASU No. 2016-02,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Leases (Topic 842)</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, which amends the FASB Accounting Standards Codification and creates Topic 842, "Leases." The new topic supersedes Topic 840, "Leases," and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and mandates a modified retrospective transition method. The Company plans to adopt this ASU on January 1, 2019. While the Company is still evaluating the timing and impact of the adoption of this guidance on its consolidated financial statements, it anticipates that the adoption could result in an increase in the assets and liabilities recorded on its consolidated balance sheet. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Intangibles - Goodwill and Other, Simplifying the Accounting for Goodwill Impairment</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.&nbsp;&nbsp;ASU 2017-04 removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. All other goodwill impairment guidance will remain largely unchanged. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. This new guidance will be applied prospectively, and is effective for calendar year end companies in 2020. Early adoption is permitted for any impairment tests performed after January 1, 2017. Adoption of this ASU is not expected to have a material impact on the Company&#x2019;s consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Recently Adopted Accounting Standards</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;"> Revenue from Contracts with Customers (Topic 606)</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">. The ASU creates a single source of revenue guidance for companies in all industries. The new standard provides guidance for all revenue arising from contracts with customers and affects all entities that enter into contracts to provide goods or services to their customers, unless the contracts are within the scope of other accounting standards. It also provides a model for the measurement and recognition of gains and losses on the sale of certain nonfinancial assets. This guidance, as amended, must be adopted using either a full retrospective approach for all periods presented or a modified retrospective approach and is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted this ASU as of January 1, 2018 using the modified retrospective approach. As of January 1, 2018, the Company had no revenue contracts and therefore the adoption did not have an impact on the Company&#x2019;s consolidated financial statements. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In August 2016, the FASB issued ASU No. 2016-15, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Cash Flow Statements, Classification of Certain Cash Receipts and Cash Payments</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which addresses eight specific cash flow classification issues with the objective of reducing diversity in practice. The amendments are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In July 2017, the FASB issued ASU No. 2017-11, which amends the FASB Accounting Standards Codification.&nbsp;&nbsp;Part I of ASU No. 2017-11, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Accounting for Certain Financial Instruments with Down Round Features</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, changes the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. The guidance is effective for reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company elected to early adopt this ASU as of January 1, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements.&nbsp; </font><font style="display: inline;font-family:Times New Roman;color:#FFFFFF;font-size:1pt;">a</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:13.2pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In June 2018, the FASB issued ASU No. 2018-07, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;">Compensation - Stock Compensation (Topic 718): Improvements to </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Nonemployee Share-Based Payment Accounting</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which amends the FASB Accounting Standards Codification in order to simplify the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. The guidance mandates the modified retrospective approach and is effective for annual and interim reporting periods beginning after December 31, 2018, with early adoption permitted. The Company elected to early adopt this ASU as </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">of June 30, 2018 and the adoption did not have an impact on the Company&#x2019;s consolidated financial statements</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to warrants, in accordance with guidance provided in ASC 815 - Derivatives and Hedging, to determine whether a given instrument is clasified as a derivative liability or as an equity instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761662272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Liabilities Measured at Fair Value</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The recurring fair value measurements of the Company&#x2019;s derivative liabilities at September 30, 2018 and December 31, 2017 consisted of the following: </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Quoted&nbsp;Prices&nbsp;in</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Active&nbsp;Markets</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Significant&nbsp;Other</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Significant</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">for&nbsp;Identical</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Observable&nbsp;Inputs</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Unobservable</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Items&nbsp;(Level&nbsp;1)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">(Level&nbsp;2)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Inputs&nbsp;(Level&nbsp;3)</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 2016 offering warrant liability</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:34.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Changes in Fair Value of Derivative Liabilities</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following table sets forth a summary of changes in the fair value of the Company's derivative liabilities:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">June 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">November 2016</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> Offering</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Offering</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrant</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrant</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Derivative</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liability</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Liabilities</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, December&nbsp;31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">260,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">292,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Changes in estimated fair value</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14,000)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exercised warrants</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(184,000)
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(184,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:41.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">136,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">154,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetByBalanceSheetClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769657264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Nine Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">September 30, </font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Basic and diluted net loss per share calculation:</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,606,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(779,000)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7,790,000)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10,486,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Change in fair value of November 2016 warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(21,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,546,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,627,000)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(779,000)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7,790,000)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(12,032,000)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Weighted average shares outstanding, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16,468,308&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,874,813&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15,418,146&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,326,139&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss per share, basic </font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.10)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.09)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.51)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1.97)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Weighted average&nbsp;&nbsp;shares outstanding, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16,496,957&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,874,813&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15,418,146&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,518,847&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss per share, diluted</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.10)
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.09)
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.51)
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2.18)
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive Securities Excluded from Computation of Diluted Weighted Shares Outstanding</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The following outstanding securities at </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> have been excluded from the computation of diluted weighted average shares outstanding for the three and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">nine months</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, as they would have been anti-dilutive: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:24.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Nine Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, </font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,116,765&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,116,765&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,126,329&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,712,220&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,294,827&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,232,056&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Common stock (Note 6)</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">523,210&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">523,210&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:43.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,275,493&nbsp;
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,352,195&nbsp;
				</td>
				<td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,443,991&nbsp;
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:18.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,872,031&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618208624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Information</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">At September 30, 2018, outstanding warrants to purchase shares of common stock, accounted for as equity or liabilities, are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares Underlying</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Expiration</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:9.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,640</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 23, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,492</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120.00&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,492</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120.00&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 41,872</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">107.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 16, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 31,519</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 31, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 106,381</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 3, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 168,498</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.57&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">November 22, 2021</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 7,920,933</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.50&nbsp;
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">May 10, 2022</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 8,294,827</font></p>
				</td>
				<td valign="bottom" style="width:03.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778066240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Stock-Based Compensation Expenses</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The table below summarizes the total stock-based compensation expense included in the Company&#x2019;s consolidated statements of operations for the periods presented: </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Three Months Ended September 30, </font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Nine Months Ended September 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">32,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">133,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">66,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">253,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">435,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:29.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">120,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">98,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">366,000&nbsp;
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">568,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:15pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock option transactions during the nine months ended September 30, 2018 are presented below:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Contractual</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Aggregate</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Term</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Intrinsic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">(Years)</font></p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Value</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Outstanding at December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,115,865&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.17&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.98&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">36,500&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.20&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Forfeited/Cancelled</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,201)
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">11.02&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Outstanding at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.08&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.28&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">118,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vested and expected to vest at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">864,051&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.80&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8.03&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:28.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">90,000&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:28.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exercisable at September 30, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.12%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">361,773&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6.20&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6.77&nbsp;
				</td>
				<td valign="bottom" style="width:01.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.96%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">39,000&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:18pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> September 30, 2018</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company had reserved shares of its common stock for future issuance as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:3.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:3.75pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Shares Reserved</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock options outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,149,164&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Employee stock purchase plan </font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">47,172&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Available for future grants under the 2016 Plan</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">447,127&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants outstanding</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,294,827&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total shares reserved</font></p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:19.42%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:16.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,938,290&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793451184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Mar. 22, 2018</div></th>
<th class="th"><div>Jan. 12, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,499,000<span></span>
</td>
<td class="nump">$ 5,132,000<span></span>
</td>
<td class="nump">$ 7,725,000<span></span>
</td>
<td class="nump">$ 5,711,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ProceedsFromEquityOfferingsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ProceedsFromEquityOfferingsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6766773488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax rebates received</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795823136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="nump">$ 292,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember', window );">June 2016 Offering Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember', window );">November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | June 2016 Offering Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | June 2016 Offering Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | June 2016 Offering Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems', window );"><strong>Schedule Of Derivative Liabilities At Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ScheduleOfDerivativeLiabilitiesAtFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796452416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_DerivativesAndFairValueLineItems', window );"><strong>Derivatives And Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">$ 292,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Changes in estimated fair value</a></td>
<td class="nump">46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Exercised warrants</a></td>
<td class="num">(184,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">154,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember', window );">June 2016 Offering Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_DerivativesAndFairValueLineItems', window );"><strong>Derivatives And Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Changes in estimated fair value</a></td>
<td class="num">(14,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember', window );">November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_DerivativesAndFairValueLineItems', window );"><strong>Derivatives And Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Changes in estimated fair value</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Exercised warrants</a></td>
<td class="num">(184,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance, derivative liability</a></td>
<td class="nump">$ 136,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_DerivativesAndFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_DerivativesAndFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=aphb_June2016OfferingLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796224096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net loss per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss, basic</a></td>
<td class="num">$ (1,606,000)<span></span>
</td>
<td class="num">$ (779,000)<span></span>
</td>
<td class="num">$ (7,790,000)<span></span>
</td>
<td class="num">$ (10,486,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToParentDiluted', window );">Net loss, diluted</a></td>
<td class="num">$ (1,627,000)<span></span>
</td>
<td class="num">$ (779,000)<span></span>
</td>
<td class="num">$ (7,790,000)<span></span>
</td>
<td class="num">$ (12,032,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="nump">16,468,308<span></span>
</td>
<td class="nump">8,874,813<span></span>
</td>
<td class="nump">15,418,146<span></span>
</td>
<td class="nump">5,326,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (1.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="nump">16,496,957<span></span>
</td>
<td class="nump">8,874,813<span></span>
</td>
<td class="nump">15,418,146<span></span>
</td>
<td class="nump">5,518,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.18)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember', window );">November 2016 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net loss per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment', window );">Changes in estimated fair value of warrants</a></td>
<td class="num">$ (21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,546,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at whicha liability could be incurred (settled) in a current transaction between willing parties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_LiabilitiesFairValueAdjustmentIncludingExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToParentDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToParentDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=aphb_November2016WarrantDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796026912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">9,275,493<span></span>
</td>
<td class="nump">10,352,195<span></span>
</td>
<td class="nump">9,443,991<span></span>
</td>
<td class="nump">9,872,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">1,149,164<span></span>
</td>
<td class="nump">1,116,765<span></span>
</td>
<td class="nump">1,149,164<span></span>
</td>
<td class="nump">1,116,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="nump">8,126,329<span></span>
</td>
<td class="nump">8,712,220<span></span>
</td>
<td class="nump">8,294,827<span></span>
</td>
<td class="nump">8,232,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted weighted shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797339056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 22, 2018</div></th>
<th class="th"><div>Jan. 12, 2018</div></th>
<th class="th"><div>Sep. 19, 2017</div></th>
<th class="th"><div>Jun. 27, 2017</div></th>
<th class="th"><div>May 10, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">2,743,640<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,584,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds from issuance of common stock and warrants</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantsExercisedDuringPeriod', window );">Warrants exercised during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantsExpiredDuringPeriod', window );">Warrants expired during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementMember', window );">Common Stock Issuance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_CapitalRaisedLimitForPriceProtectionObligation', window );">Capital raised limit for Price Protection Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued per agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementSecondIssuanceMember', window );">CSIA Second Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued per agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementSecondIssuanceMember', window );">CSIA Second Issuance [Member] | General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense', window );">Charges related to common stock included in general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,483,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember', window );">Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationTermFollowingExercisableDate', window );">Expiration term of warrants (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_CapitalRaisedLimitForPriceProtectionObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of capital that must be raised before the Price Protection Obligation ceases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_CapitalRaisedLimitForPriceProtectionObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents charges related to common stock issued to parties and included in general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ChargesRelatedToCommonStockIncludedInGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ProceedsFromEquityOfferingsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ProceedsFromEquityOfferingsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantExpirationTermFollowingExercisableDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration term of warrants issued, expressed as the period of time following the date of effectiveness of the warrants or initial date warrants become exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantExpirationTermFollowingExercisableDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of securities called by warrants that were exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantsExpiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants to purchase shares of stock that expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantsExpiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementSecondIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aphb_CommonStockIssuanceAgreementSecondIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795558944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Summary of Warrants Outstanding) (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">8,294,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice82.50Member', window );">Exercise Price 82.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">8,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 82.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Dec. 23,  2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice107.50Member', window );">Exercise Price 107.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">41,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 107.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 16,  2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice40.50Member', window );">Exercise Price 40.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">31,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 40.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IMember', window );">Exercise Price 120.00 I [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">8,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IiMember', window );">Exercise Price 120.00 II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">8,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Mar.  01,  2019<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice22.50Member', window );">Exercise Price 22.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">106,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 22.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Jun.  03,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice0.57Member', window );">Exercise Price 0.57 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">168,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">Nov. 22,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice1.50Member', window );">Exercise Price 1.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants | shares</a></td>
<td class="nump">7,920,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationDate', window );">Warrant Expiration Date</a></td>
<td class="text">May 10,  2022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the terms related with expiration of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice82.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice82.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice107.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice107.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice40.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice40.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice120.00IiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice22.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice22.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice0.57Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice0.57Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice1.50Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_ExercisePrice1.50Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785589344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock closing price</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested options</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining period for recognition of compensation costs related to unvested options</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of share-based payment award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of share-based compensation award</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP', window );">Additional shares added to the Plan during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_IncreaseInSharesReservedForFutureIssuance', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_IncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the number of shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_IncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the number of shares provided to the Employee Stock Ownership Plan (ESOP) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785462512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="nump">$ 568,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785300608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance at December 31, 2017</a></td>
<td class="nump">1,115,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(3,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Balance at September 30, 2018</a></td>
<td class="nump">1,149,164<span></span>
</td>
<td class="nump">1,115,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested or expected to vest at September 30, 2018</a></td>
<td class="nump">864,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable at September 30, 2018</a></td>
<td class="nump">361,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at December 31, 2017</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">11.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at September 30, 2018</a></td>
<td class="nump">3.08<span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested or expected to vest at September 30, 2018</a></td>
<td class="nump">3.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at September 30, 2018</a></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average Remaining Contractual Term (Years), Outstanding at December 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi', window );">Average Remaining Contractual Term (Years), Outstanding at September 30, 2018</a></td>
<td class="text">8 years 3 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Average Remaining Contractual Term (Years), Vested or expected to vest at September 30, 2018</a></td>
<td class="text">8 years 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Average Remaining Contractual Term (Years), Exercisable at September 30, 2018</a></td>
<td class="text">6 years 9 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic Value, Outstanding at September 30, 2018</a></td>
<td class="nump">$ 118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic Value, Vested or expected to vest at September 30, 2018</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic Value, Exercisable at September 30, 2018</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average remaining contractual term for options outstanding at end of reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermIi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758046752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation (Shares Reserved for Future Issuance) (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="nump">1,149,164<span></span>
</td>
<td class="nump">1,115,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares', window );">Employee stock purchase plan</a></td>
<td class="nump">47,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants</a></td>
<td class="nump">8,294,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">9,938,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member', window );">Equity Incentive Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future grants under the 2016 Plan</a></td>
<td class="nump">447,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares that, although not legally released, will be released by a future scheduled and committed debt service payment and will be allocated to employees for service rendered in the current accounting period. The ESOP documents typically define the period of service to which the shares relate. ESOP shares are released to compensate employees directly, to settle employer liabilities for other employee benefits, and to replace dividends on allocated shares that are used for debt service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfCommittedToBeReleasedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=aphb_EquityIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778116880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 22, 2018</div></th>
<th class="th"><div>Jan. 12, 2018</div></th>
<th class="th"><div>May 10, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">2,743,640<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">2,584,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsMember', window );">One Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">2,743,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsManagementLimitedMember', window );">One Funds Management Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">181,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsManagementLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aphb_OneFundsManagementLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797003664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Oct. 16, 2018</div></th>
<th class="th"><div>Mar. 22, 2018</div></th>
<th class="th"><div>Jan. 12, 2018</div></th>
<th class="th"><div>May 10, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,743,640<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">2,584,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,483,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember', window );">Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationTermFollowingExercisableDate', window );">Expiration term of warrants (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">14,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_ProceedsFromEquityOfferingsGross', window );">Proceeds from equity offerings, gross</a></td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-Funded Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="nump">2,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_SaleOfWarrantPricePerWarrant', window );">Sale of warrant, price per warrant</a></td>
<td class="nump">$ 0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities called by warrants</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aphb_WarrantExpirationTermFollowingExercisableDate', window );">Expiration term of warrants (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_ProceedsFromEquityOfferingsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow, before deducting the underwriting discount and commissions and other offering expenses payable from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_ProceedsFromEquityOfferingsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_SaleOfWarrantPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per warrant amount received for each warrant issued or sold in the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_SaleOfWarrantPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aphb_WarrantExpirationTermFollowingExercisableDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration term of warrants issued, expressed as the period of time following the date of effectiveness of the warrants or initial date warrants become exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aphb_WarrantExpirationTermFollowingExercisableDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aphb_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=aphb_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>47
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\F[$9C#_8?&U\%NQ9^W47W!5!+ P04    " !K@&A-F5R<(Q &  "<)P
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M*_UEV?-?<JY UW0WNERE;\0QH% J,]WJN>COA3Y0O!VN/#S>N_D?4$L#!!0
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M+TZJ0)PG39/9.!J-HV$<XI5'0SY42< [17"2,%A'B..4(G6$.$D?+)\$Y9=
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MF$/;W2IW7P_G'<-#:\_C64YT.U!:_P=02P,$%     @ :X!H3?:*,:[) P
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M]K]!=."E'&[\"'7^@ZV&@L:%XWM_-O.8S8;#8?E!;/W&Y6]02P,$%     @
M:X!H3:/WG&NT 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M?5/;;MLP#/T501]0Q4YZ06 ;:%H4'; !08MMSXI-VT)U<24Y[OZ^E.QXWF;L
M11(IGL-#BLH&8]]<"^#)AY+:Y;3UOMLSYLH6%'=7I@.--[6QBGLT;<-<9X%7
M$:0D2S>;&Z:XT+3(HN]HB\ST7@H-1TM<KQ2WOPX@S9#3A%X<+Z)I?7"P(NMX
M Z_@OW='BQ:;62JA0#MA-+%0Y_0^V1]V(3X&_! PN,69A$I.QKP%XTN5TTT0
M!!)*'Q@X;F=X "D#$<IXGSCIG#( E^<+^U.L'6LY<0</1OX4E6]S>D=)!37O
MI7\QPS-,]5Q3,A7_%<X@,3PHP1RED2ZNI.R=-VIB02F*?XR[T'$?QIOM!;8.
M2"= .@/N(H"-B:+R1^YYD5DS$#OVON/AB9-]BKTI@S.V(MZA>(?><Y$DUQD[
M!Z(IYC#&I,N8.8(A^YPB74MQ2/^!I^OP[:K";81O_U!XLTZP6R7818+=?TM<
MB[G]*PE;]%2!;>(T.5*:7L=)7GCG@;U/XYO\#A^G_1NWC=".G(S'EXW]KXWQ
M@%(V5SA"+7ZPV9!0^W"\Q;,=QVPTO.FF'\3F;UQ\ E!+ P04    " !K@&A-
M0KB.D+4!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q]4V%O
MW" ,_2N('U 2[M;=3DFD7J=IDU;IU&G;9RYQ$E2(4R"7]M\/2)IE6[0O@(W?
M\[,QV8CFR;8 CKQHU=F<ML[U1\9LV8(6]@9[Z/Q-C48+YTW3,-L;$%4$:<5X
MDMPR+61'BRSZSJ;(<'!*=G VQ Y:"_-Z H5C3E/ZYGB43>N"@Q59+QKX!NY[
M?S;>8@M+)35T5F)'#-0YO4N/IWV(CP$_)(QV=2:AD@OB4S"^5#E-@B!04+K
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MP19#0>W#\2.>[31FD^%-/_\@MGSCXB=02P,$%     @ :X!H338$>?.T 0
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M^W#\A&<[C=ED>-///X@MW[CX U!+ P04    " !K@&A-N7^/]K4!  #2 P
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MX=F-8S8:P7;3#V+S-R[^ %!+ P04    " !K@&A-Z5.AGK,!  #2 P  &0
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MJ+3='LU>3JT_&5KT\U0CRVC-_P!02P,$%     @ :X!H3?IH$1O% 0  -P0
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL;53;;IPP$/T5RQ\0+RPD
MJQ4@91-%K=1*JU1MG[TP@!5?J&V6].]K&T+IUB_8,SYSSHS'0S$I_69Z (O>
M!9>FQ+VUPY$04_<@J+E3 TAWTBHMJ'6F[H@9-- F! E.TMWNG@C*)*Z*X#OK
MJE"CY4S"62,S"D'U[Q-P-94XP1^.5];UUCM(50RT@V]@OP]G[2RRLC1,@#1,
M2:2A+?%C<CSE'A\ /QA,9K-'OI*+4F_>^-R4>.<3 @ZU]0S4+5=X LX]D4OC
MU\*)5TD?N-U_L+^$VETM%VK@2?&?K+%]B0\8-=#2D=M7-7V"I9X<HZ7X+W %
M[N ^$Z=1*V["%]6CL4HL+"X50=_GE<FP3O-)=EC"X@'I$I"N 8>@0V:AD/DS
MM;0JM)J0GN]^H+[%R3%U=U-[9[B*<.:2-\Y[K9(L*\C5$RV8TXQ)MY@501S[
M*I'&)$[I?^%I/'P?S7 ?PO=;]60?)\BB!%D@R/XI,;\I,8:YCXOD49$\0O!P
M(Q+#'&Y$R*9Q G07GJQ!M1IE&)>-=YV*QS0T_B]\'JFO5'=,&G11UCV?T.16
M*0LNE=V=RZ5W4[P:'%KKMP]NK^>W/!M6#<N8DO5?4?T!4$L#!!0    ( &N
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M*A9#0&W]]M[M]30PDV%5/[\%9'F0BK]02P,$%     @ :X!H35= -0 F @
MR08  !D   !X;"]W;W)K<VAE971S+W-H965T,C$N>&ULC95K;YLP%(;_"N('
MU-PA$4%:TK69M$E1JVV?G>0DH!K,;"=T_WZV<5' ;$L^Q+?G?7V.+SCO*'OC
M)8!PWFO2\)5;"M$N$>*'$FK,'V@+C1PY459C(9OLC'C+ !^UJ"8H\+P$U;AJ
MW"+7?3M6Y/0B2-7 CCG\4M>8_5X#H=W*]=V/CI?J7 K5@8J\Q6=X!?&]W3'9
M0H/+L:JAX15M' :GE?O)7VYCQ6O@1P4=OZD[*I,]I6^J\>6X<CT5$! X".6
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M!\X5U>F$#[KH2M](Q@FC!V6&J1Z+OBWW$\6[X<H1C/>>XB]02P,$%     @
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MIN:^'<XSA@>MCN-9370Y,%K_ 5!+ P04    " !K@&A-T6GG-$L"  !-!P
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MPAO=-36(D[W'I5/P<V.;R&AUZ!4OH;VK/N!=H_E!Q:EJI+/G2M]X]EXZ<JY
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MO9T:-)G5= ,$XXSE@4HS$)0!H,P#93,0S3.$8$P.8G( DWN8?(;Y0 G",*8
M,06 *3Q, 6Q;6N+<V]X-I'MG>QE8$ ,*8EY!; 9B>8JR0.,ER"D!3NEQ2N U
MXF)R &\X&,%'&,U)#/EG>!"Q*6J!BP HX!48 &$?Y!P%3=_2(G#2,.@&]Y@
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M^^:&GAB3H"3#E5*KU2,_!11.4D]S->?VJ;.!9/WXB@?37TGU#U!+ P04
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M1M1R987$V]=P1/$M4I)P(#FRE,D_V#"GK;<EN6L?)&'#)GA$#TFY+ECDXA@
M*;(HA+V5"( BB!-8@D #M_\9L+08):VJ[LRIXD[8+D1Q@">3_KFW 60FQO,F
M\=XLBQ3'&TZ;QL-#7!.["Q)FG0]97( :"]K$S3I>&KVFH@WY2)EGM]C%:$.\
M*FZEOG.Y'YQC!&@,T]W=98C3D7>7D;GCJ#L$>VOF)]/^7.W*5Y8@S%PN"W4
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M:TSA$:5*1D$=$->B4F26H%21;L4>#'.(:LL A4L0&>L\-9LG<1FMM;J^ >$
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M2?]9R/'27"PP.YU!40'=/Y'+&-K7?8=.+#ZRQ"R6N1BK.Y1B*?I.WWNOHR8
M*U %TEQ;R;91C/$.,TEU<*WUK^.[Q ZABR5GW/"[UJS'K-")]C#L(96;M8J
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M3/GSZ;PE4]X6?&Z-\O P39WK?.H2(H1JG8>JTA<M3PAKXPU-WBHI4F^L2N,
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M8Y:'^JS[X3O[ E!+ 0(4 Q0    ( &N :$T?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &N :$TGZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ :X!H39J*2J7N    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ :X!H39E<G",0!@  G"<  !,
M         ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !K
M@&A-B#22]F0"   4"   &               @ 'W"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ :X!H38]/@)L_ P  %PX  !@
M         ( !D0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( &N :$VZ(QV*^ $  (,%   8              "  08/  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !K@&A-%N&VN?(#  !<$@
M&               @ $T$0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ :X!H3?:*,:[) P  3Q$  !@              ( !7!4  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( &N :$VU&A,.M $
M -(#   8              "  5L9  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " !K@&A-+8+U$K0!  #2 P  &               @ %%
M&P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ :X!H384W
M4-FT 0  T@,  !@              ( !+QT  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( &N :$V*Y5OWLP$  -(#   8
M  "  1D?  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !K
M@&A-H_><:[0!  #2 P  &0              @ $"(0  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &N :$U"N(Z0M0$  -(#   9
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M970Q-2YX;6Q02P$"% ,4    " !K@&A-AO"UYNX!  !F!0  &0
M    @ &$+   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M &N :$WZ:!$;Q0$  #<$   9              "  :DN  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ :X!H3=-K(Y;! 0  -P0  !D
M             ( !I3   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " !K@&A-D29RZ+<!  #2 P  &0              @ &=,@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( &N :$USMG$0TP$
M )P$   9              "  8LT  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ :X!H35= -0 F @  R08  !D              ( !
ME38  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !K@&A-
M/D!G3]H!  !A!   &0              @ 'R.   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( &N :$V"EZQK&@,  *8/   9
M      "  0,[  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ :X!H38<@(9=U @   PD  !D              ( !5#X  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !K@&A-?^Y<,O "   3"P
M&0              @ $ 00  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( &N :$VM:^$,J (  (,)   9              "  2=$  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ :X!H3;W6G=/@
M P  D!(  !D              ( !!D<  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " !K@&A-BT:B>'\#   \$@  &0
M@ $=2P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( &N
M:$W1:><T2P(  $T'   9              "  =-.  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ :X!H3:6<WE=Q @  6 @  !D
M         ( !55$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " !K@&A-N:,".@4#  #["P  &0              @ ']4P  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( &N :$UOY(SZ^P$  'D%
M   9              "  3E7  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ :X!H34-.I4$8 @  5@8  !D              ( !:UD
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !K@&A-V/YF
MP5,#  #<#@  &0              @ &Z6P  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( &N :$V7)!\8^"P   OI   4
M  "  41?  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( &N :$TG
M3NLX/@(  !\+   -              "  6Z,  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ :X!H39H3;$]U P  .Q<   \              ( !UXX  'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &N :$TSW*/_@P$  &L5   :
M          "  7F2  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( &N :$V: LD&E@$  /@5   3              "  324  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     K "L GPL  /N5      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>100</ContextCount>
  <ElementCount>145</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00050 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00150 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureRelatedParty</Role>
      <ShortName>Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Liquidity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureLiquidityNarrativeDetails</Role>
      <ShortName>Liquidity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureLiquidity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsFairValueOfFinancialLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Financial Liabilities Measured on Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsChangeInFairValueOfDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements (Change in Fair Value of Derivative Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareBasicAndDilutedIncomeLossPerShareDetails</Role>
      <ShortName>Net Loss per Common Share (Basic and Diluted Income (Loss) Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureNetLossPerCommonShareAntidilutiveSharesExcludedFromComputationOfDilutedSharesOutstandingDetails</Role>
      <ShortName>Net Loss per Common Share (Antidilutive Shares Excluded from Computation of Diluted Shares Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Stockholders' Equity (Summary of Warrants Outstanding) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockholdersEquitySummaryOfWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity (Summary of Warrants Outstanding) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Stock-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationAllocationOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation (Allocation of Stock-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40704 - Disclosure - Stock-Based Compensation (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40705 - Disclosure - Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Stock-Based Compensation (Shares Reserved for Future Issuance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureStockBasedCompensationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureRelatedPartyDetails</Role>
      <ShortName>Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureRelatedParty</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aphb-20180930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ampliphibio.com/role/DisclosureSubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ampliphibio.com/role/DisclosureSubsequentEvent</ParentRole>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aphb-20180930.xml</File>
    <File>aphb-20180930.xsd</File>
    <File>aphb-20180930_cal.xml</File>
    <File>aphb-20180930_def.xml</File>
    <File>aphb-20180930_lab.xml</File>
    <File>aphb-20180930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0001144204-18-058340-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-058340-xbrl.zip
M4$L#!!0    ( &N :$WDYP6(!:H  (J(#P 1    87!H8BTR,#$X,#DS,"YX
M;6SL?6MWV\BQ[>=DK?R'ODSFW)FU*)H W_+89\FRG2AGQM*Q-,G-)ZT6T!01
M@P '#\G*K[_5C0<!$!1? -D ZLR]L4B _=I5NZJKNZM__N_O<Y,\,<<U;.M=
M2^ET6X19FJT;UN.[EN^>45<SC-9_O__3'W_^/V=G_^_#UU^(;FO^G%D>T1Q&
M/::3AQ=RR1R/?_71<#73=GV'D5^I11^9>''847N=;D<A9V=A01^H"S^T+2)*
M5#M*_.0R+-2VSHFBO!F_4;O*F"CGZNA<Z9.;7X,7OS\X)H&F6^Z[ULSS%N=O
MWCP_/W?XUQW;>80?=7MO#,OUJ*6Q5O#FN6E8WUYYG3]^@'9%KW]?>?^Y)]Y6
M)I/)&_$T?A4*THWXW62YPS?!P^A5NI@]I JE\X5I+&;&@V%W-'LN^MN=]+K1
M#P"$1TH7\6^FU'T0A8</^ ]&9UWEK*=$/S%<NZ\JH]>&)G@CV7YCAY'46::S
M+M,ZC_;3&WC V]-/M^>[:^2-(Q2MO/E_O_YRJ\W8G)[%E0# A/S,Q_?<%8^^
MLBD1XWWNO2S8NY9KP)CQQHCO9@Z;OFOQ<3V+QJ[SW=5;Y$U0$!<JV_+8=X_<
M,LT#01<R!$^T\&M#?]?ZZ#N4/[N?W"N3>SZF]W=VXD,XVO=WT(+KZ87C4"N0
M[HOOAGO/:[^_M.=SV[KU;.W;E>OZO"\7CPX3;T'-MJ5'7__*Y@_,"3H*[8#G
MAO<2?H+/ALZ_F1K,(6( 6&KTHK&^O/J?UOLN_-]$512E__.;Y<^61;GLD5<?
M?P%?!?)XSKZ#W&F&%[2%Z :\%[! V-7SW*ZVWO.^GN_:UY_?Y%:[;.B;=$M_
M?I,:E)\7S#%L/=$OCSK>1V"*]X'X3\Z4"901?QN_R"Q]Y;7HNZBJ1.$_OPF%
MXA4)&=ZKHUA"EA\.E)!ZR\1QI&!XIHZVD(+@M?VDX,*]OYXB+\C*"X$1\5+J
M'GVWI[HK\%^D[8IZWPL^E0[2KK*OP/_;+/N*"G;Y4-GO=?D0C&/9_P3FV'YA
M3,!^_6R!.SDS%C<FM3[=7M\L?4+WPPO_<JD9GW[WH8=7( W0U2?&'T+!PVJH
MP1Z]#I7DU6Z7J!%CKA&];E$:,0X\))2&"DE#BC7&V[%&+#:'L$;O7E73<O*5
MF7RF=P-5O]R!+7&I<,YA@))/EN)Q;;'/OJ6[U9"'[7L7BD&Z>^6R0.],5?=E
M@0R<)[>#1?=,X49>PIXI8+L/9NZE%@)UHTJ>5"6S5!R([D8J#EX[< I;EAS$
M,;]?C+D![]5=,/+[6R=)&=PKW7CZ$W\X.3=F9S^#,Z6[Q<P_>.W (7G=_?T(
MA3U1[LE= 5<[(E3^U7"_+;7E[[[%N(=W/9W"N];C+P9],$SH;#6TY;4.AOJQ
MH8<U<&IC81B]*@S@U=MS=D>_7_C>S':@#U_HG E1B%ZY\&$0J6E0"UX39<*H
M&56)!:WO8.M]],[K/2Q;&$;'%X914AA&* R2",-H.V$8%20,AYJ)+_:3Z#PG
MTG]2'FWUEC^JG\W8I;MU,B"AF Q3X>4A1M,J%TT;;B<WPW)B\!?/U-'YRDS*
MGJ3'<<$%KAH"D.K.TGJL[4_EH^:(7]49?9UF%FOIXV(_4\/Y!S5]]N$E_O-O
M@!]UM-G++^R)F2E)BM^YLA:^YXH7>M60I2,[#[LT;3L0EO+_"@KR,ECU!%M%
MP99 L%44[*(%6T'!ED"PE?H*]H;(+7H?)82[T>&HHOC6Q\>HF/C6V*TXHOC6
MQY.HF/A6UGEHCLEOM)%MCFELM#%JC@EI-&GC,K-$R\PRP(V;SR0'=7G$K +Q
MR(HX=#6/1Y;O:\8'!QLCV17Q86LNV>6[U\V3[(JX[367[/)G%*>3;%Q$JG\8
ML\X^!ZXBU5]^Z^Q9X#)2_>6WNOY#<ZQ^L^UL<ZQCL^U1<ZQ(LWD;EY+D7$J2
MUL^L <2G6TLJ!M7NO3),KQ!>FM1UKZ>AO%X[7XW'62)7Y8TC,ILP/7PA,V.X
M]1]<]KL/O?CT!/^S<EXM\[P:<K!V2$(AR!^3(B<$:X9U:4ERQ[74E4RE>Z8,
MCRU]0?90%+U,.E64NP.W16P0NT_?F:,9+KMQ#(V-U<Z@6P_I6=<OV;= ' 9@
MOUM/ !/]JC> :DTU4&V*!BIJM]/M7M40PE3/&@&B45\4C4; V!W5DTV3':LY
MA#4%L"'P@=LVJB%\RV[)#M\RA>U!0;"JH[=?&.NP"UB"?+M'!2\G9%)UY/:(
M IT:MCC[Z<DS16=O!"KL?,90IJX-#ULNV#*=\04T1S=,GZ^9W#+-=PS/8.ZG
M[YKI Z]\=NPYB.K"]\*\KI^H8QG6HWO#G-L9==B'E_P"4G'<2FENB0.R#,*6
MJO@2I$L^H;!5+Z_B,03NZ-D9CRET&])P(L/5G>%.D-P9&4XR@:MC_MDM;R%
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MUZEEX?B=*PNFU:YX05DW,F\*[]4&-[/(7JE%]RK1C=SI9SG=Z&TGML>EL;4
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MT@ETP/.A@<CM[]\,$ 40 VJ: +^7(^SZ&F%/W<-WD,#_"NV">JECVJOB7FJ
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M.<% _5,HI'LXZ, O//*+[;HBL8T0&U+-OC8N1P+/Z!0D N")7H*#[R[S>'8
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MQ-(!W1.;SPQ+AR$\5];M^3I1?Z\L\ID].#YU7OAIJ4&;>#-&/E_<?B"&Z_K
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MT]W6CZLPBES=*#+ZRS6U0:_03%5QJ.02Y(JKB\!( 0SREIPHH'I( 0SREJ3
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M!S]=H^)I(RV<D$=-O511ZU1"+T!P!ZEJ6"$$J9]FL96VSRHA:52<?78/K*+
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MP$+\R L-!^X% CZ;HG) L"OM,/X#_^9P<].)+/C4=L7/4(6&>Q\;+DAY\BI
ME8C(8V!C;1#"?Q8@@X!Y,^8MN511P&:>+RZQ%#H.V-+G 7R-6R_9/K9_L :V
MN?'1-'"@=V>,,\'][C]:B3]+59K<<>)X^J;5;8G7P=(PD]?Q[V,L!S!VC&7
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MF9<Y\N0NMB%L3U]&OCD'HV4!FF_ O!F8SF+AN3 >L*HV,TP34 N;V6>>SXR
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MY5U/KGM=\:+%(M>67_P&?V@M9G'37AA.\*;5;;T=#,=  #-S*+SY@0,</SS
M<7: XQT#[ V')0WP'*5_PQ?@9._N5U_Y8MSC6^=WAF^)__DW#T+PY2_<MSU+
M6TU+FPP/F==U/)KKCXNEX]US+HSBXLX%FYC;RR^.X7Z\O/CRP0Y,QPLBGP?O
M[O'-\Q]V<&TLY]-K:3F?7(0%^Y;CAW#AX>]BE:+U]DO_O[O$\K@I%PASNOO*
MT_4KKYY-*Z^[DJ2N[3#A8TM2ZZZ+LHP)EV24GR,<)8 *?AJ<WQJV@W#\B^?_
MBG"2%:N>%^MY<'TQ.YX<UQQ97_/D?G^DZ:,23':'0$HRWXLE?C&(GVV.-_CD
MAK[M!K;Y;\.)>!891MJ#@M\%<9--A*MDQ"49Y.9]I$8R AF.#Q+(NJGTAMIH
MU"O!5+8-M3))_$?P&FZ= S<S;GC\"1</:\W*9W*0?'I9^>BMM\..OC,DEC[\
MROQJ[:9?^<*P70A'[T% OF&&D>%<<7^1<[CN013C[9?A?R>_CSY4XF3[#K]<
MFP.TFW$[1)3^M!%@M<&3*-B&.\*7RC.W@I&7*QH1!=)K_^I[09 5S4$L;C=2
M#7:STR<-O5S97$1A$!HN)JOYX) %I]Y3HIFF[9-1E##BR@2S$<T&A0+1].N>
M5IACK1N)IH%##@>5R*2*>/: +'2M^Z3(KFG]B3;LUU$4>X;V0?\P8UF/[;V.
M5@9)/FS\SRVTX6$$>E-FW;$*,GL"H=A^TVV$0L\:W6"/FE#&!M]^&?]7TW[7
M>R52HD?,H%RSPRH&W-/%1)R;\.>5AV]EQG5^<^/S&R/DVV/?Z"FQ#Q.Y$D/?
MHR=T;+ENYG^%(+AWE!@/^]U!B91SWQD<6V[[HN/@B>@X/JI1'@\T#Q[+/KGE
M\+ $04)IB3A:WJ0.-.?@\,1M7TYT4+UWESUK6J>K'V#0)<^K9*GF4[Y]!3HJ
M5:"'E9/*FU&!*-=FVM.V1!)M(GE-4M.^NE_RBUEFE*NJ-4QCX;FBV/TI""+#
M-?DYA$WQK4L.%[>2MXL+V>OBZG8FDS5Q[3D;O;]GA5Z($Z<D9E%<MQ?"WF_$
MX##KT;1HQ/:-:\]L$[1W;II>Y(HU(<^Q39NO%BNSNMG!.M>1$I=-LTNH\'=^
M[5@NXN/B=?Q:+LOG5K.W+#FO+2MW_U&X]KRU4^_)79MW\LY3S[$*V^EZ'9:1
M+UL)F"42WF?E6KUY[]NL^(0)B0X)V[7 75]JV[H*CC;#JSEG"(R&>Q]/%I]C
M\"I@04:]QDJ]RUB]#)P.O#(P?7O*+;@[PYX UF.AQT*X)CB2Z*L%,F^QF>T"
M'MF& Z.&-P3JPD],)[+D;\-MHSAW70C_["M?>G[(/)=!=%N 2,[^A\T\7_SN
MGAL^XRY>J;1^TB))K3]\;+.1M,R[M4%H#DSIS@[G8IH [9%OAT+TKL4^_C#G
M&!M0; L["+!EX<5*=N]?77Y\OWKYX=5/Z+ 0$\2U4"O,F\'?7L +M=/&[X&&
MY\8M9U/.7>9Z; &?^O@]>>L@T?5C[*?#T/)L[!"R%_M;B[A??+E 3B&]OY"+
M#6_?S3W'N6?>G0M7"Z)I8%NVX:/DWMD>(KSO.>PW>V'#W=KL',*0O9S;3[2>
ML^VZA+N&?.YZCA>+2!MJK[YS]M7X7SOXCA(&%X 7M]X?E=H4LSH>_&L+08EI
M?X%IGT<!T&S'-MB7\)[]%EH==NXX.?T)-9F)E!/IXU7@E\"H3$&4,L;"'9"N
MB]KL-!,VJP@,SQWA\4(O[1#N;!:;L1'8PN>^0&H!:A#DJ)Z3/\DPCXXK7!AQ
M.'*-R$( W -[UV VF'N18X&C,Y\;(GS#)?Z(7($"JX"57+_PDH@=+J!B(.,,
M!!)#W ??;W9@?P+O676]:IOG^I?O#V.].WGU/YM$Y./[3K4*V3#60A-:19NE
MSY= 1Q-3!/N!T'XO1YRE'CZ(WEXZ</\;[D+ZCB0!/N?+<*4-3#CAU27>1UCD
M^0(8BFGDR=6WSF6'_7I^_B5'L83E)I1FJ]G#C7!0OH4I^DJLM@MA.(HC*?A#
M0G3_'X1C<#J?S\!/\!=RH,#;8O\!UUE"*#>Q>8/=1+:\+B#U@F/LAL_%;\47
M(V!\0"(-;'=CZ230]V;8%)X((9/.76*1#K+W .S4$GP@W*":YY=YJBGY1=$U
MOBT%]5S[];?\KV.X^2458.&EWGGPG_R5?CF_?)?GO,T$\^:'JT_2#KVE[:*U
M@47 -PU9"6NG.4"*#_NG#^#SS+#^ ,HKWP_G1BA268P]X%'^ GZ'YNMCNN7C
MQ8'&1O %P7:3;[L0,H+ \._38#4S;!^!*"5&:U$S#^^K,2Z]P!9?E]?'F!I$
MC@RZF,MX2RZK4!(\3".8,]PE$:1W7HJZ9)#<'"@W^Q1C4'(M,60O3(<-:@")
M6,*9;\7<DV^FTXE 4"( PQL8]&>1D(*\66E^U3@W4IW#?PN$NC\&H8W9/%7I
MU,/#W7N9D1])SI,BS3X(N,&-5@3 YW]&-F! !F:1+RR,[YSQQ%8$ !E!$"V6
M,4L1<#B;<3.4F+R0A0%?L%;)J1##=@].7#F+Z(+;=-@%XB+0WQL/WYQB MK.
MCI'?&DYDQ&E$L#[6/R+K)JYFW<UM<RYP4*Q3(J.>VT'H(;63@ ]<R09V*,:8
MXJ:H<$ *(O^$']T">'H1P#*F+9O"R QMRAV;WTJ")E.EP',%1P.BQ27*FK9O
M1@M<!S5QMN_N\5V((S+DM+/3@9$'T?0/(6H/A6*[F#C!C2R.JS]H!)""<3\T
M@(&*6E@;>5T0F7/X0ZRBIO-:&/<,R!RRPIGO+3+#SH>I]/X-(%)/.)F@-KCX
M<#S8+8&OX$/B81UH[1_ >AUO*8P9U^[= &ZHI%Q6VEMM"6VXK>8T964TQ1--
M(6*8<Y@>X!D@1I9'"CH,[!:IXNX+Q=2YC? .("R1+YP#( .N!H8C*NMM /E
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M=,6"0]Q[AZ :!,DZN\4Q:<3BG3V37\0[R&^NJ0GC2-I]A/%)O+Y;&_LTK@>
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MV(Q[CS$73\+B#="0./_RD#:D%6>(VJ*2*Y?^\:CW592365M,$!)IBXXP4:[
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MQ.O<&Q<N+#5M'7;"OW+#%]O!!,MHK'UZ6?%KDVQ+9?P+0;;$49;BR/]J"?P
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M&)9WN7#9:NFQ2,S[KYQMY(5%*RP%U7^)E937'#^O6>OAKE:(0-L#V^+^@\%
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M1UI&"TAUE;?P/9=P<07K0W'%,5#88?EL"&L9&7]'H906F W*[WJ%=05 1R4
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MW?!15?8XQ1^$SA>2N.=/A.,YN2=*>?A=O4BM%OH >VHRC6E2;6VG[VU/V6Q
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M"35Q[:I75U?EX%LNRM U"]H_$QMX@>E3QV4I)<1_Q5"L*"X5J[5BO5J:,:?
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MS,]O]6^-1NVR<G%1;5S6+R\;7R,CCWA$DZZ# -0.]?./6TZRGKQ(B3+S1Z-
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M0<N[,-LN6'0%9=6"B/96^EM-:4EAO^)23*(%9)<KJ?S.+]7*$,:'#FQ"5AT
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M42U(K47 +T/6#+M ]Z__#U!+ P04    " !K@&A-&]Z;#YDY  #[.0, %0
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MQN5%$A0%$XAM;O1A?N0QH)IP3J"H;LO.$0< :/ Y.O?RMSP8'?0+#N@^F><
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MZ3IHRH'AUDW32Z599_'!E9U+%JCA@.^TBD5WHT8&1WM<HG;X1;UXXQR +\D
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MW26%PQ%::Z,T#I54Z)&#N4XI]#J8V:[/KM*TO7Y*Y= /DW8I?$I+.J$4#-_
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M=!IDB:G)6PU*#^W TW[#P<LMY:I-\;:#P G5!4#MHYVV>77%K&V='0&"G,'
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G+3(P,3@P.3,P7W!R92YX;6Q02P4&      8 !@"* 0  030!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
